{"custom_id": "Carvedilol-Ibuprofen-Metoprolol-GRPR-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Carvedilol\nDRUG 1 BACKGROUND INFORMATION: Carvedilol, a nonselective beta-adrenergic blocker with alpha-1 adrenergic receptor antagonism, is clinically utilized for managing hypertension and chronic heart failure with reduced ejection fraction (HFrEF), often despite beta-blockers not being preferred first-line antihypertensives due to inferior cardiovascular outcomes and safety profiles relative to alternative hypertensives. While its pharmacodynamic mechanisms contributing to therapeutic efficacy in HFrEF remain incompletely elucidated, vasodilation resultant from alpha-1 blockade may play a role. Adverse reactions encompass orthostatic hypotension, asthenia, arthralgia, nausea, and dyspnea, with bronchospasm as a potential severe manifestation. The drug's pharmacokinetics necessitate cautious use during gestation and lactation and contraindicate administration in hepatic impairment cases. Despite exhibiting a broad safety spectrum, carvedilol's utilization extends to over 17 million annual prescriptions in the U.S., affirming its presence on the WHO's List of Essential Medicines and availability in generic formulations.\n\nDRUG 2 NAME: Ibuprofen\nDRUG 2 BACKGROUND INFORMATION: Ibuprofen, a widely utilized nonsteroidal anti-inflammatory drug (NSAID), exerts its therapeutic effects primarily through the attenuation of cyclooxygenase (COX) enzymatic activity, thereby reducing the biosynthesis of pro-inflammatory prostaglandins. Indicated for alleviating nociceptive and inflammatory perturbations such as dysmenorrhea, migrainous episodes, and inflammatory arthropathies, ibuprofen demonstrates notable pharmacokinetics with onset of action within one hour post administration via oral or parenteral routes. Despite its efficacy, ibuprofen's pharmacodynamic profile correlates with several adverse outcomes, notably gastrointestinal mucosal irritation leading to potential bleeding, renal impairment with prolonged administration, and rare hepatotoxicity. It possesses a variable cardiovascular risk profile, posing increased myocardial infarction risk at higher dosages. Notably, ibuprofen is contraindicated in advanced gestational periods due to its deleterious fetal effects and can exacerbate asthmatic conditions. Although it constitutes a less potent anti-inflammatory than other NSAIDs, its inclusion in the WHO's List of Essential Medicines underscores its clinical utility across various domains. Despite its prevalence, ongoing vigilance is advised due to its side effect spectrum.\n\nDRUG 3 NAME: Metoprolol\nDRUG 3 BACKGROUND INFORMATION: Metoprolol, a cardioselective \u03b21-adrenergic receptor antagonist, is clinically utilized in the management of angina pectoris, hypertension, tachyarrhythmias, post-myocardial infarction secondary prophylaxis, and migraine prophylaxis. Its therapeutic efficacy is mediated via negative chronotropic and inotropic effects which result in decreased myocardial oxygen demand and improved exercise tolerance. The pharmacokinetics of metoprolol is influenced by hepatic cytochrome P450 2D6 isoenzyme variability leading to significant interpatient variability in drug metabolism, necessitating individualized dosing. Adverse effects prominently include insomnia, asthenia, presyncope, and gastrointestinal disturbances, with higher doses presenting risk for pronounced toxicity. Though teratogenic risk during pregnancy has not been conclusively excluded, its excretion into breast milk is considered clinically insignificant. Metoprolol is widely dispensed, reflecting its inclusion in the WHO's Essential Medicines, and its prescription frequency underscores its pivotal role in cardiovascular therapeutics.\n\nPROTEIN NAME: GRPR\nPROTEIN BACKGROUND INFORMATION: The gastrin-releasing peptide receptor (GRPR), now properly known as BB2  is a G protein-coupled receptor whose endogenous ligand is gastrin releasing peptide. In humans it is highly expressed in the pancreas and is also expressed in the stomach, adrenal cortex and brain.\nGastrin-releasing peptide (GRP) regulates numerous functions of the gastrointestinal and central nervous systems, including release of gastrointestinal hormones, smooth muscle cell contraction, and epithelial cell proliferation and is a potent mitogen for neoplastic tissues. The effects of GRP are mediated through the gastrin-releasing peptide receptor. This receptor is a glycosylated, 7-transmembrane G-protein coupled receptor that activates the phospholipase C signaling pathway. The receptor is aberrantly expressed in numerous cancers such as those of the lung, colon, and prostate. An individual with autism and multiple exostoses was found to have a balanced translocation between chromosome 8 and a chromosome X breakpoint located within the gastrin-releasing peptide receptor gene.\nThe transcription factor CREB is a regulator of human GRP-R expression in colon cancer.\nActivation MOR1D\u2010GRPR heteromers in the spinal cord mediate the common troublesome opioid-induced itch.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Carvedilol-cholecystitis-Ibuprofen\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Ibuprofen-cholecystitis-Metoprolol\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Metoprolol-binding and activation-GRPR"}]}}
{"custom_id": "Cimetidine-Citalopram-Fluphenazine-ADRA1A-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Cimetidine\nDRUG 1 BACKGROUND INFORMATION: Cimetidine, sold under the brand name Tagamet among others, is a histamine H2 receptor antagonist that inhibits stomach acid production. It is mainly used in the treatment of heartburn and peptic ulcers.\nWith the development of proton pump inhibitors, such as omeprazole, approved for the same indications, cimetidine is available as an over-the-counter formulation to prevent heartburn or acid indigestion, along with the other H2-receptor antagonists.\nCimetidine was developed in 1971 and came into commercial use in 1977. Cimetidine was approved in the United Kingdom in 1976, and was approved in the United States by the Food and Drug Administration in 1979.\n\nDRUG 2 NAME: Citalopram\nDRUG 2 BACKGROUND INFORMATION: Citalopram, a chiral bicyclic phthalane derivative and selective serotonin reuptake inhibitor (SSRI), is primarily employed in the pharmacotherapy of major depressive disorder, obsessive-compulsive disorder, panic disorder, and social phobia through modulation of serotonergic neurotransmission. The therapeutic latency ranges from one to four weeks post-administration. It is predominantly administered orally, though parenteral administration via intravenous injection is utilized in specific regions to expedite therapeutic onset. The pharmacokinetic profile of citalopram encompasses hepatic metabolism predominantly via CYP2C19, CYP3A4, and CYP2D6, yielding demethylated metabolites. It is imperative to monitor for adverse reactions, including, but not limited to, gastrointestinal disturbances, insomnia, sexual dysfunction, tremors, somnolence, hyperhidrosis, serotonin toxicity, and cardiotoxicity as manifested by QT interval prolongation. Contraindications entail concurrent MAO inhibitor therapy due to risk of serotonin syndrome and potential teratogenicity warrants cautious use in pregnancy. The potential for exacerbating suicidality in individuals under 25 necessitates vigilant monitoring. Citalopram's clinical prominence is evidenced by its inclusion in the WHO's List of Essential Medicines and its extensive prescribing frequency in the United States, underscoring its integral role in psychiatric treatment regimens.\n\nDRUG 3 NAME: Fluphenazine\nDRUG 3 BACKGROUND INFORMATION: Fluphenazine is a high-affinity typical antipsychotic of the phenothiazine cohort primarily prescribed for chronic psychotic disorders such as schizophrenia, offering efficacy comparable to chlorpromazine. Administered via oral, intramuscular, subcutaneous routes\u2014or as a long-acting depot, fluphenazine decanoate\u2014this compound exhibits prolonged dopaminergic antagonism with an extended half-life conducive to monthly dosing regimens. Notably contraindicated in severe depressive states, its pharmacological action is ascribed to dopamine receptor blockade, though precision in its mechanism remains indeterminate. The pharmacodynamic profile of fluphenazine entails extrapyramidal symptoms, somnolence, depressive mood alterations, and metabolic side effects, with grave adverse events encompassing neuroleptic malignant syndrome, agranulocytosis, and irreversible tardive dyskinesia. Moreover, in the geriatric cohort with dementia-related psychoses, mortality risk is potentiated. Prolactin secretion perturbations may elicit galactorrhea, gynecomastia, erectile dysfunction, and amenorrhea, with teratogenic safety in gestation unresolved. Chronic administration associates with hepatocellular enzyme elevation in a substantial patient subset. Despite its broad utilization reflected in its inclusion on the World Health Organization's Essential Medicines list, its production cessation in some regions underscores its dynamic availability landscape.\n\nPROTEIN NAME: ADRA1A\nPROTEIN BACKGROUND INFORMATION: The alpha-1A adrenergic receptor (\u03b11A adrenoreceptor), also known as ADRA1A, formerly known also as the  alpha-1C adrenergic receptor, is an alpha-1 adrenergic receptor, and also denotes the human gene encoding it. There is no longer a subtype \u03b11C receptor. At one time, there was a subtype known as \u03b11C, but it was found to be identical to the previously discovered \u03b11A receptor subtype. To avoid confusion, the naming convention was continued with the letter D.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Cimetidine-gastric inflammation-Citalopram\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Citalopram-cholecystitis-Fluphenazine\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Fluphenazine-binding and inhibition-ADRA1A"}]}}
{"custom_id": "Naproxen-Lamotrigine-Pilocarpine-CHRM1-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: Lamotrigine\nDRUG 2 BACKGROUND INFORMATION: Lamotrigine, a phenyltriazine anticonvulsant, is primarily utilized in the pharmacological management of epilepsy, encompassing focal, tonic-clonic, and Lennox-Gastaut syndrome seizures, as well as serving as a mood-stabilizing agent in bipolar disorder. While it does not consistently ameliorate acute depressive states in bipolar disorders outside of severe depression contexts, it efficaciously mitigates the risk of recurrent depressive episodes in euthymic individuals. Additionally, lamotrigine is prescribed off-label for major depressive disorder and depersonalization-derealization disorder. Its pharmacodynamics are hypothesized to involve the inhibition of excitatory neurotransmitter release through modulation of voltage-sensitive sodium channels and voltage-gated calcium channels. Despite its therapeutic efficacy, lamotrigine's adverse effect profile includes both common side effects such as nausea, somnolence, headache, emesis, ataxia, and dermatological reactions, and serious reactions like hemolytic anemia, suicidality, and potentially fatal Stevens\u2013Johnson syndrome.\n\nDRUG 3 NAME: Pilocarpine\nDRUG 3 BACKGROUND INFORMATION: Pilocarpine, a muscarinic agonist in the miotics pharmacological class, exerts its therapeutic effects primarily through cholinergic receptor activation, specifically targeting muscarinic acetylcholine receptors to facilitate aqueous humor outflow via the trabecular meshwork. While its ophthalmic formulation is indicated for acute intervention in angle-closure glaucoma, ocular hypertension, and primary open-angle glaucoma, its utility is limited in chronic management due to adverse effects such as ocular irritation, lacrimation increase, cephalalgia, and transient visual disturbances, with potential complications including retinal detachment and hypersensitivity reactions. Pilocarpine's pharmacodynamics involve onset within one hour with effects persisting up to 24 hours. Systemic administration is employed in xerostomia management secondary to Sj\u00f6gren syndrome or post-radiation sequelae. Nonetheless, its use contraindicated during pregnancy underscores its safety profile concerns. Initially derived from Pilocarpus spp., pilocarpine remains inextricably linked to its historical provenance yet maintains its clinical relevance as delineated in the WHO Essential Medicines list.\n\nPROTEIN NAME: CHRM1\nPROTEIN BACKGROUND INFORMATION: The muscarinic acetylcholine receptor M1, also known as the cholinergic receptor, muscarinic 1, is a muscarinic receptor that in humans is encoded by the CHRM1 gene. It is localized to 11q13.\nThis receptor is found mediating slow EPSP at the ganglion in the postganglionic nerve, is common in exocrine glands and in the CNS.\nIt is predominantly found bound to G proteins of class Gq that use upregulation of phospholipase C and, therefore, inositol trisphosphate and intracellular calcium as a signalling pathway. A receptor so bound would not be susceptible to CTX or PTX. However, Gi (causing a downstream decrease in cAMP) and Gs (causing an increase in cAMP) have also been shown to be involved in interactions in certain tissues, and so would be susceptible to PTX and CTX respectively.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Naproxen-abnormal EEG-Lamotrigine\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Lamotrigine-agitated-Pilocarpine\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Pilocarpine-binding and activation-CHRM1"}]}}
{"custom_id": "alendronic acid-Lamivudine-Metoprolol-PTGIR-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: alendronic acid\nDRUG 1 BACKGROUND INFORMATION: Alendronic acid, sold under the brand name Fosamax among others, is a bisphosphonate medication used to treat osteoporosis and Paget's disease of bone. It is taken by mouth. Use is often recommended together with vitamin D, calcium supplementation, and lifestyle changes.\nCommon side effects (1 to 10% of patients) include constipation, abdominal pain, nausea, and acid reflux. Use is not recommended during pregnancy or in those with poor kidney function. Alendronic acid works by decreasing the activity of cells that break down bone.\nAlendronic acid was first described in 1978 and approved for medical use in the United States in 1995. It is available as a generic medication. In 2022, it was the 103rd most commonly prescribed medication in the United States, with more than 6 million prescriptions.\n\nDRUG 2 NAME: Lamivudine\nDRUG 2 BACKGROUND INFORMATION: Lamivudine, or 3TC, is a nucleoside reverse transcriptase inhibitor with efficacy against HIV-1, HIV-2, and chronic hepatitis B virus. It functions by competitive inhibition of HIV reverse transcriptase and hepatitis B virus polymerase, disrupting viral DNA synthesis. Clinically, lamivudine is integral to combination antiretroviral therapy, often co-administered with agents such as zidovudine, dolutegravir, and abacavir, and forms part of post-exposure prophylactic regimens. It is available for oral administration as liquid or tablet formulations, maintaining therapeutic flexibility through its dosing independence from food intake. While generally well-tolerated, adverse effects can include gastrointestinal disturbances, cephalalgia, asthenia, and respiratory symptoms; however, clinicians must vigilantly monitor for hepatotoxicity, lactic acidosis, and hepatitis B exacerbations. Suitable for patients over three months and deemed safe in pregnancy, lamivudine is recognized as an essential medicine, underscoring its pivotal role in antiretroviral pharmacotherapy despite potential genotypic resistance mutations.\n\nDRUG 3 NAME: Metoprolol\nDRUG 3 BACKGROUND INFORMATION: Metoprolol, a cardioselective \u03b21-adrenergic receptor antagonist, is clinically utilized in the management of angina pectoris, hypertension, tachyarrhythmias, post-myocardial infarction secondary prophylaxis, and migraine prophylaxis. Its therapeutic efficacy is mediated via negative chronotropic and inotropic effects which result in decreased myocardial oxygen demand and improved exercise tolerance. The pharmacokinetics of metoprolol is influenced by hepatic cytochrome P450 2D6 isoenzyme variability leading to significant interpatient variability in drug metabolism, necessitating individualized dosing. Adverse effects prominently include insomnia, asthenia, presyncope, and gastrointestinal disturbances, with higher doses presenting risk for pronounced toxicity. Though teratogenic risk during pregnancy has not been conclusively excluded, its excretion into breast milk is considered clinically insignificant. Metoprolol is widely dispensed, reflecting its inclusion in the WHO's Essential Medicines, and its prescription frequency underscores its pivotal role in cardiovascular therapeutics.\n\nPROTEIN NAME: PTGIR\nPROTEIN BACKGROUND INFORMATION: The prostacyclin receptor, also termed the prostaglandin I2 receptor or just IP, is a receptor belonging to the prostaglandin (PG) group of receptors. IP binds to and mediates the biological actions of prostacyclin (also termed prostaglandin I2, PGI2, or when used as a drug, epoprostenol). IP is encoded in humans by the PTGIR gene. While possessing many functions as defined in animal model studies, the major clinical relevancy of IP is as a powerful vasodilator: stimulators of IP are used to treat severe and even life-threatening diseases involving pathological vasoconstriction.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): alendronic acid-Adenopathy-Lamivudine\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Lamivudine-dysarthria-Metoprolol\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Metoprolol-binding and activation-PTGIR"}]}}
{"custom_id": "alendronic acid-Alprazolam-Terazosin-ADRA1A-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: alendronic acid\nDRUG 1 BACKGROUND INFORMATION: Alendronic acid, sold under the brand name Fosamax among others, is a bisphosphonate medication used to treat osteoporosis and Paget's disease of bone. It is taken by mouth. Use is often recommended together with vitamin D, calcium supplementation, and lifestyle changes.\nCommon side effects (1 to 10% of patients) include constipation, abdominal pain, nausea, and acid reflux. Use is not recommended during pregnancy or in those with poor kidney function. Alendronic acid works by decreasing the activity of cells that break down bone.\nAlendronic acid was first described in 1978 and approved for medical use in the United States in 1995. It is available as a generic medication. In 2022, it was the 103rd most commonly prescribed medication in the United States, with more than 6 million prescriptions.\n\nDRUG 2 NAME: Alprazolam\nDRUG 2 BACKGROUND INFORMATION: Alprazolam is a high-affinity triazolobenzodiazepine functioning as a potent anxiolytic agent through modulation of the GABA_A receptor chloride channel activity, facilitating enhanced inhibitory neurotransmission. Its pharmacodynamic profile encompasses rapid onset and moderate duration of action, predominantly prescribed for anxiety spectrum disorders, including panic disorder and GAD, and adjunctively for chemotherapy-related emesis control. The pharmacokinetic trajectory involves oral administration, exhibiting bioavailability conducive to therapeutic efficacy within a week for GAD. The acute adverse neurological sequelae are characterized by CNS depression manifesting as somnolence, psychomotor impairment, cognitive attenuation, and dose-dependent anterograde amnesia. Tolerance development mitigates some sedative effects over time. Abrupt cessation precipitates benzodiazepine withdrawal symptomatology. As a Schedule IV controlled substance, alprazolam's potential for abuse and dependency necessitates judicious prescription monitoring. Its clinical ubiquity is substantiated by its standing as the 41st most prescribed drug in the US, with significant generic dissemination.\n\nDRUG 3 NAME: Terazosin\nDRUG 3 BACKGROUND INFORMATION: Terazosin, sold under the brand name Hytrin among others, is a medication used to treat symptoms of an enlarged prostate and high blood pressure. For high blood pressure, it is a less preferred option. It is taken by mouth.\nCommon side effects include dizziness, headache, feeling tired, swelling, nausea, and low blood pressure with standing. Severe side effects may include priapism and low blood pressure. Prostate cancer should be ruled out before starting treatment. It is an alpha-1 blocker and works by relaxing blood vessels and the opening of the bladder.\nTerazosin was patented in 1975 and came into medical use in 1985. It is available as a generic medication. In 2021, it was the 234th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nPROTEIN NAME: ADRA1A\nPROTEIN BACKGROUND INFORMATION: The alpha-1A adrenergic receptor (\u03b11A adrenoreceptor), also known as ADRA1A, formerly known also as the  alpha-1C adrenergic receptor, is an alpha-1 adrenergic receptor, and also denotes the human gene encoding it. There is no longer a subtype \u03b11C receptor. At one time, there was a subtype known as \u03b11C, but it was found to be identical to the previously discovered \u03b11A receptor subtype. To avoid confusion, the naming convention was continued with the letter D.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): alendronic acid-cholecystitis-Alprazolam\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Alprazolam-apoplexy-Terazosin\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Terazosin-binding and inhibition-ADRA1A"}]}}
{"custom_id": "Naproxen-Risedronic acid-Trazodone-ADRA2A-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: Risedronic acid\nDRUG 2 BACKGROUND INFORMATION: Risedronic acid, often used as its sodium salt risedronate sodium, is a bisphosphonate. It slows down the cells which break down bone. It's used to treat or prevent osteoporosis, and treat Paget's disease of bone. It is taken by mouth.\nIt was patented in 1984 and approved for medical use in 1998.\n\nDRUG 3 NAME: Trazodone\nDRUG 3 BACKGROUND INFORMATION: Trazodone is an antidepressant medication used to treat major depressive disorder, anxiety disorders, and insomnia. It is a phenylpiperazine compound of the serotonin antagonist and reuptake inhibitor (SARI) class. The medication is taken orally.\nCommon side effects include dry mouth, feeling faint, vomiting, and headache. More serious side effects may include suicide, mania, irregular heart rate, and pathologically prolonged erections. It is unclear if use during pregnancy or breastfeeding is safe.  Trazodone also has sedating effects.\nTrazodone was approved for medical use in the United States in 1981. It is available as a generic medication. In 2022, it was the eighteenth most commonly prescribed medication in the United States, with more than 27 million prescriptions.\n\nPROTEIN NAME: ADRA2A\nPROTEIN BACKGROUND INFORMATION: The alpha-2A adrenergic receptor (\u03b12A adrenoceptor), also known as ADRA2A, is an \u03b12-adrenergic receptor, and also denotes the human gene encoding it.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Naproxen-erythema-Risedronic acid\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Risedronic acid-failure to thrive-Trazodone\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Trazodone-binding and inhibition-ADRA2A"}]}}
{"custom_id": "Alprazolam-Lidocaine-Metoprolol-ADRA2A-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Alprazolam\nDRUG 1 BACKGROUND INFORMATION: Alprazolam is a high-affinity triazolobenzodiazepine functioning as a potent anxiolytic agent through modulation of the GABA_A receptor chloride channel activity, facilitating enhanced inhibitory neurotransmission. Its pharmacodynamic profile encompasses rapid onset and moderate duration of action, predominantly prescribed for anxiety spectrum disorders, including panic disorder and GAD, and adjunctively for chemotherapy-related emesis control. The pharmacokinetic trajectory involves oral administration, exhibiting bioavailability conducive to therapeutic efficacy within a week for GAD. The acute adverse neurological sequelae are characterized by CNS depression manifesting as somnolence, psychomotor impairment, cognitive attenuation, and dose-dependent anterograde amnesia. Tolerance development mitigates some sedative effects over time. Abrupt cessation precipitates benzodiazepine withdrawal symptomatology. As a Schedule IV controlled substance, alprazolam's potential for abuse and dependency necessitates judicious prescription monitoring. Its clinical ubiquity is substantiated by its standing as the 41st most prescribed drug in the US, with significant generic dissemination.\n\nDRUG 2 NAME: Lidocaine\nDRUG 2 BACKGROUND INFORMATION: Lidocaine, or lignocaine, is a quintessential amino amide local anesthetic utilized extensively for its neuromodulatory and cardiac electrophysiological properties. As a class Ib antiarrhythmic agent, lidocaine exerts its mechanistic effect via blockade of voltage-gated sodium channels, thereby attenuating myocardial depolarization and stabilizing aberrant conduction pathways responsible for ventricular tachycardia and fibrillation. Its onset of action, contingent upon peripheral nerve administration, is typically rapid, achieving effective anesthesia within minutes, with a duration ranging from 30 minutes to three hours, and efficacy can be potentiated when co-administered with adrenaline due to vasoconstriction and augmented tissue retention. Topical formulations enhance transdermal absorption for sensory blockade across dermal and mucosal surfaces. In systemic circulation, particularly when administered intravenously, lidocaine may induce neurotoxic side effects including CNS agitation, visual disturbances, paresthesia, and emesis, in addition to cardiovascular effects such as hypotension and dysrhythmogenesis. Caution is advised with intra-articular administration due to chondrotoxicity concerns, and dose adjustments are necessary in hepatic insufficiency, yet it remains a favorable option in patients with hypersensitivity to ester-type anesthetics like tetracaine. Due to its obstetric safety profile, lidocaine is deemed viable during gestation and its inclusion in the WHO's List of Essential Medicines underlines its critical therapeutic value and accessibility as a generic formulation.\n\nDRUG 3 NAME: Metoprolol\nDRUG 3 BACKGROUND INFORMATION: Metoprolol, a cardioselective \u03b21-adrenergic receptor antagonist, is clinically utilized in the management of angina pectoris, hypertension, tachyarrhythmias, post-myocardial infarction secondary prophylaxis, and migraine prophylaxis. Its therapeutic efficacy is mediated via negative chronotropic and inotropic effects which result in decreased myocardial oxygen demand and improved exercise tolerance. The pharmacokinetics of metoprolol is influenced by hepatic cytochrome P450 2D6 isoenzyme variability leading to significant interpatient variability in drug metabolism, necessitating individualized dosing. Adverse effects prominently include insomnia, asthenia, presyncope, and gastrointestinal disturbances, with higher doses presenting risk for pronounced toxicity. Though teratogenic risk during pregnancy has not been conclusively excluded, its excretion into breast milk is considered clinically insignificant. Metoprolol is widely dispensed, reflecting its inclusion in the WHO's Essential Medicines, and its prescription frequency underscores its pivotal role in cardiovascular therapeutics.\n\nPROTEIN NAME: ADRA2A\nPROTEIN BACKGROUND INFORMATION: The alpha-2A adrenergic receptor (\u03b12A adrenoceptor), also known as ADRA2A, is an \u03b12-adrenergic receptor, and also denotes the human gene encoding it.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Alprazolam-right heart failure-Lidocaine\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Lidocaine-cholecystitis-Metoprolol\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Metoprolol-binding and inhibition-ADRA2A"}]}}
{"custom_id": "Naproxen-alendronic acid-Salmeterol-ADRB1-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: alendronic acid\nDRUG 2 BACKGROUND INFORMATION: Alendronic acid, sold under the brand name Fosamax among others, is a bisphosphonate medication used to treat osteoporosis and Paget's disease of bone. It is taken by mouth. Use is often recommended together with vitamin D, calcium supplementation, and lifestyle changes.\nCommon side effects (1 to 10% of patients) include constipation, abdominal pain, nausea, and acid reflux. Use is not recommended during pregnancy or in those with poor kidney function. Alendronic acid works by decreasing the activity of cells that break down bone.\nAlendronic acid was first described in 1978 and approved for medical use in the United States in 1995. It is available as a generic medication. In 2022, it was the 103rd most commonly prescribed medication in the United States, with more than 6 million prescriptions.\n\nDRUG 3 NAME: Salmeterol\nDRUG 3 BACKGROUND INFORMATION: Salmeterol is a long-acting \u03b22 adrenergic receptor agonist (LABA) used in the treatment and prevention of asthma symptoms and control of chronic obstructive pulmonary disease (COPD) symptoms. Symptoms of bronchospasm include shortness of breath, wheezing, coughing and chest tightness. It is also used to prevent breathing difficulties during exercise (exercise-induced bronchoconstriction).\nIt was patented in 1983 and came into medical use in 1990. It is marketed as Serevent in the US. It is available as a dry-powder inhaler (DPI) that releases a powdered form of the drug. It was previously available as a metered-dose inhaler (MDI) but was discontinued in the US in 2002. It is available as an MDI in other countries as of 2020.\n\nPROTEIN NAME: ADRB1\nPROTEIN BACKGROUND INFORMATION: The beta-1 adrenergic receptor (\u03b21 adrenoceptor), also known as ADRB1, can refer to either the protein-encoding gene (gene ADRB1) or one of the four adrenergic receptors. It is a G-protein coupled receptor associated with the Gs heterotrimeric G-protein that is expressed predominantly in cardiac tissue. In addition to cardiac tissue, beta-1 adrenergic receptors are also expressed in the cerebral cortex.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Naproxen-gastric inflammation-alendronic acid\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): alendronic acid-cholecystitis-Salmeterol\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Salmeterol-binding and activation-ADRB1"}]}}
{"custom_id": "Doxazosin-Metoprolol-Perphenazine-ADRA1A-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Doxazosin\nDRUG 1 BACKGROUND INFORMATION: Doxazosin, sold under the brand name Cardura among others, is a medication used to treat symptoms of benign prostatic hyperplasia (enlarged prostate), hypertension (high blood pressure), and post-traumatic stress disorder (PTSD). For high blood pressure, it is a less preferred option. It is taken by mouth.\nCommon side effects include dizziness, sleepiness, swelling, nausea, shortness of breath, and abdominal pain. Severe side effects may include low blood pressure with standing, an irregular heart beat, and priapism. It is a selective \u03b11-adrenergic blocker in the quinazoline class of compounds.\nDoxazosin was patented in 1977 and came into medical use in 1988. It is available as a generic medication. In 2022, it was the 180th most commonly prescribed medication in the United States, with more than 2 million prescriptions.\n\nDRUG 2 NAME: Metoprolol\nDRUG 2 BACKGROUND INFORMATION: Metoprolol, a cardioselective \u03b21-adrenergic receptor antagonist, is clinically utilized in the management of angina pectoris, hypertension, tachyarrhythmias, post-myocardial infarction secondary prophylaxis, and migraine prophylaxis. Its therapeutic efficacy is mediated via negative chronotropic and inotropic effects which result in decreased myocardial oxygen demand and improved exercise tolerance. The pharmacokinetics of metoprolol is influenced by hepatic cytochrome P450 2D6 isoenzyme variability leading to significant interpatient variability in drug metabolism, necessitating individualized dosing. Adverse effects prominently include insomnia, asthenia, presyncope, and gastrointestinal disturbances, with higher doses presenting risk for pronounced toxicity. Though teratogenic risk during pregnancy has not been conclusively excluded, its excretion into breast milk is considered clinically insignificant. Metoprolol is widely dispensed, reflecting its inclusion in the WHO's Essential Medicines, and its prescription frequency underscores its pivotal role in cardiovascular therapeutics.\n\nDRUG 3 NAME: Perphenazine\nDRUG 3 BACKGROUND INFORMATION: Perphenazine is a typical antipsychotic drug.  Chemically, it is classified as a piperazinyl phenothiazine. Originally marketed in the United States as Trilafon, it has been in clinical use for decades.\nPerphenazine is roughly ten times as potent as chlorpromazine at the dopamine-2 (D2) receptor; thus perphenazine is considered a medium-potency antipsychotic.\n\nPROTEIN NAME: ADRA1A\nPROTEIN BACKGROUND INFORMATION: The alpha-1A adrenergic receptor (\u03b11A adrenoreceptor), also known as ADRA1A, formerly known also as the  alpha-1C adrenergic receptor, is an alpha-1 adrenergic receptor, and also denotes the human gene encoding it. There is no longer a subtype \u03b11C receptor. At one time, there was a subtype known as \u03b11C, but it was found to be identical to the previously discovered \u03b11A receptor subtype. To avoid confusion, the naming convention was continued with the letter D.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Doxazosin-gastric inflammation-Metoprolol\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Metoprolol-insulin dependent diabetes mellitus-Perphenazine\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Perphenazine-binding and inhibition-ADRA1A"}]}}
{"custom_id": "Candesartan-Citalopram-Fluphenazine-ADRA2C-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Candesartan\nDRUG 1 BACKGROUND INFORMATION: Candesartan is an angiotensin receptor blocker used mainly for the treatment of high blood pressure and congestive heart failure. Candesartan has a very low maintenance dose. Like olmesartan, the metabolism of the drug is unusual as it is a cascading prodrug. Candesartan has good bioavailibility and is the most potent by weight of the AT-1 receptor antagonists.\nIt was patented in 1990 and approved for medical use in 1997.\n\nDRUG 2 NAME: Citalopram\nDRUG 2 BACKGROUND INFORMATION: Citalopram, a chiral bicyclic phthalane derivative and selective serotonin reuptake inhibitor (SSRI), is primarily employed in the pharmacotherapy of major depressive disorder, obsessive-compulsive disorder, panic disorder, and social phobia through modulation of serotonergic neurotransmission. The therapeutic latency ranges from one to four weeks post-administration. It is predominantly administered orally, though parenteral administration via intravenous injection is utilized in specific regions to expedite therapeutic onset. The pharmacokinetic profile of citalopram encompasses hepatic metabolism predominantly via CYP2C19, CYP3A4, and CYP2D6, yielding demethylated metabolites. It is imperative to monitor for adverse reactions, including, but not limited to, gastrointestinal disturbances, insomnia, sexual dysfunction, tremors, somnolence, hyperhidrosis, serotonin toxicity, and cardiotoxicity as manifested by QT interval prolongation. Contraindications entail concurrent MAO inhibitor therapy due to risk of serotonin syndrome and potential teratogenicity warrants cautious use in pregnancy. The potential for exacerbating suicidality in individuals under 25 necessitates vigilant monitoring. Citalopram's clinical prominence is evidenced by its inclusion in the WHO's List of Essential Medicines and its extensive prescribing frequency in the United States, underscoring its integral role in psychiatric treatment regimens.\n\nDRUG 3 NAME: Fluphenazine\nDRUG 3 BACKGROUND INFORMATION: Fluphenazine is a high-affinity typical antipsychotic of the phenothiazine cohort primarily prescribed for chronic psychotic disorders such as schizophrenia, offering efficacy comparable to chlorpromazine. Administered via oral, intramuscular, subcutaneous routes\u2014or as a long-acting depot, fluphenazine decanoate\u2014this compound exhibits prolonged dopaminergic antagonism with an extended half-life conducive to monthly dosing regimens. Notably contraindicated in severe depressive states, its pharmacological action is ascribed to dopamine receptor blockade, though precision in its mechanism remains indeterminate. The pharmacodynamic profile of fluphenazine entails extrapyramidal symptoms, somnolence, depressive mood alterations, and metabolic side effects, with grave adverse events encompassing neuroleptic malignant syndrome, agranulocytosis, and irreversible tardive dyskinesia. Moreover, in the geriatric cohort with dementia-related psychoses, mortality risk is potentiated. Prolactin secretion perturbations may elicit galactorrhea, gynecomastia, erectile dysfunction, and amenorrhea, with teratogenic safety in gestation unresolved. Chronic administration associates with hepatocellular enzyme elevation in a substantial patient subset. Despite its broad utilization reflected in its inclusion on the World Health Organization's Essential Medicines list, its production cessation in some regions underscores its dynamic availability landscape.\n\nPROTEIN NAME: ADRA2C\nPROTEIN BACKGROUND INFORMATION: The alpha-2C adrenergic receptor (\u03b12C adrenoceptor), also known as ADRA2C, is an alpha-2 adrenergic receptor, and also denotes the human gene encoding it.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Candesartan-myelodysplasia-Citalopram\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Citalopram-cholecystitis-Fluphenazine\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Fluphenazine-binding and inhibition-ADRA2C"}]}}
{"custom_id": "Aciclovir-Dipyridamole-oxybutynin-CHRM1-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Aciclovir\nDRUG 1 BACKGROUND INFORMATION: Aciclovir, an antiviral guanosine analogue, exhibits its therapeutic efficacy predominantly by inhibiting viral DNA polymerase through its metabolization to aciclovir triphosphate, resulting in the cessation of herpesvirus DNA elongation across Herpes Simplex Virus, varicella-zoster, and CMV prophylaxis post-transplantation. Administerable orally, topically, or intravenously, its pharmacokinetic profile necessitates careful consideration in patients with compromised renal or hepatic function due to potential nephrotoxicity and thrombocytopenia. While demonstrating an acceptable safety margin during gestation and lactation, adverse events such as gastrointestinal discomfort and diarrhea are common. Its inclusion in the WHO's Essential Medicines list underscores its global pivotal role in antiviral therapy, with its generic accessibility enhancing universal healthcare implementation.\n\nDRUG 2 NAME: Dipyridamole\nDRUG 2 BACKGROUND INFORMATION: Dipyridamole, sold under the brand name Persantine among others, is an antiplatelet drug of the nucleoside transport inhibitor and PDE3 inhibitor class that inhibits blood clot formation when given chronically and causes blood vessel dilation when given at high doses over a short time.\n\nDRUG 3 NAME: oxybutynin\nDRUG 3 BACKGROUND INFORMATION: Oxybutynin, marketed as Ditropan, is a quintessential anticholinergic agent employed predominantly for the amelioration of overactive bladder symptoms, capitalizing on its potent antimuscarinic properties that effectively circumvent acetylcholine-mediated smooth muscle contractions. Its pharmacotherapeutic action, analogous to tolterodine, darifenacin, and solifenacin, renders it a superior first-line therapeutic option due to its robust safety and efficacy profile over prolonged usage, despite plausible off-label utilizations in hyperhidrosis management. Contrarily, its application for pediatric nocturnal enuresis has seen diminished prevalence, given its questionable efficacy. Administrable orally or transdermally, oxybutynin's pharmacokinetic profile necessitates vigilance regarding adverse effects such as xerostomia, gastrointestinal hypomotility, and thermoregulatory dysfunction, encompassing severe sequelae like urinary retention and thermophilic impairments manifesting as heat stroke. Its teratogenic and lactogenic safety paradigms remain speculative, underscoring the need for judicious administration during pregnancy and lactation. As a generically available pharmacologic entity, it maintains substantial prescription frequency, embodying a pivotal role in managing cholinergic-mediated urological disorders.\n\nPROTEIN NAME: CHRM1\nPROTEIN BACKGROUND INFORMATION: The muscarinic acetylcholine receptor M1, also known as the cholinergic receptor, muscarinic 1, is a muscarinic receptor that in humans is encoded by the CHRM1 gene. It is localized to 11q13.\nThis receptor is found mediating slow EPSP at the ganglion in the postganglionic nerve, is common in exocrine glands and in the CNS.\nIt is predominantly found bound to G proteins of class Gq that use upregulation of phospholipase C and, therefore, inositol trisphosphate and intracellular calcium as a signalling pathway. A receptor so bound would not be susceptible to CTX or PTX. However, Gi (causing a downstream decrease in cAMP) and Gs (causing an increase in cAMP) have also been shown to be involved in interactions in certain tissues, and so would be susceptible to PTX and CTX respectively.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Aciclovir-eruption-Dipyridamole\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Dipyridamole-apoplexy-oxybutynin\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): oxybutynin-binding and inhibition-CHRM1"}]}}
{"custom_id": "Cimetidine-Citalopram-Fluphenazine-ADRA2A-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Cimetidine\nDRUG 1 BACKGROUND INFORMATION: Cimetidine, sold under the brand name Tagamet among others, is a histamine H2 receptor antagonist that inhibits stomach acid production. It is mainly used in the treatment of heartburn and peptic ulcers.\nWith the development of proton pump inhibitors, such as omeprazole, approved for the same indications, cimetidine is available as an over-the-counter formulation to prevent heartburn or acid indigestion, along with the other H2-receptor antagonists.\nCimetidine was developed in 1971 and came into commercial use in 1977. Cimetidine was approved in the United Kingdom in 1976, and was approved in the United States by the Food and Drug Administration in 1979.\n\nDRUG 2 NAME: Citalopram\nDRUG 2 BACKGROUND INFORMATION: Citalopram, a chiral bicyclic phthalane derivative and selective serotonin reuptake inhibitor (SSRI), is primarily employed in the pharmacotherapy of major depressive disorder, obsessive-compulsive disorder, panic disorder, and social phobia through modulation of serotonergic neurotransmission. The therapeutic latency ranges from one to four weeks post-administration. It is predominantly administered orally, though parenteral administration via intravenous injection is utilized in specific regions to expedite therapeutic onset. The pharmacokinetic profile of citalopram encompasses hepatic metabolism predominantly via CYP2C19, CYP3A4, and CYP2D6, yielding demethylated metabolites. It is imperative to monitor for adverse reactions, including, but not limited to, gastrointestinal disturbances, insomnia, sexual dysfunction, tremors, somnolence, hyperhidrosis, serotonin toxicity, and cardiotoxicity as manifested by QT interval prolongation. Contraindications entail concurrent MAO inhibitor therapy due to risk of serotonin syndrome and potential teratogenicity warrants cautious use in pregnancy. The potential for exacerbating suicidality in individuals under 25 necessitates vigilant monitoring. Citalopram's clinical prominence is evidenced by its inclusion in the WHO's List of Essential Medicines and its extensive prescribing frequency in the United States, underscoring its integral role in psychiatric treatment regimens.\n\nDRUG 3 NAME: Fluphenazine\nDRUG 3 BACKGROUND INFORMATION: Fluphenazine is a high-affinity typical antipsychotic of the phenothiazine cohort primarily prescribed for chronic psychotic disorders such as schizophrenia, offering efficacy comparable to chlorpromazine. Administered via oral, intramuscular, subcutaneous routes\u2014or as a long-acting depot, fluphenazine decanoate\u2014this compound exhibits prolonged dopaminergic antagonism with an extended half-life conducive to monthly dosing regimens. Notably contraindicated in severe depressive states, its pharmacological action is ascribed to dopamine receptor blockade, though precision in its mechanism remains indeterminate. The pharmacodynamic profile of fluphenazine entails extrapyramidal symptoms, somnolence, depressive mood alterations, and metabolic side effects, with grave adverse events encompassing neuroleptic malignant syndrome, agranulocytosis, and irreversible tardive dyskinesia. Moreover, in the geriatric cohort with dementia-related psychoses, mortality risk is potentiated. Prolactin secretion perturbations may elicit galactorrhea, gynecomastia, erectile dysfunction, and amenorrhea, with teratogenic safety in gestation unresolved. Chronic administration associates with hepatocellular enzyme elevation in a substantial patient subset. Despite its broad utilization reflected in its inclusion on the World Health Organization's Essential Medicines list, its production cessation in some regions underscores its dynamic availability landscape.\n\nPROTEIN NAME: ADRA2A\nPROTEIN BACKGROUND INFORMATION: The alpha-2A adrenergic receptor (\u03b12A adrenoceptor), also known as ADRA2A, is an \u03b12-adrenergic receptor, and also denotes the human gene encoding it.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Cimetidine-gastric inflammation-Citalopram\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Citalopram-cholecystitis-Fluphenazine\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Fluphenazine-binding and inhibition-ADRA2A"}]}}
{"custom_id": "Aciclovir-Doxazosin-Metoprolol-GRPR-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Aciclovir\nDRUG 1 BACKGROUND INFORMATION: Aciclovir, an antiviral guanosine analogue, exhibits its therapeutic efficacy predominantly by inhibiting viral DNA polymerase through its metabolization to aciclovir triphosphate, resulting in the cessation of herpesvirus DNA elongation across Herpes Simplex Virus, varicella-zoster, and CMV prophylaxis post-transplantation. Administerable orally, topically, or intravenously, its pharmacokinetic profile necessitates careful consideration in patients with compromised renal or hepatic function due to potential nephrotoxicity and thrombocytopenia. While demonstrating an acceptable safety margin during gestation and lactation, adverse events such as gastrointestinal discomfort and diarrhea are common. Its inclusion in the WHO's Essential Medicines list underscores its global pivotal role in antiviral therapy, with its generic accessibility enhancing universal healthcare implementation.\n\nDRUG 2 NAME: Doxazosin\nDRUG 2 BACKGROUND INFORMATION: Doxazosin, sold under the brand name Cardura among others, is a medication used to treat symptoms of benign prostatic hyperplasia (enlarged prostate), hypertension (high blood pressure), and post-traumatic stress disorder (PTSD). For high blood pressure, it is a less preferred option. It is taken by mouth.\nCommon side effects include dizziness, sleepiness, swelling, nausea, shortness of breath, and abdominal pain. Severe side effects may include low blood pressure with standing, an irregular heart beat, and priapism. It is a selective \u03b11-adrenergic blocker in the quinazoline class of compounds.\nDoxazosin was patented in 1977 and came into medical use in 1988. It is available as a generic medication. In 2022, it was the 180th most commonly prescribed medication in the United States, with more than 2 million prescriptions.\n\nDRUG 3 NAME: Metoprolol\nDRUG 3 BACKGROUND INFORMATION: Metoprolol, a cardioselective \u03b21-adrenergic receptor antagonist, is clinically utilized in the management of angina pectoris, hypertension, tachyarrhythmias, post-myocardial infarction secondary prophylaxis, and migraine prophylaxis. Its therapeutic efficacy is mediated via negative chronotropic and inotropic effects which result in decreased myocardial oxygen demand and improved exercise tolerance. The pharmacokinetics of metoprolol is influenced by hepatic cytochrome P450 2D6 isoenzyme variability leading to significant interpatient variability in drug metabolism, necessitating individualized dosing. Adverse effects prominently include insomnia, asthenia, presyncope, and gastrointestinal disturbances, with higher doses presenting risk for pronounced toxicity. Though teratogenic risk during pregnancy has not been conclusively excluded, its excretion into breast milk is considered clinically insignificant. Metoprolol is widely dispensed, reflecting its inclusion in the WHO's Essential Medicines, and its prescription frequency underscores its pivotal role in cardiovascular therapeutics.\n\nPROTEIN NAME: GRPR\nPROTEIN BACKGROUND INFORMATION: The gastrin-releasing peptide receptor (GRPR), now properly known as BB2  is a G protein-coupled receptor whose endogenous ligand is gastrin releasing peptide. In humans it is highly expressed in the pancreas and is also expressed in the stomach, adrenal cortex and brain.\nGastrin-releasing peptide (GRP) regulates numerous functions of the gastrointestinal and central nervous systems, including release of gastrointestinal hormones, smooth muscle cell contraction, and epithelial cell proliferation and is a potent mitogen for neoplastic tissues. The effects of GRP are mediated through the gastrin-releasing peptide receptor. This receptor is a glycosylated, 7-transmembrane G-protein coupled receptor that activates the phospholipase C signaling pathway. The receptor is aberrantly expressed in numerous cancers such as those of the lung, colon, and prostate. An individual with autism and multiple exostoses was found to have a balanced translocation between chromosome 8 and a chromosome X breakpoint located within the gastrin-releasing peptide receptor gene.\nThe transcription factor CREB is a regulator of human GRP-R expression in colon cancer.\nActivation MOR1D\u2010GRPR heteromers in the spinal cord mediate the common troublesome opioid-induced itch.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Aciclovir-gastric inflammation-Doxazosin\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Doxazosin-gastric inflammation-Metoprolol\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Metoprolol-binding and activation-GRPR"}]}}
{"custom_id": "acetazolamide-Celecoxib-Desloratadine-HRH1-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: acetazolamide\nDRUG 1 BACKGROUND INFORMATION: Acetazolamide, marketed under the trade name Diamox, serves as a versatile pharmaceutical agent within the realm of carbonic anhydrase inhibitors, effectively modulating intraocular pressure via the diminution of aqueous humor production and osmolality. Its clinical utility spans across conditions such as glaucoma\u2014both open-angle and acute angle closure\u2014epilepsy, acute mountain sickness, periodic paralysis, idiopathic intracranial hypertension, and heart failure, with an ancillary role in urinary alkalinization. Therapeutic administration is achievable through oral and intravenous modalities. Mechanistically, acetazolamide exerts its effects by disrupting the equilibria of carbon dioxide hydration and subsequent bicarbonate ion production, thereby reducing intracellular hydrogen ion availability. The pharmacodynamic profile encompasses neuro-sensory side effects like paresthesia and tinnitus, alongside anorexia, emesis, and somnolence. Contraindications are notable in individuals with renal or hepatic impairment, and those with hypersensitivity to sulfonamide derivatives. As a diuretic and enzymatic inhibitor, it holds a position on the WHO's List of Essential Medicines, emphasizing its critical global accessibility as a generic formulation.\n\nDRUG 2 NAME: Celecoxib\nDRUG 2 BACKGROUND INFORMATION: Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, functions as a nonsteroidal anti-inflammatory drug (NSAID) utilized primarily for its analgesic and anti-inflammatory efficacy in osteoarthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, dysmenorrhea, acute pain management, and juvenile rheumatoid arthritis. Additionally, celecoxib has prophylactic applications in reducing colorectal adenomatous formations in familial adenomatous polyposis due to its COX-2 inhibition, which mitigates pro-inflammatory prostaglandin synthesis while sparing COX-1, ostensibly minimizing gastrointestinal mucosal damage relative to non-selective NSAIDs. The pharmacokinetics permit oral administration, with pharmacodynamic effects commencing typically within one hour post-ingestion. Notable adverse reactions span gastrointestinal disturbances such as abdominal pain, nausea, and diarrhea, with severe risk profiles including cardiovascular thrombotic events, gastrointestinal perforation, renal impairment, and hypersensitivity reactions like anaphylaxis, contraindicating its use in populations with significant cardiovascular risk profiles. The risk profile parallels that of other NSAIDs like ibuprofen and naproxen, and caution is advised during late-stage gestation and lactation. Celecoxib's generic availability and widespread prescription underscore its clinical significance, albeit with requisite consideration of its potential side-effect burden.\n\nDRUG 3 NAME: Desloratadine\nDRUG 3 BACKGROUND INFORMATION: Desloratadine sold under the brand name Aerius among others, is a tricyclic H1 inverse agonist that is used to treat allergies. It is an active metabolite of loratadine.\nIt was patented in 1984 and came into medical use in 2001. It was brought to the market in the US by Schering Corporation, later named Schering-Plough.\n\nPROTEIN NAME: HRH1\nPROTEIN BACKGROUND INFORMATION: The H1 receptor is a histamine receptor belonging to the family of rhodopsin-like G-protein-coupled receptors. This receptor is activated by the biogenic amine histamine. It is expressed in smooth muscles, on vascular endothelial cells, in the heart, and in the central nervous system. The H1 receptor is linked to an intracellular G-protein (Gq) that activates phospholipase C and the inositol triphosphate (IP3) signalling pathway. Antihistamines, which act on this receptor, are used as anti-allergy drugs. The crystal structure of the receptor has been determined (shown on the right/below) and used to discover new histamine H1 receptor ligands in structure-based virtual screening studies.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): acetazolamide-Pain-Celecoxib\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Celecoxib-cholecystitis-Desloratadine\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Desloratadine-binding and inhibition-HRH1"}]}}
{"custom_id": "Aciclovir-Citalopram-Fluphenazine-ADRA1A-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Aciclovir\nDRUG 1 BACKGROUND INFORMATION: Aciclovir, an antiviral guanosine analogue, exhibits its therapeutic efficacy predominantly by inhibiting viral DNA polymerase through its metabolization to aciclovir triphosphate, resulting in the cessation of herpesvirus DNA elongation across Herpes Simplex Virus, varicella-zoster, and CMV prophylaxis post-transplantation. Administerable orally, topically, or intravenously, its pharmacokinetic profile necessitates careful consideration in patients with compromised renal or hepatic function due to potential nephrotoxicity and thrombocytopenia. While demonstrating an acceptable safety margin during gestation and lactation, adverse events such as gastrointestinal discomfort and diarrhea are common. Its inclusion in the WHO's Essential Medicines list underscores its global pivotal role in antiviral therapy, with its generic accessibility enhancing universal healthcare implementation.\n\nDRUG 2 NAME: Citalopram\nDRUG 2 BACKGROUND INFORMATION: Citalopram, a chiral bicyclic phthalane derivative and selective serotonin reuptake inhibitor (SSRI), is primarily employed in the pharmacotherapy of major depressive disorder, obsessive-compulsive disorder, panic disorder, and social phobia through modulation of serotonergic neurotransmission. The therapeutic latency ranges from one to four weeks post-administration. It is predominantly administered orally, though parenteral administration via intravenous injection is utilized in specific regions to expedite therapeutic onset. The pharmacokinetic profile of citalopram encompasses hepatic metabolism predominantly via CYP2C19, CYP3A4, and CYP2D6, yielding demethylated metabolites. It is imperative to monitor for adverse reactions, including, but not limited to, gastrointestinal disturbances, insomnia, sexual dysfunction, tremors, somnolence, hyperhidrosis, serotonin toxicity, and cardiotoxicity as manifested by QT interval prolongation. Contraindications entail concurrent MAO inhibitor therapy due to risk of serotonin syndrome and potential teratogenicity warrants cautious use in pregnancy. The potential for exacerbating suicidality in individuals under 25 necessitates vigilant monitoring. Citalopram's clinical prominence is evidenced by its inclusion in the WHO's List of Essential Medicines and its extensive prescribing frequency in the United States, underscoring its integral role in psychiatric treatment regimens.\n\nDRUG 3 NAME: Fluphenazine\nDRUG 3 BACKGROUND INFORMATION: Fluphenazine is a high-affinity typical antipsychotic of the phenothiazine cohort primarily prescribed for chronic psychotic disorders such as schizophrenia, offering efficacy comparable to chlorpromazine. Administered via oral, intramuscular, subcutaneous routes\u2014or as a long-acting depot, fluphenazine decanoate\u2014this compound exhibits prolonged dopaminergic antagonism with an extended half-life conducive to monthly dosing regimens. Notably contraindicated in severe depressive states, its pharmacological action is ascribed to dopamine receptor blockade, though precision in its mechanism remains indeterminate. The pharmacodynamic profile of fluphenazine entails extrapyramidal symptoms, somnolence, depressive mood alterations, and metabolic side effects, with grave adverse events encompassing neuroleptic malignant syndrome, agranulocytosis, and irreversible tardive dyskinesia. Moreover, in the geriatric cohort with dementia-related psychoses, mortality risk is potentiated. Prolactin secretion perturbations may elicit galactorrhea, gynecomastia, erectile dysfunction, and amenorrhea, with teratogenic safety in gestation unresolved. Chronic administration associates with hepatocellular enzyme elevation in a substantial patient subset. Despite its broad utilization reflected in its inclusion on the World Health Organization's Essential Medicines list, its production cessation in some regions underscores its dynamic availability landscape.\n\nPROTEIN NAME: ADRA1A\nPROTEIN BACKGROUND INFORMATION: The alpha-1A adrenergic receptor (\u03b11A adrenoreceptor), also known as ADRA1A, formerly known also as the  alpha-1C adrenergic receptor, is an alpha-1 adrenergic receptor, and also denotes the human gene encoding it. There is no longer a subtype \u03b11C receptor. At one time, there was a subtype known as \u03b11C, but it was found to be identical to the previously discovered \u03b11A receptor subtype. To avoid confusion, the naming convention was continued with the letter D.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Aciclovir-methaemoglobinaemia-Citalopram\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Citalopram-cholecystitis-Fluphenazine\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Fluphenazine-binding and inhibition-ADRA1A"}]}}
{"custom_id": "Lidocaine-Metoprolol-Perphenazine-ADRA1A-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Lidocaine\nDRUG 1 BACKGROUND INFORMATION: Lidocaine, or lignocaine, is a quintessential amino amide local anesthetic utilized extensively for its neuromodulatory and cardiac electrophysiological properties. As a class Ib antiarrhythmic agent, lidocaine exerts its mechanistic effect via blockade of voltage-gated sodium channels, thereby attenuating myocardial depolarization and stabilizing aberrant conduction pathways responsible for ventricular tachycardia and fibrillation. Its onset of action, contingent upon peripheral nerve administration, is typically rapid, achieving effective anesthesia within minutes, with a duration ranging from 30 minutes to three hours, and efficacy can be potentiated when co-administered with adrenaline due to vasoconstriction and augmented tissue retention. Topical formulations enhance transdermal absorption for sensory blockade across dermal and mucosal surfaces. In systemic circulation, particularly when administered intravenously, lidocaine may induce neurotoxic side effects including CNS agitation, visual disturbances, paresthesia, and emesis, in addition to cardiovascular effects such as hypotension and dysrhythmogenesis. Caution is advised with intra-articular administration due to chondrotoxicity concerns, and dose adjustments are necessary in hepatic insufficiency, yet it remains a favorable option in patients with hypersensitivity to ester-type anesthetics like tetracaine. Due to its obstetric safety profile, lidocaine is deemed viable during gestation and its inclusion in the WHO's List of Essential Medicines underlines its critical therapeutic value and accessibility as a generic formulation.\n\nDRUG 2 NAME: Metoprolol\nDRUG 2 BACKGROUND INFORMATION: Metoprolol, a cardioselective \u03b21-adrenergic receptor antagonist, is clinically utilized in the management of angina pectoris, hypertension, tachyarrhythmias, post-myocardial infarction secondary prophylaxis, and migraine prophylaxis. Its therapeutic efficacy is mediated via negative chronotropic and inotropic effects which result in decreased myocardial oxygen demand and improved exercise tolerance. The pharmacokinetics of metoprolol is influenced by hepatic cytochrome P450 2D6 isoenzyme variability leading to significant interpatient variability in drug metabolism, necessitating individualized dosing. Adverse effects prominently include insomnia, asthenia, presyncope, and gastrointestinal disturbances, with higher doses presenting risk for pronounced toxicity. Though teratogenic risk during pregnancy has not been conclusively excluded, its excretion into breast milk is considered clinically insignificant. Metoprolol is widely dispensed, reflecting its inclusion in the WHO's Essential Medicines, and its prescription frequency underscores its pivotal role in cardiovascular therapeutics.\n\nDRUG 3 NAME: Perphenazine\nDRUG 3 BACKGROUND INFORMATION: Perphenazine is a typical antipsychotic drug.  Chemically, it is classified as a piperazinyl phenothiazine. Originally marketed in the United States as Trilafon, it has been in clinical use for decades.\nPerphenazine is roughly ten times as potent as chlorpromazine at the dopamine-2 (D2) receptor; thus perphenazine is considered a medium-potency antipsychotic.\n\nPROTEIN NAME: ADRA1A\nPROTEIN BACKGROUND INFORMATION: The alpha-1A adrenergic receptor (\u03b11A adrenoreceptor), also known as ADRA1A, formerly known also as the  alpha-1C adrenergic receptor, is an alpha-1 adrenergic receptor, and also denotes the human gene encoding it. There is no longer a subtype \u03b11C receptor. At one time, there was a subtype known as \u03b11C, but it was found to be identical to the previously discovered \u03b11A receptor subtype. To avoid confusion, the naming convention was continued with the letter D.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Lidocaine-cholecystitis-Metoprolol\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Metoprolol-insulin dependent diabetes mellitus-Perphenazine\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Perphenazine-binding and inhibition-ADRA1A"}]}}
{"custom_id": "Lamivudine-Metoprolol-Perphenazine-HRH1-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Lamivudine\nDRUG 1 BACKGROUND INFORMATION: Lamivudine, or 3TC, is a nucleoside reverse transcriptase inhibitor with efficacy against HIV-1, HIV-2, and chronic hepatitis B virus. It functions by competitive inhibition of HIV reverse transcriptase and hepatitis B virus polymerase, disrupting viral DNA synthesis. Clinically, lamivudine is integral to combination antiretroviral therapy, often co-administered with agents such as zidovudine, dolutegravir, and abacavir, and forms part of post-exposure prophylactic regimens. It is available for oral administration as liquid or tablet formulations, maintaining therapeutic flexibility through its dosing independence from food intake. While generally well-tolerated, adverse effects can include gastrointestinal disturbances, cephalalgia, asthenia, and respiratory symptoms; however, clinicians must vigilantly monitor for hepatotoxicity, lactic acidosis, and hepatitis B exacerbations. Suitable for patients over three months and deemed safe in pregnancy, lamivudine is recognized as an essential medicine, underscoring its pivotal role in antiretroviral pharmacotherapy despite potential genotypic resistance mutations.\n\nDRUG 2 NAME: Metoprolol\nDRUG 2 BACKGROUND INFORMATION: Metoprolol, a cardioselective \u03b21-adrenergic receptor antagonist, is clinically utilized in the management of angina pectoris, hypertension, tachyarrhythmias, post-myocardial infarction secondary prophylaxis, and migraine prophylaxis. Its therapeutic efficacy is mediated via negative chronotropic and inotropic effects which result in decreased myocardial oxygen demand and improved exercise tolerance. The pharmacokinetics of metoprolol is influenced by hepatic cytochrome P450 2D6 isoenzyme variability leading to significant interpatient variability in drug metabolism, necessitating individualized dosing. Adverse effects prominently include insomnia, asthenia, presyncope, and gastrointestinal disturbances, with higher doses presenting risk for pronounced toxicity. Though teratogenic risk during pregnancy has not been conclusively excluded, its excretion into breast milk is considered clinically insignificant. Metoprolol is widely dispensed, reflecting its inclusion in the WHO's Essential Medicines, and its prescription frequency underscores its pivotal role in cardiovascular therapeutics.\n\nDRUG 3 NAME: Perphenazine\nDRUG 3 BACKGROUND INFORMATION: Perphenazine is a typical antipsychotic drug.  Chemically, it is classified as a piperazinyl phenothiazine. Originally marketed in the United States as Trilafon, it has been in clinical use for decades.\nPerphenazine is roughly ten times as potent as chlorpromazine at the dopamine-2 (D2) receptor; thus perphenazine is considered a medium-potency antipsychotic.\n\nPROTEIN NAME: HRH1\nPROTEIN BACKGROUND INFORMATION: The H1 receptor is a histamine receptor belonging to the family of rhodopsin-like G-protein-coupled receptors. This receptor is activated by the biogenic amine histamine. It is expressed in smooth muscles, on vascular endothelial cells, in the heart, and in the central nervous system. The H1 receptor is linked to an intracellular G-protein (Gq) that activates phospholipase C and the inositol triphosphate (IP3) signalling pathway. Antihistamines, which act on this receptor, are used as anti-allergy drugs. The crystal structure of the receptor has been determined (shown on the right/below) and used to discover new histamine H1 receptor ligands in structure-based virtual screening studies.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Lamivudine-dysarthria-Metoprolol\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Metoprolol-insulin dependent diabetes mellitus-Perphenazine\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Perphenazine-binding and inhibition-HRH1"}]}}
{"custom_id": "Metolazone-Metoprolol-Perphenazine-HRH1-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Metolazone\nDRUG 1 BACKGROUND INFORMATION: Metolazone is a thiazide-like diuretic marketed under the brand names Zytanix, Metoz, Zaroxolyn, and Mykrox. It is primarily used to treat congestive heart failure and high blood pressure. Metolazone indirectly decreases the amount of water reabsorbed into the bloodstream by the kidney, so that blood volume decreases and urine volume increases. This lowers blood pressure and prevents excess fluid accumulation in heart failure. Metolazone is sometimes used together with loop diuretics such as furosemide or bumetanide, but these highly effective combinations can lead to dehydration and electrolyte abnormalities.\nIt was patented in 1966 and approved for medical use in 1974.\n\nDRUG 2 NAME: Metoprolol\nDRUG 2 BACKGROUND INFORMATION: Metoprolol, a cardioselective \u03b21-adrenergic receptor antagonist, is clinically utilized in the management of angina pectoris, hypertension, tachyarrhythmias, post-myocardial infarction secondary prophylaxis, and migraine prophylaxis. Its therapeutic efficacy is mediated via negative chronotropic and inotropic effects which result in decreased myocardial oxygen demand and improved exercise tolerance. The pharmacokinetics of metoprolol is influenced by hepatic cytochrome P450 2D6 isoenzyme variability leading to significant interpatient variability in drug metabolism, necessitating individualized dosing. Adverse effects prominently include insomnia, asthenia, presyncope, and gastrointestinal disturbances, with higher doses presenting risk for pronounced toxicity. Though teratogenic risk during pregnancy has not been conclusively excluded, its excretion into breast milk is considered clinically insignificant. Metoprolol is widely dispensed, reflecting its inclusion in the WHO's Essential Medicines, and its prescription frequency underscores its pivotal role in cardiovascular therapeutics.\n\nDRUG 3 NAME: Perphenazine\nDRUG 3 BACKGROUND INFORMATION: Perphenazine is a typical antipsychotic drug.  Chemically, it is classified as a piperazinyl phenothiazine. Originally marketed in the United States as Trilafon, it has been in clinical use for decades.\nPerphenazine is roughly ten times as potent as chlorpromazine at the dopamine-2 (D2) receptor; thus perphenazine is considered a medium-potency antipsychotic.\n\nPROTEIN NAME: HRH1\nPROTEIN BACKGROUND INFORMATION: The H1 receptor is a histamine receptor belonging to the family of rhodopsin-like G-protein-coupled receptors. This receptor is activated by the biogenic amine histamine. It is expressed in smooth muscles, on vascular endothelial cells, in the heart, and in the central nervous system. The H1 receptor is linked to an intracellular G-protein (Gq) that activates phospholipase C and the inositol triphosphate (IP3) signalling pathway. Antihistamines, which act on this receptor, are used as anti-allergy drugs. The crystal structure of the receptor has been determined (shown on the right/below) and used to discover new histamine H1 receptor ligands in structure-based virtual screening studies.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Metolazone-cholecystitis-Metoprolol\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Metoprolol-insulin dependent diabetes mellitus-Perphenazine\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Perphenazine-binding and inhibition-HRH1"}]}}
{"custom_id": "Aciclovir-Ibuprofen-Metoprolol-HRH3-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Aciclovir\nDRUG 1 BACKGROUND INFORMATION: Aciclovir, an antiviral guanosine analogue, exhibits its therapeutic efficacy predominantly by inhibiting viral DNA polymerase through its metabolization to aciclovir triphosphate, resulting in the cessation of herpesvirus DNA elongation across Herpes Simplex Virus, varicella-zoster, and CMV prophylaxis post-transplantation. Administerable orally, topically, or intravenously, its pharmacokinetic profile necessitates careful consideration in patients with compromised renal or hepatic function due to potential nephrotoxicity and thrombocytopenia. While demonstrating an acceptable safety margin during gestation and lactation, adverse events such as gastrointestinal discomfort and diarrhea are common. Its inclusion in the WHO's Essential Medicines list underscores its global pivotal role in antiviral therapy, with its generic accessibility enhancing universal healthcare implementation.\n\nDRUG 2 NAME: Ibuprofen\nDRUG 2 BACKGROUND INFORMATION: Ibuprofen, a widely utilized nonsteroidal anti-inflammatory drug (NSAID), exerts its therapeutic effects primarily through the attenuation of cyclooxygenase (COX) enzymatic activity, thereby reducing the biosynthesis of pro-inflammatory prostaglandins. Indicated for alleviating nociceptive and inflammatory perturbations such as dysmenorrhea, migrainous episodes, and inflammatory arthropathies, ibuprofen demonstrates notable pharmacokinetics with onset of action within one hour post administration via oral or parenteral routes. Despite its efficacy, ibuprofen's pharmacodynamic profile correlates with several adverse outcomes, notably gastrointestinal mucosal irritation leading to potential bleeding, renal impairment with prolonged administration, and rare hepatotoxicity. It possesses a variable cardiovascular risk profile, posing increased myocardial infarction risk at higher dosages. Notably, ibuprofen is contraindicated in advanced gestational periods due to its deleterious fetal effects and can exacerbate asthmatic conditions. Although it constitutes a less potent anti-inflammatory than other NSAIDs, its inclusion in the WHO's List of Essential Medicines underscores its clinical utility across various domains. Despite its prevalence, ongoing vigilance is advised due to its side effect spectrum.\n\nDRUG 3 NAME: Metoprolol\nDRUG 3 BACKGROUND INFORMATION: Metoprolol, a cardioselective \u03b21-adrenergic receptor antagonist, is clinically utilized in the management of angina pectoris, hypertension, tachyarrhythmias, post-myocardial infarction secondary prophylaxis, and migraine prophylaxis. Its therapeutic efficacy is mediated via negative chronotropic and inotropic effects which result in decreased myocardial oxygen demand and improved exercise tolerance. The pharmacokinetics of metoprolol is influenced by hepatic cytochrome P450 2D6 isoenzyme variability leading to significant interpatient variability in drug metabolism, necessitating individualized dosing. Adverse effects prominently include insomnia, asthenia, presyncope, and gastrointestinal disturbances, with higher doses presenting risk for pronounced toxicity. Though teratogenic risk during pregnancy has not been conclusively excluded, its excretion into breast milk is considered clinically insignificant. Metoprolol is widely dispensed, reflecting its inclusion in the WHO's Essential Medicines, and its prescription frequency underscores its pivotal role in cardiovascular therapeutics.\n\nPROTEIN NAME: HRH3\nPROTEIN BACKGROUND INFORMATION: Histamine H3 receptors are expressed in the central nervous system and to a lesser extent the peripheral nervous system, where they act as autoreceptors in presynaptic histaminergic neurons and control histamine turnover by feedback inhibition of histamine synthesis and release. The H3 receptor has also been shown to presynaptically inhibit the release of a number of other neurotransmitters (i.e. it acts as an inhibitory heteroreceptor) including, but probably not limited to dopamine, GABA, acetylcholine, noradrenaline, histamine and serotonin.\nThe gene sequence for H3 receptors expresses only about 22% and 20% homology with both H1 and H2 receptors respectively.\nThere is much interest in the histamine H3 receptor as a potential therapeutic target because of its involvement in the neuronal mechanism behind many cognitive disorders and especially its location in the central nervous system.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Aciclovir-cholecystitis-Ibuprofen\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Ibuprofen-cholecystitis-Metoprolol\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Metoprolol-binding and activation-HRH3"}]}}
{"custom_id": "Cimetidine-Labetalol-Metoprolol-GRPR-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Cimetidine\nDRUG 1 BACKGROUND INFORMATION: Cimetidine, sold under the brand name Tagamet among others, is a histamine H2 receptor antagonist that inhibits stomach acid production. It is mainly used in the treatment of heartburn and peptic ulcers.\nWith the development of proton pump inhibitors, such as omeprazole, approved for the same indications, cimetidine is available as an over-the-counter formulation to prevent heartburn or acid indigestion, along with the other H2-receptor antagonists.\nCimetidine was developed in 1971 and came into commercial use in 1977. Cimetidine was approved in the United Kingdom in 1976, and was approved in the United States by the Food and Drug Administration in 1979.\n\nDRUG 2 NAME: Labetalol\nDRUG 2 BACKGROUND INFORMATION: Labetalol is a medication used to treat high blood pressure and in long term management of angina. This includes essential hypertension, hypertensive emergencies, and hypertension of pregnancy. In essential hypertension it is generally less preferred than a number of other blood pressure medications. It can be given by mouth or by injection into a vein.\nCommon side effects include low blood pressure with standing, dizziness, feeling tired, and nausea. Serious side effects may include low blood pressure, liver problems, heart failure, and bronchospasm. Use appears safe in the latter part of pregnancy and it is not expected to cause problems during breastfeeding. It works by blocking the activation of \u03b2- and \u03b1-adrenergic receptors.\nLabetalol was patented in 1966 and came into medical use in 1977. It is available as a generic medication. In 2022, it was the 215th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG 3 NAME: Metoprolol\nDRUG 3 BACKGROUND INFORMATION: Metoprolol, a cardioselective \u03b21-adrenergic receptor antagonist, is clinically utilized in the management of angina pectoris, hypertension, tachyarrhythmias, post-myocardial infarction secondary prophylaxis, and migraine prophylaxis. Its therapeutic efficacy is mediated via negative chronotropic and inotropic effects which result in decreased myocardial oxygen demand and improved exercise tolerance. The pharmacokinetics of metoprolol is influenced by hepatic cytochrome P450 2D6 isoenzyme variability leading to significant interpatient variability in drug metabolism, necessitating individualized dosing. Adverse effects prominently include insomnia, asthenia, presyncope, and gastrointestinal disturbances, with higher doses presenting risk for pronounced toxicity. Though teratogenic risk during pregnancy has not been conclusively excluded, its excretion into breast milk is considered clinically insignificant. Metoprolol is widely dispensed, reflecting its inclusion in the WHO's Essential Medicines, and its prescription frequency underscores its pivotal role in cardiovascular therapeutics.\n\nPROTEIN NAME: GRPR\nPROTEIN BACKGROUND INFORMATION: The gastrin-releasing peptide receptor (GRPR), now properly known as BB2  is a G protein-coupled receptor whose endogenous ligand is gastrin releasing peptide. In humans it is highly expressed in the pancreas and is also expressed in the stomach, adrenal cortex and brain.\nGastrin-releasing peptide (GRP) regulates numerous functions of the gastrointestinal and central nervous systems, including release of gastrointestinal hormones, smooth muscle cell contraction, and epithelial cell proliferation and is a potent mitogen for neoplastic tissues. The effects of GRP are mediated through the gastrin-releasing peptide receptor. This receptor is a glycosylated, 7-transmembrane G-protein coupled receptor that activates the phospholipase C signaling pathway. The receptor is aberrantly expressed in numerous cancers such as those of the lung, colon, and prostate. An individual with autism and multiple exostoses was found to have a balanced translocation between chromosome 8 and a chromosome X breakpoint located within the gastrin-releasing peptide receptor gene.\nThe transcription factor CREB is a regulator of human GRP-R expression in colon cancer.\nActivation MOR1D\u2010GRPR heteromers in the spinal cord mediate the common troublesome opioid-induced itch.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Cimetidine-back injury-Labetalol\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Labetalol-apoplexy-Metoprolol\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Metoprolol-binding and activation-GRPR"}]}}
{"custom_id": "Ketorolac-Ondansetron-Salmeterol-ADRB3-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Ketorolac\nDRUG 1 BACKGROUND INFORMATION: Ketorolac, marketed under names such as Toradol, Acular, and Sprix, is a potent nonsteroidal anti-inflammatory drug (NSAID) indicated for the management of moderate to severe nociceptive pain with a treatment limitation not exceeding six to seven days, varying by country guidelines. Administration routes include oral, nasal, intravenous, intramuscular, and ophthalmic, with onset of analgesia within one hour and duration of efficacy up to eight hours. Its mechanism of action involves the inhibition of cyclooxygenase enzymes 1 and 2 (COX-1 and COX-2), resulting in the attenuation of prostaglandin synthesis, and it possesses ancillary antipyretic properties. Common adverse reactions encompass sedation, vertigo, gastrointestinal discomfort, and emesis, while severe complications may involve gastrointestinal hemorrhage, nephrotoxicity, myocardial infarction, bronchospasm, heart failure, and hypersensitivity reactions. It is contraindicated in later stages of gestation and lactation due to potential fetal and neonatal risks. Despite its initial appeal as a non-opioid analgesic alternative with lower addictive potential, its correlation with significant adverse outcomes such as gastrointestinal and renal sequelae led to market withdrawal in specific regions like Germany. As a robust prostaglandin synthesis inhibitor, ketorolac compromises renal autoregulation under conditions of hemodynamic stress or elevated catecholamine states, limiting its utilization in those with underlying renal or cardiovascular vulnerabilities.\n\nDRUG 2 NAME: Ondansetron\nDRUG 2 BACKGROUND INFORMATION: Ondansetron, a potent antiemetic utilized to mitigate nausea and emesis associated with chemotherapy, radiation, migraine, and surgical procedures, exerts its pharmacological action as a selective serotonin 5-HT3 receptor antagonist. Absence of affinity for dopaminergic and muscarinic acetylcholine receptors precludes extrapyramidal side effects such as akathisia. Administered via oral, intravenous, or intramuscular routes, ondansetron's pharmacokinetic profile is characterized by hepatic metabolism and renal excretion. Adverse effects frequently reported encompass gastrointestinal dysmotility manifesting as diarrhea or constipation, central nervous system manifestations including headache and somnolence, and dermal pruritus, with more severe toxicities including QT interval prolongation on electrocardiographic assessment and anaphylaxis. Although the teratogenic risk is minimal, comprehensive teratological data in gravid populations remain insufficient. Recognized on the WHO's List of Essential Medicines, ondansetron is extensively prescribed, highlighting its clinical utility and incorporation into treatment protocols, with significant utilization confirmed by its high prescription frequency in the United States.\n\nDRUG 3 NAME: Salmeterol\nDRUG 3 BACKGROUND INFORMATION: Salmeterol is a long-acting \u03b22 adrenergic receptor agonist (LABA) used in the treatment and prevention of asthma symptoms and control of chronic obstructive pulmonary disease (COPD) symptoms. Symptoms of bronchospasm include shortness of breath, wheezing, coughing and chest tightness. It is also used to prevent breathing difficulties during exercise (exercise-induced bronchoconstriction).\nIt was patented in 1983 and came into medical use in 1990. It is marketed as Serevent in the US. It is available as a dry-powder inhaler (DPI) that releases a powdered form of the drug. It was previously available as a metered-dose inhaler (MDI) but was discontinued in the US in 2002. It is available as an MDI in other countries as of 2020.\n\nPROTEIN NAME: ADRB3\nPROTEIN BACKGROUND INFORMATION: The beta-3 adrenergic receptor (\u03b23-adrenoceptor), also known as ADRB3, is a beta-adrenergic receptor, and also denotes the human gene encoding it.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Ketorolac-Adenopathy-Ondansetron\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Ondansetron-cholecystitis-Salmeterol\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Salmeterol-binding and activation-ADRB3"}]}}
{"custom_id": "Doxazosin-Metoprolol-Perphenazine-ADRA2A-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Doxazosin\nDRUG 1 BACKGROUND INFORMATION: Doxazosin, sold under the brand name Cardura among others, is a medication used to treat symptoms of benign prostatic hyperplasia (enlarged prostate), hypertension (high blood pressure), and post-traumatic stress disorder (PTSD). For high blood pressure, it is a less preferred option. It is taken by mouth.\nCommon side effects include dizziness, sleepiness, swelling, nausea, shortness of breath, and abdominal pain. Severe side effects may include low blood pressure with standing, an irregular heart beat, and priapism. It is a selective \u03b11-adrenergic blocker in the quinazoline class of compounds.\nDoxazosin was patented in 1977 and came into medical use in 1988. It is available as a generic medication. In 2022, it was the 180th most commonly prescribed medication in the United States, with more than 2 million prescriptions.\n\nDRUG 2 NAME: Metoprolol\nDRUG 2 BACKGROUND INFORMATION: Metoprolol, a cardioselective \u03b21-adrenergic receptor antagonist, is clinically utilized in the management of angina pectoris, hypertension, tachyarrhythmias, post-myocardial infarction secondary prophylaxis, and migraine prophylaxis. Its therapeutic efficacy is mediated via negative chronotropic and inotropic effects which result in decreased myocardial oxygen demand and improved exercise tolerance. The pharmacokinetics of metoprolol is influenced by hepatic cytochrome P450 2D6 isoenzyme variability leading to significant interpatient variability in drug metabolism, necessitating individualized dosing. Adverse effects prominently include insomnia, asthenia, presyncope, and gastrointestinal disturbances, with higher doses presenting risk for pronounced toxicity. Though teratogenic risk during pregnancy has not been conclusively excluded, its excretion into breast milk is considered clinically insignificant. Metoprolol is widely dispensed, reflecting its inclusion in the WHO's Essential Medicines, and its prescription frequency underscores its pivotal role in cardiovascular therapeutics.\n\nDRUG 3 NAME: Perphenazine\nDRUG 3 BACKGROUND INFORMATION: Perphenazine is a typical antipsychotic drug.  Chemically, it is classified as a piperazinyl phenothiazine. Originally marketed in the United States as Trilafon, it has been in clinical use for decades.\nPerphenazine is roughly ten times as potent as chlorpromazine at the dopamine-2 (D2) receptor; thus perphenazine is considered a medium-potency antipsychotic.\n\nPROTEIN NAME: ADRA2A\nPROTEIN BACKGROUND INFORMATION: The alpha-2A adrenergic receptor (\u03b12A adrenoceptor), also known as ADRA2A, is an \u03b12-adrenergic receptor, and also denotes the human gene encoding it.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Doxazosin-gastric inflammation-Metoprolol\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Metoprolol-insulin dependent diabetes mellitus-Perphenazine\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Perphenazine-binding and inhibition-ADRA2A"}]}}
{"custom_id": "acetazolamide-Haloperidol-oxybutynin-CHRM1-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: acetazolamide\nDRUG 1 BACKGROUND INFORMATION: Acetazolamide, marketed under the trade name Diamox, serves as a versatile pharmaceutical agent within the realm of carbonic anhydrase inhibitors, effectively modulating intraocular pressure via the diminution of aqueous humor production and osmolality. Its clinical utility spans across conditions such as glaucoma\u2014both open-angle and acute angle closure\u2014epilepsy, acute mountain sickness, periodic paralysis, idiopathic intracranial hypertension, and heart failure, with an ancillary role in urinary alkalinization. Therapeutic administration is achievable through oral and intravenous modalities. Mechanistically, acetazolamide exerts its effects by disrupting the equilibria of carbon dioxide hydration and subsequent bicarbonate ion production, thereby reducing intracellular hydrogen ion availability. The pharmacodynamic profile encompasses neuro-sensory side effects like paresthesia and tinnitus, alongside anorexia, emesis, and somnolence. Contraindications are notable in individuals with renal or hepatic impairment, and those with hypersensitivity to sulfonamide derivatives. As a diuretic and enzymatic inhibitor, it holds a position on the WHO's List of Essential Medicines, emphasizing its critical global accessibility as a generic formulation.\n\nDRUG 2 NAME: Haloperidol\nDRUG 2 BACKGROUND INFORMATION: Haloperidol, a butyrophenone derivative, exerts its therapeutic efficacy as a typical antipsychotic primarily through potent antagonism of central dopaminergic D2 receptors, ameliorating positive psychotic symptoms in conditions such as schizophrenia, Tourette syndrome, acute mania in bipolar disorder, delirium, and alcohol withdrawal-related hallucinations. Exhibiting rapid onset post-oral or parenteral administration, haloperidol can be deployed via bi-weekly intramuscular depot injections for long-term management of schizophrenia spectrum disorders in non-compliant patients. While efficacious, haloperidol is implicated in extrapyramidal side effects, notably irreversible tardive dyskinesia and akathisia, along with the rare but severe neuroleptic malignant syndrome and dose-dependent QT interval prolongation, the latter significantly observed with intravenous routes. Its contraindication in patients with Parkinson's disease and increased mortality risk in dementia-related psychosis underscore the necessity for judicious application. Adverse fetal outcomes restrict its use during pregnancy. Despite these safety concerns, haloperidol maintains its status as an essential medication per the World Health Organization's compendium, continually ranking among the most prescribed antipsychotics in clinical practice.\n\nDRUG 3 NAME: oxybutynin\nDRUG 3 BACKGROUND INFORMATION: Oxybutynin, marketed as Ditropan, is a quintessential anticholinergic agent employed predominantly for the amelioration of overactive bladder symptoms, capitalizing on its potent antimuscarinic properties that effectively circumvent acetylcholine-mediated smooth muscle contractions. Its pharmacotherapeutic action, analogous to tolterodine, darifenacin, and solifenacin, renders it a superior first-line therapeutic option due to its robust safety and efficacy profile over prolonged usage, despite plausible off-label utilizations in hyperhidrosis management. Contrarily, its application for pediatric nocturnal enuresis has seen diminished prevalence, given its questionable efficacy. Administrable orally or transdermally, oxybutynin's pharmacokinetic profile necessitates vigilance regarding adverse effects such as xerostomia, gastrointestinal hypomotility, and thermoregulatory dysfunction, encompassing severe sequelae like urinary retention and thermophilic impairments manifesting as heat stroke. Its teratogenic and lactogenic safety paradigms remain speculative, underscoring the need for judicious administration during pregnancy and lactation. As a generically available pharmacologic entity, it maintains substantial prescription frequency, embodying a pivotal role in managing cholinergic-mediated urological disorders.\n\nPROTEIN NAME: CHRM1\nPROTEIN BACKGROUND INFORMATION: The muscarinic acetylcholine receptor M1, also known as the cholinergic receptor, muscarinic 1, is a muscarinic receptor that in humans is encoded by the CHRM1 gene. It is localized to 11q13.\nThis receptor is found mediating slow EPSP at the ganglion in the postganglionic nerve, is common in exocrine glands and in the CNS.\nIt is predominantly found bound to G proteins of class Gq that use upregulation of phospholipase C and, therefore, inositol trisphosphate and intracellular calcium as a signalling pathway. A receptor so bound would not be susceptible to CTX or PTX. However, Gi (causing a downstream decrease in cAMP) and Gs (causing an increase in cAMP) have also been shown to be involved in interactions in certain tissues, and so would be susceptible to PTX and CTX respectively.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): acetazolamide-confusion-Haloperidol\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Haloperidol-apoplexy-oxybutynin\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): oxybutynin-binding and inhibition-CHRM1"}]}}
{"custom_id": "acetazolamide-Famotidine-Pilocarpine-CHRM1-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: acetazolamide\nDRUG 1 BACKGROUND INFORMATION: Acetazolamide, marketed under the trade name Diamox, serves as a versatile pharmaceutical agent within the realm of carbonic anhydrase inhibitors, effectively modulating intraocular pressure via the diminution of aqueous humor production and osmolality. Its clinical utility spans across conditions such as glaucoma\u2014both open-angle and acute angle closure\u2014epilepsy, acute mountain sickness, periodic paralysis, idiopathic intracranial hypertension, and heart failure, with an ancillary role in urinary alkalinization. Therapeutic administration is achievable through oral and intravenous modalities. Mechanistically, acetazolamide exerts its effects by disrupting the equilibria of carbon dioxide hydration and subsequent bicarbonate ion production, thereby reducing intracellular hydrogen ion availability. The pharmacodynamic profile encompasses neuro-sensory side effects like paresthesia and tinnitus, alongside anorexia, emesis, and somnolence. Contraindications are notable in individuals with renal or hepatic impairment, and those with hypersensitivity to sulfonamide derivatives. As a diuretic and enzymatic inhibitor, it holds a position on the WHO's List of Essential Medicines, emphasizing its critical global accessibility as a generic formulation.\n\nDRUG 2 NAME: Famotidine\nDRUG 2 BACKGROUND INFORMATION: Famotidine, sold under the brand name Pepcid among others, is a histamine H2 receptor antagonist medication that decreases stomach acid production. It is used to treat peptic ulcer disease, gastroesophageal reflux disease, and Zollinger\u2013Ellison syndrome. It is taken by mouth or by injection into a vein. It begins working within an hour.\nCommon side effects include headache, abdominal pain, diarrhea or constipation, and dizziness. Serious side effects may include pneumonia and seizures. Use in pregnancy appears safe but has not been well studied, while use during breastfeeding is not recommended.\nFamotidine was patented in 1979 and came into medical use in 1985. It is available as a generic medication. In 2022, it was the 49th most commonly prescribed medication in the United States, with more than 13 million prescriptions.\n\nDRUG 3 NAME: Pilocarpine\nDRUG 3 BACKGROUND INFORMATION: Pilocarpine, a muscarinic agonist in the miotics pharmacological class, exerts its therapeutic effects primarily through cholinergic receptor activation, specifically targeting muscarinic acetylcholine receptors to facilitate aqueous humor outflow via the trabecular meshwork. While its ophthalmic formulation is indicated for acute intervention in angle-closure glaucoma, ocular hypertension, and primary open-angle glaucoma, its utility is limited in chronic management due to adverse effects such as ocular irritation, lacrimation increase, cephalalgia, and transient visual disturbances, with potential complications including retinal detachment and hypersensitivity reactions. Pilocarpine's pharmacodynamics involve onset within one hour with effects persisting up to 24 hours. Systemic administration is employed in xerostomia management secondary to Sj\u00f6gren syndrome or post-radiation sequelae. Nonetheless, its use contraindicated during pregnancy underscores its safety profile concerns. Initially derived from Pilocarpus spp., pilocarpine remains inextricably linked to its historical provenance yet maintains its clinical relevance as delineated in the WHO Essential Medicines list.\n\nPROTEIN NAME: CHRM1\nPROTEIN BACKGROUND INFORMATION: The muscarinic acetylcholine receptor M1, also known as the cholinergic receptor, muscarinic 1, is a muscarinic receptor that in humans is encoded by the CHRM1 gene. It is localized to 11q13.\nThis receptor is found mediating slow EPSP at the ganglion in the postganglionic nerve, is common in exocrine glands and in the CNS.\nIt is predominantly found bound to G proteins of class Gq that use upregulation of phospholipase C and, therefore, inositol trisphosphate and intracellular calcium as a signalling pathway. A receptor so bound would not be susceptible to CTX or PTX. However, Gi (causing a downstream decrease in cAMP) and Gs (causing an increase in cAMP) have also been shown to be involved in interactions in certain tissues, and so would be susceptible to PTX and CTX respectively.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): acetazolamide-Back Ache-Famotidine\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Famotidine-deglutition disorder-Pilocarpine\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Pilocarpine-binding and activation-CHRM1"}]}}
{"custom_id": "Naproxen-Risedronic acid-Trazodone-ADRA2C-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: Risedronic acid\nDRUG 2 BACKGROUND INFORMATION: Risedronic acid, often used as its sodium salt risedronate sodium, is a bisphosphonate. It slows down the cells which break down bone. It's used to treat or prevent osteoporosis, and treat Paget's disease of bone. It is taken by mouth.\nIt was patented in 1984 and approved for medical use in 1998.\n\nDRUG 3 NAME: Trazodone\nDRUG 3 BACKGROUND INFORMATION: Trazodone is an antidepressant medication used to treat major depressive disorder, anxiety disorders, and insomnia. It is a phenylpiperazine compound of the serotonin antagonist and reuptake inhibitor (SARI) class. The medication is taken orally.\nCommon side effects include dry mouth, feeling faint, vomiting, and headache. More serious side effects may include suicide, mania, irregular heart rate, and pathologically prolonged erections. It is unclear if use during pregnancy or breastfeeding is safe.  Trazodone also has sedating effects.\nTrazodone was approved for medical use in the United States in 1981. It is available as a generic medication. In 2022, it was the eighteenth most commonly prescribed medication in the United States, with more than 27 million prescriptions.\n\nPROTEIN NAME: ADRA2C\nPROTEIN BACKGROUND INFORMATION: The alpha-2C adrenergic receptor (\u03b12C adrenoceptor), also known as ADRA2C, is an alpha-2 adrenergic receptor, and also denotes the human gene encoding it.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Naproxen-erythema-Risedronic acid\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Risedronic acid-failure to thrive-Trazodone\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Trazodone-binding and inhibition-ADRA2C"}]}}
{"custom_id": "Aciclovir-Citalopram-Fluphenazine-ADRA2A-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Aciclovir\nDRUG 1 BACKGROUND INFORMATION: Aciclovir, an antiviral guanosine analogue, exhibits its therapeutic efficacy predominantly by inhibiting viral DNA polymerase through its metabolization to aciclovir triphosphate, resulting in the cessation of herpesvirus DNA elongation across Herpes Simplex Virus, varicella-zoster, and CMV prophylaxis post-transplantation. Administerable orally, topically, or intravenously, its pharmacokinetic profile necessitates careful consideration in patients with compromised renal or hepatic function due to potential nephrotoxicity and thrombocytopenia. While demonstrating an acceptable safety margin during gestation and lactation, adverse events such as gastrointestinal discomfort and diarrhea are common. Its inclusion in the WHO's Essential Medicines list underscores its global pivotal role in antiviral therapy, with its generic accessibility enhancing universal healthcare implementation.\n\nDRUG 2 NAME: Citalopram\nDRUG 2 BACKGROUND INFORMATION: Citalopram, a chiral bicyclic phthalane derivative and selective serotonin reuptake inhibitor (SSRI), is primarily employed in the pharmacotherapy of major depressive disorder, obsessive-compulsive disorder, panic disorder, and social phobia through modulation of serotonergic neurotransmission. The therapeutic latency ranges from one to four weeks post-administration. It is predominantly administered orally, though parenteral administration via intravenous injection is utilized in specific regions to expedite therapeutic onset. The pharmacokinetic profile of citalopram encompasses hepatic metabolism predominantly via CYP2C19, CYP3A4, and CYP2D6, yielding demethylated metabolites. It is imperative to monitor for adverse reactions, including, but not limited to, gastrointestinal disturbances, insomnia, sexual dysfunction, tremors, somnolence, hyperhidrosis, serotonin toxicity, and cardiotoxicity as manifested by QT interval prolongation. Contraindications entail concurrent MAO inhibitor therapy due to risk of serotonin syndrome and potential teratogenicity warrants cautious use in pregnancy. The potential for exacerbating suicidality in individuals under 25 necessitates vigilant monitoring. Citalopram's clinical prominence is evidenced by its inclusion in the WHO's List of Essential Medicines and its extensive prescribing frequency in the United States, underscoring its integral role in psychiatric treatment regimens.\n\nDRUG 3 NAME: Fluphenazine\nDRUG 3 BACKGROUND INFORMATION: Fluphenazine is a high-affinity typical antipsychotic of the phenothiazine cohort primarily prescribed for chronic psychotic disorders such as schizophrenia, offering efficacy comparable to chlorpromazine. Administered via oral, intramuscular, subcutaneous routes\u2014or as a long-acting depot, fluphenazine decanoate\u2014this compound exhibits prolonged dopaminergic antagonism with an extended half-life conducive to monthly dosing regimens. Notably contraindicated in severe depressive states, its pharmacological action is ascribed to dopamine receptor blockade, though precision in its mechanism remains indeterminate. The pharmacodynamic profile of fluphenazine entails extrapyramidal symptoms, somnolence, depressive mood alterations, and metabolic side effects, with grave adverse events encompassing neuroleptic malignant syndrome, agranulocytosis, and irreversible tardive dyskinesia. Moreover, in the geriatric cohort with dementia-related psychoses, mortality risk is potentiated. Prolactin secretion perturbations may elicit galactorrhea, gynecomastia, erectile dysfunction, and amenorrhea, with teratogenic safety in gestation unresolved. Chronic administration associates with hepatocellular enzyme elevation in a substantial patient subset. Despite its broad utilization reflected in its inclusion on the World Health Organization's Essential Medicines list, its production cessation in some regions underscores its dynamic availability landscape.\n\nPROTEIN NAME: ADRA2A\nPROTEIN BACKGROUND INFORMATION: The alpha-2A adrenergic receptor (\u03b12A adrenoceptor), also known as ADRA2A, is an \u03b12-adrenergic receptor, and also denotes the human gene encoding it.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Aciclovir-methaemoglobinaemia-Citalopram\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Citalopram-cholecystitis-Fluphenazine\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Fluphenazine-binding and inhibition-ADRA2A"}]}}
{"custom_id": "Naproxen-Cetirizine-Terazosin-ADRA1A-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: Cetirizine\nDRUG 2 BACKGROUND INFORMATION: Cetirizine, a second-generation selective H1 antihistaminergic agent, is primarily administered orally for the amelioration of allergic rhinitis, dermatitis, and urticaria, exerting its pharmacodynamic effects predominantly extracellularly, thereby minimizing central nervous system penetration and consequent sedative effects typical of first-generation antihistamines such as diphenhydramine. Its clinical onset transpires within thirty minutes, maintaining therapeutic efficacy for approximately 24 hours with an adverse effect profile that includes somnolence, xerostomia, cephalalgia, and abdominal discomfort, albeit with a diminished proclivity for sedation compared to its first-generation counterparts due to its peripheral selectivity. Amongst its second-generation analogs, cetirizine exhibits a comparatively higher incidence of somnolence vis-\u00e0-vis fexofenadine and loratadine. It is contraindicated in lactation but permissible during gestation and extends its utility to pediatric cohorts with caution advised regarding potential somnolence. Being generically available and included in the World Health Organization's List of Essential Medicines, cetirizine\u2019s broad prescriptive prevalence, as evidenced by over 13 million US prescriptions in 2022, underscores its efficacy and widespread utilitarian value in allergy management.\n\nDRUG 3 NAME: Terazosin\nDRUG 3 BACKGROUND INFORMATION: Terazosin, sold under the brand name Hytrin among others, is a medication used to treat symptoms of an enlarged prostate and high blood pressure. For high blood pressure, it is a less preferred option. It is taken by mouth.\nCommon side effects include dizziness, headache, feeling tired, swelling, nausea, and low blood pressure with standing. Severe side effects may include priapism and low blood pressure. Prostate cancer should be ruled out before starting treatment. It is an alpha-1 blocker and works by relaxing blood vessels and the opening of the bladder.\nTerazosin was patented in 1975 and came into medical use in 1985. It is available as a generic medication. In 2021, it was the 234th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nPROTEIN NAME: ADRA1A\nPROTEIN BACKGROUND INFORMATION: The alpha-1A adrenergic receptor (\u03b11A adrenoreceptor), also known as ADRA1A, formerly known also as the  alpha-1C adrenergic receptor, is an alpha-1 adrenergic receptor, and also denotes the human gene encoding it. There is no longer a subtype \u03b11C receptor. At one time, there was a subtype known as \u03b11C, but it was found to be identical to the previously discovered \u03b11A receptor subtype. To avoid confusion, the naming convention was continued with the letter D.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Naproxen-cholecystitis-Cetirizine\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Cetirizine-elevated erythrocyte sedimentation rate-Terazosin\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Terazosin-binding and inhibition-ADRA1A"}]}}
{"custom_id": "Famotidine-Metolazone-Metoprolol-HRH3-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Famotidine\nDRUG 1 BACKGROUND INFORMATION: Famotidine, sold under the brand name Pepcid among others, is a histamine H2 receptor antagonist medication that decreases stomach acid production. It is used to treat peptic ulcer disease, gastroesophageal reflux disease, and Zollinger\u2013Ellison syndrome. It is taken by mouth or by injection into a vein. It begins working within an hour.\nCommon side effects include headache, abdominal pain, diarrhea or constipation, and dizziness. Serious side effects may include pneumonia and seizures. Use in pregnancy appears safe but has not been well studied, while use during breastfeeding is not recommended.\nFamotidine was patented in 1979 and came into medical use in 1985. It is available as a generic medication. In 2022, it was the 49th most commonly prescribed medication in the United States, with more than 13 million prescriptions.\n\nDRUG 2 NAME: Metolazone\nDRUG 2 BACKGROUND INFORMATION: Metolazone is a thiazide-like diuretic marketed under the brand names Zytanix, Metoz, Zaroxolyn, and Mykrox. It is primarily used to treat congestive heart failure and high blood pressure. Metolazone indirectly decreases the amount of water reabsorbed into the bloodstream by the kidney, so that blood volume decreases and urine volume increases. This lowers blood pressure and prevents excess fluid accumulation in heart failure. Metolazone is sometimes used together with loop diuretics such as furosemide or bumetanide, but these highly effective combinations can lead to dehydration and electrolyte abnormalities.\nIt was patented in 1966 and approved for medical use in 1974.\n\nDRUG 3 NAME: Metoprolol\nDRUG 3 BACKGROUND INFORMATION: Metoprolol, a cardioselective \u03b21-adrenergic receptor antagonist, is clinically utilized in the management of angina pectoris, hypertension, tachyarrhythmias, post-myocardial infarction secondary prophylaxis, and migraine prophylaxis. Its therapeutic efficacy is mediated via negative chronotropic and inotropic effects which result in decreased myocardial oxygen demand and improved exercise tolerance. The pharmacokinetics of metoprolol is influenced by hepatic cytochrome P450 2D6 isoenzyme variability leading to significant interpatient variability in drug metabolism, necessitating individualized dosing. Adverse effects prominently include insomnia, asthenia, presyncope, and gastrointestinal disturbances, with higher doses presenting risk for pronounced toxicity. Though teratogenic risk during pregnancy has not been conclusively excluded, its excretion into breast milk is considered clinically insignificant. Metoprolol is widely dispensed, reflecting its inclusion in the WHO's Essential Medicines, and its prescription frequency underscores its pivotal role in cardiovascular therapeutics.\n\nPROTEIN NAME: HRH3\nPROTEIN BACKGROUND INFORMATION: Histamine H3 receptors are expressed in the central nervous system and to a lesser extent the peripheral nervous system, where they act as autoreceptors in presynaptic histaminergic neurons and control histamine turnover by feedback inhibition of histamine synthesis and release. The H3 receptor has also been shown to presynaptically inhibit the release of a number of other neurotransmitters (i.e. it acts as an inhibitory heteroreceptor) including, but probably not limited to dopamine, GABA, acetylcholine, noradrenaline, histamine and serotonin.\nThe gene sequence for H3 receptors expresses only about 22% and 20% homology with both H1 and H2 receptors respectively.\nThere is much interest in the histamine H3 receptor as a potential therapeutic target because of its involvement in the neuronal mechanism behind many cognitive disorders and especially its location in the central nervous system.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Famotidine-right heart failure-Metolazone\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Metolazone-cholecystitis-Metoprolol\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Metoprolol-binding and activation-HRH3"}]}}
{"custom_id": "acetazolamide-Citalopram-Fluphenazine-ADRA1A-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: acetazolamide\nDRUG 1 BACKGROUND INFORMATION: Acetazolamide, marketed under the trade name Diamox, serves as a versatile pharmaceutical agent within the realm of carbonic anhydrase inhibitors, effectively modulating intraocular pressure via the diminution of aqueous humor production and osmolality. Its clinical utility spans across conditions such as glaucoma\u2014both open-angle and acute angle closure\u2014epilepsy, acute mountain sickness, periodic paralysis, idiopathic intracranial hypertension, and heart failure, with an ancillary role in urinary alkalinization. Therapeutic administration is achievable through oral and intravenous modalities. Mechanistically, acetazolamide exerts its effects by disrupting the equilibria of carbon dioxide hydration and subsequent bicarbonate ion production, thereby reducing intracellular hydrogen ion availability. The pharmacodynamic profile encompasses neuro-sensory side effects like paresthesia and tinnitus, alongside anorexia, emesis, and somnolence. Contraindications are notable in individuals with renal or hepatic impairment, and those with hypersensitivity to sulfonamide derivatives. As a diuretic and enzymatic inhibitor, it holds a position on the WHO's List of Essential Medicines, emphasizing its critical global accessibility as a generic formulation.\n\nDRUG 2 NAME: Citalopram\nDRUG 2 BACKGROUND INFORMATION: Citalopram, a chiral bicyclic phthalane derivative and selective serotonin reuptake inhibitor (SSRI), is primarily employed in the pharmacotherapy of major depressive disorder, obsessive-compulsive disorder, panic disorder, and social phobia through modulation of serotonergic neurotransmission. The therapeutic latency ranges from one to four weeks post-administration. It is predominantly administered orally, though parenteral administration via intravenous injection is utilized in specific regions to expedite therapeutic onset. The pharmacokinetic profile of citalopram encompasses hepatic metabolism predominantly via CYP2C19, CYP3A4, and CYP2D6, yielding demethylated metabolites. It is imperative to monitor for adverse reactions, including, but not limited to, gastrointestinal disturbances, insomnia, sexual dysfunction, tremors, somnolence, hyperhidrosis, serotonin toxicity, and cardiotoxicity as manifested by QT interval prolongation. Contraindications entail concurrent MAO inhibitor therapy due to risk of serotonin syndrome and potential teratogenicity warrants cautious use in pregnancy. The potential for exacerbating suicidality in individuals under 25 necessitates vigilant monitoring. Citalopram's clinical prominence is evidenced by its inclusion in the WHO's List of Essential Medicines and its extensive prescribing frequency in the United States, underscoring its integral role in psychiatric treatment regimens.\n\nDRUG 3 NAME: Fluphenazine\nDRUG 3 BACKGROUND INFORMATION: Fluphenazine is a high-affinity typical antipsychotic of the phenothiazine cohort primarily prescribed for chronic psychotic disorders such as schizophrenia, offering efficacy comparable to chlorpromazine. Administered via oral, intramuscular, subcutaneous routes\u2014or as a long-acting depot, fluphenazine decanoate\u2014this compound exhibits prolonged dopaminergic antagonism with an extended half-life conducive to monthly dosing regimens. Notably contraindicated in severe depressive states, its pharmacological action is ascribed to dopamine receptor blockade, though precision in its mechanism remains indeterminate. The pharmacodynamic profile of fluphenazine entails extrapyramidal symptoms, somnolence, depressive mood alterations, and metabolic side effects, with grave adverse events encompassing neuroleptic malignant syndrome, agranulocytosis, and irreversible tardive dyskinesia. Moreover, in the geriatric cohort with dementia-related psychoses, mortality risk is potentiated. Prolactin secretion perturbations may elicit galactorrhea, gynecomastia, erectile dysfunction, and amenorrhea, with teratogenic safety in gestation unresolved. Chronic administration associates with hepatocellular enzyme elevation in a substantial patient subset. Despite its broad utilization reflected in its inclusion on the World Health Organization's Essential Medicines list, its production cessation in some regions underscores its dynamic availability landscape.\n\nPROTEIN NAME: ADRA1A\nPROTEIN BACKGROUND INFORMATION: The alpha-1A adrenergic receptor (\u03b11A adrenoreceptor), also known as ADRA1A, formerly known also as the  alpha-1C adrenergic receptor, is an alpha-1 adrenergic receptor, and also denotes the human gene encoding it. There is no longer a subtype \u03b11C receptor. At one time, there was a subtype known as \u03b11C, but it was found to be identical to the previously discovered \u03b11A receptor subtype. To avoid confusion, the naming convention was continued with the letter D.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): acetazolamide-Back Ache-Citalopram\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Citalopram-cholecystitis-Fluphenazine\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Fluphenazine-binding and inhibition-ADRA1A"}]}}
{"custom_id": "alendronic acid-Alprazolam-Doxazosin-ADRA1D-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: alendronic acid\nDRUG 1 BACKGROUND INFORMATION: Alendronic acid, sold under the brand name Fosamax among others, is a bisphosphonate medication used to treat osteoporosis and Paget's disease of bone. It is taken by mouth. Use is often recommended together with vitamin D, calcium supplementation, and lifestyle changes.\nCommon side effects (1 to 10% of patients) include constipation, abdominal pain, nausea, and acid reflux. Use is not recommended during pregnancy or in those with poor kidney function. Alendronic acid works by decreasing the activity of cells that break down bone.\nAlendronic acid was first described in 1978 and approved for medical use in the United States in 1995. It is available as a generic medication. In 2022, it was the 103rd most commonly prescribed medication in the United States, with more than 6 million prescriptions.\n\nDRUG 2 NAME: Alprazolam\nDRUG 2 BACKGROUND INFORMATION: Alprazolam is a high-affinity triazolobenzodiazepine functioning as a potent anxiolytic agent through modulation of the GABA_A receptor chloride channel activity, facilitating enhanced inhibitory neurotransmission. Its pharmacodynamic profile encompasses rapid onset and moderate duration of action, predominantly prescribed for anxiety spectrum disorders, including panic disorder and GAD, and adjunctively for chemotherapy-related emesis control. The pharmacokinetic trajectory involves oral administration, exhibiting bioavailability conducive to therapeutic efficacy within a week for GAD. The acute adverse neurological sequelae are characterized by CNS depression manifesting as somnolence, psychomotor impairment, cognitive attenuation, and dose-dependent anterograde amnesia. Tolerance development mitigates some sedative effects over time. Abrupt cessation precipitates benzodiazepine withdrawal symptomatology. As a Schedule IV controlled substance, alprazolam's potential for abuse and dependency necessitates judicious prescription monitoring. Its clinical ubiquity is substantiated by its standing as the 41st most prescribed drug in the US, with significant generic dissemination.\n\nDRUG 3 NAME: Doxazosin\nDRUG 3 BACKGROUND INFORMATION: Doxazosin, sold under the brand name Cardura among others, is a medication used to treat symptoms of benign prostatic hyperplasia (enlarged prostate), hypertension (high blood pressure), and post-traumatic stress disorder (PTSD). For high blood pressure, it is a less preferred option. It is taken by mouth.\nCommon side effects include dizziness, sleepiness, swelling, nausea, shortness of breath, and abdominal pain. Severe side effects may include low blood pressure with standing, an irregular heart beat, and priapism. It is a selective \u03b11-adrenergic blocker in the quinazoline class of compounds.\nDoxazosin was patented in 1977 and came into medical use in 1988. It is available as a generic medication. In 2022, it was the 180th most commonly prescribed medication in the United States, with more than 2 million prescriptions.\n\nPROTEIN NAME: ADRA1D\nPROTEIN BACKGROUND INFORMATION: The alpha-1D adrenergic receptor (\u03b11D adrenoreceptor), also known as ADRA1D, is an alpha-1 adrenergic receptor, and also denotes the human gene encoding it.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): alendronic acid-cholecystitis-Alprazolam\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Alprazolam-myelodysplasia-Doxazosin\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Doxazosin-binding and inhibition-ADRA1D"}]}}
{"custom_id": "phenytoin-Dapsone-Pyrimethamine-CHRM1-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: phenytoin\nDRUG 1 BACKGROUND INFORMATION: Phenytoin (PHT), marketed as Dilantin, is a hydantoin derivative functioning as a voltage-gated sodium channel inhibitor, efficacious in mitigating hyperexcitable neuronal circuits characteristic of tonic-clonic and focal seizures, yet ineffective against absence seizures. Its prodrug, fosphenytoin, is formulated for intravenous administration to manage benzodiazepine-refractory status epilepticus. Pharmacokinetics reveal rapid onset within 30 minutes post-intravenous administration, with a therapeutic window extending approximately 24 hours; plasma concentration monitoring is imperative for dosage calibration. Adverse effects range from benign, such as gastrointestinal disturbances, to serious, including cerebellar degeneration, toxic epidermal necrolysis, and hematological suppression. Teratogenicity is documented, contraindicating its use in pregnancy, though lactation appears unaffected. Ethanol co-administration may perturb its antiepileptic efficacy. Despite the presence of a myriad of generic versions, phenytoin remains listed by WHO as essential due to its distinct pharmacodynamic profile and is widely prescribed, underscoring its significance in the therapeutic armamentarium for seizure disorders.\n\nDRUG 2 NAME: Dapsone\nDRUG 2 BACKGROUND INFORMATION: Dapsone, chemically delineated as 4,4'-sulfonyldianiline or diaminodiphenyl sulfone, operates as a bacteriostatic antimicrobial agent within the sulfone class, frequently co-administered with rifampicin and clofazimine in leprosy management. It serves as an adjunctive therapeutic in pneumocystis pneumonia prophylaxis and toxoplasmosis prevention within immunocompromised cohorts, as well as for dermatological conditions such as acne and dermatitis herpetiformis, available in both oral and topical formulations. Pharmacodynamically, dapsone's modes of action encompass inhibition of bacterial dihydropteroate synthetase, although it is associated with grave hematological adverse effects, notably hemolytic anemia exacerbated by glucose-6-phosphate dehydrogenase deficiency and agranulocytosis, alongside potential hepatotoxicity manifested as hepatic inflammation. Methemoglobinemia and dermatological hypersensitivity reactions, encompassing a variety of rash presentations, constitute additional risk factors. The teratogenic profile remains equivocal; however, continuation during gestation is advised in leprosy cases. Economically accessible as a generic formulation, dapsone retains its inclusion on the WHO Essential Medicines List, underscoring its clinical utility and indispensable status in global health pharmacopeias.\n\nDRUG 3 NAME: Pyrimethamine\nDRUG 3 BACKGROUND INFORMATION: Pyrimethamine, a folic acid antagonist deployed primarily in conjunction with leucovorin to mitigate its hematological toxicity, serves as a therapeutic agent against Toxoplasma gondii and Cystoisospora belli infections. Leveraged as a second-line prophylactic strategy when paired with dapsone, it targets Pneumocystis jiroveci pneumonia in HIV/AIDS cohorts, though its historical anti-malarial application has waned due to resistance. The pharmacological mechanism centers on the inhibition of dihydrofolate reductase, disrupting protozoal DNA synthesis and cell replication. Clinically, the oral administration of pyrimethamine necessitates vigilance due to adverse effects, notably gastrointestinal distress, hypersensitivity reactions, and potential for bone marrow suppression, contraindicating its application in folate-deficient anemia. Oncology concerns persist about its carcinogenic potential, and its teratogenicity risk mandates caution during gestation. Despite these concerns, pyrimethamine retains its status as a World Health Organization Essential Medicine and was ratified as a generic option in the U.S. pharmacopoeia as of early 2020.\n\nPROTEIN NAME: CHRM1\nPROTEIN BACKGROUND INFORMATION: The muscarinic acetylcholine receptor M1, also known as the cholinergic receptor, muscarinic 1, is a muscarinic receptor that in humans is encoded by the CHRM1 gene. It is localized to 11q13.\nThis receptor is found mediating slow EPSP at the ganglion in the postganglionic nerve, is common in exocrine glands and in the CNS.\nIt is predominantly found bound to G proteins of class Gq that use upregulation of phospholipase C and, therefore, inositol trisphosphate and intracellular calcium as a signalling pathway. A receptor so bound would not be susceptible to CTX or PTX. However, Gi (causing a downstream decrease in cAMP) and Gs (causing an increase in cAMP) have also been shown to be involved in interactions in certain tissues, and so would be susceptible to PTX and CTX respectively.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): phenytoin-haemorrhage intracranial-Dapsone\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Dapsone-neumonia-Pyrimethamine\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Pyrimethamine-binding and inhibition-CHRM1"}]}}
{"custom_id": "Amlodipine-Metolazone-Metoprolol-GRPR-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Amlodipine\nDRUG 1 BACKGROUND INFORMATION: Amlodipine, a dihydropyridine-type long-acting calcium channel antagonist, exerts its pharmacological action primarily through vasodilation by impeding calcium ion influx through L-type calcium channels in vascular smooth muscle, which ameliorates hypertension, coronary artery disease, and variant angina. Administered orally, its pharmacokinetic profile necessitates caution in hepatic impairment and geriatric populations, requiring dose modulation. Although the teratogenic risk during gestation or lactation remains indeterminate, its side effect profile encompasses peripheral edema, lethargy, gastrointestinal distress, and potential hypotension or myocardial infarction. This compound's significant therapeutic utility has merited its inclusion on the WHO Essential Medicines List and extensive global prescription prevalence while remaining generically accessible.\n\nDRUG 2 NAME: Metolazone\nDRUG 2 BACKGROUND INFORMATION: Metolazone is a thiazide-like diuretic marketed under the brand names Zytanix, Metoz, Zaroxolyn, and Mykrox. It is primarily used to treat congestive heart failure and high blood pressure. Metolazone indirectly decreases the amount of water reabsorbed into the bloodstream by the kidney, so that blood volume decreases and urine volume increases. This lowers blood pressure and prevents excess fluid accumulation in heart failure. Metolazone is sometimes used together with loop diuretics such as furosemide or bumetanide, but these highly effective combinations can lead to dehydration and electrolyte abnormalities.\nIt was patented in 1966 and approved for medical use in 1974.\n\nDRUG 3 NAME: Metoprolol\nDRUG 3 BACKGROUND INFORMATION: Metoprolol, a cardioselective \u03b21-adrenergic receptor antagonist, is clinically utilized in the management of angina pectoris, hypertension, tachyarrhythmias, post-myocardial infarction secondary prophylaxis, and migraine prophylaxis. Its therapeutic efficacy is mediated via negative chronotropic and inotropic effects which result in decreased myocardial oxygen demand and improved exercise tolerance. The pharmacokinetics of metoprolol is influenced by hepatic cytochrome P450 2D6 isoenzyme variability leading to significant interpatient variability in drug metabolism, necessitating individualized dosing. Adverse effects prominently include insomnia, asthenia, presyncope, and gastrointestinal disturbances, with higher doses presenting risk for pronounced toxicity. Though teratogenic risk during pregnancy has not been conclusively excluded, its excretion into breast milk is considered clinically insignificant. Metoprolol is widely dispensed, reflecting its inclusion in the WHO's Essential Medicines, and its prescription frequency underscores its pivotal role in cardiovascular therapeutics.\n\nPROTEIN NAME: GRPR\nPROTEIN BACKGROUND INFORMATION: The gastrin-releasing peptide receptor (GRPR), now properly known as BB2  is a G protein-coupled receptor whose endogenous ligand is gastrin releasing peptide. In humans it is highly expressed in the pancreas and is also expressed in the stomach, adrenal cortex and brain.\nGastrin-releasing peptide (GRP) regulates numerous functions of the gastrointestinal and central nervous systems, including release of gastrointestinal hormones, smooth muscle cell contraction, and epithelial cell proliferation and is a potent mitogen for neoplastic tissues. The effects of GRP are mediated through the gastrin-releasing peptide receptor. This receptor is a glycosylated, 7-transmembrane G-protein coupled receptor that activates the phospholipase C signaling pathway. The receptor is aberrantly expressed in numerous cancers such as those of the lung, colon, and prostate. An individual with autism and multiple exostoses was found to have a balanced translocation between chromosome 8 and a chromosome X breakpoint located within the gastrin-releasing peptide receptor gene.\nThe transcription factor CREB is a regulator of human GRP-R expression in colon cancer.\nActivation MOR1D\u2010GRPR heteromers in the spinal cord mediate the common troublesome opioid-induced itch.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Amlodipine-cholecystitis-Metolazone\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Metolazone-cholecystitis-Metoprolol\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Metoprolol-binding and activation-GRPR"}]}}
{"custom_id": "Naproxen-Carvedilol-Dobutamine-ADRB1-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: Carvedilol\nDRUG 2 BACKGROUND INFORMATION: Carvedilol, a nonselective beta-adrenergic blocker with alpha-1 adrenergic receptor antagonism, is clinically utilized for managing hypertension and chronic heart failure with reduced ejection fraction (HFrEF), often despite beta-blockers not being preferred first-line antihypertensives due to inferior cardiovascular outcomes and safety profiles relative to alternative hypertensives. While its pharmacodynamic mechanisms contributing to therapeutic efficacy in HFrEF remain incompletely elucidated, vasodilation resultant from alpha-1 blockade may play a role. Adverse reactions encompass orthostatic hypotension, asthenia, arthralgia, nausea, and dyspnea, with bronchospasm as a potential severe manifestation. The drug's pharmacokinetics necessitate cautious use during gestation and lactation and contraindicate administration in hepatic impairment cases. Despite exhibiting a broad safety spectrum, carvedilol's utilization extends to over 17 million annual prescriptions in the U.S., affirming its presence on the WHO's List of Essential Medicines and availability in generic formulations.\n\nDRUG 3 NAME: Dobutamine\nDRUG 3 BACKGROUND INFORMATION: Dobutamine, administered intravenously or intraosseously, is an adrenergic agonist specifically targeting \u03b21-adrenergic receptors, eliciting a pronounced inotropic response without significant chronotropic impact, thereby enhancing myocardial contractility and systemic perfusion in the management of cardiogenic shock and severe heart failure. The pharmacokinetics of dobutamine are characterized by rapid onset within two minutes and an elimination half-life of two minutes, necessitating titration to effect and favoring short-term administration, although it may be employed in extended durations in the context of pre-transplant heart failure symptomatology management. Adverse reactions primarily include tachyarrhythmias, injection site reactions, and contraindication in hypertrophic subaortic stenosis. Synthetically derived from isoproterenol, dobutamine has been devoid of significant chronotropic effects, making it distinct among inotropes.\n\nPROTEIN NAME: ADRB1\nPROTEIN BACKGROUND INFORMATION: The beta-1 adrenergic receptor (\u03b21 adrenoceptor), also known as ADRB1, can refer to either the protein-encoding gene (gene ADRB1) or one of the four adrenergic receptors. It is a G-protein coupled receptor associated with the Gs heterotrimeric G-protein that is expressed predominantly in cardiac tissue. In addition to cardiac tissue, beta-1 adrenergic receptors are also expressed in the cerebral cortex.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Naproxen-Adenopathy-Carvedilol\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Carvedilol-hepatitis-Dobutamine\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Dobutamine-binding and activation-ADRB1"}]}}
{"custom_id": "Naproxen-Orphenadrine-Trazodone-ADRA1A-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: Orphenadrine\nDRUG 2 BACKGROUND INFORMATION: Orphenadrine (sold under many brand names) is an anticholinergic drug of the ethanolamine antihistamine class; it is closely related to diphenhydramine. It is a muscle relaxant that is used to treat muscle pain and to help with motor control in Parkinson's disease, but has largely been superseded by newer drugs. It is considered a dirty drug due to its multiple mechanisms of action in different pathways. It was discovered and developed in the 1940s.\n\nDRUG 3 NAME: Trazodone\nDRUG 3 BACKGROUND INFORMATION: Trazodone is an antidepressant medication used to treat major depressive disorder, anxiety disorders, and insomnia. It is a phenylpiperazine compound of the serotonin antagonist and reuptake inhibitor (SARI) class. The medication is taken orally.\nCommon side effects include dry mouth, feeling faint, vomiting, and headache. More serious side effects may include suicide, mania, irregular heart rate, and pathologically prolonged erections. It is unclear if use during pregnancy or breastfeeding is safe.  Trazodone also has sedating effects.\nTrazodone was approved for medical use in the United States in 1981. It is available as a generic medication. In 2022, it was the eighteenth most commonly prescribed medication in the United States, with more than 27 million prescriptions.\n\nPROTEIN NAME: ADRA1A\nPROTEIN BACKGROUND INFORMATION: The alpha-1A adrenergic receptor (\u03b11A adrenoreceptor), also known as ADRA1A, formerly known also as the  alpha-1C adrenergic receptor, is an alpha-1 adrenergic receptor, and also denotes the human gene encoding it. There is no longer a subtype \u03b11C receptor. At one time, there was a subtype known as \u03b11C, but it was found to be identical to the previously discovered \u03b11A receptor subtype. To avoid confusion, the naming convention was continued with the letter D.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Naproxen-loss of weight-Orphenadrine\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Orphenadrine-Back Ache-Trazodone\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Trazodone-binding and inhibition-ADRA1A"}]}}
{"custom_id": "alendronic acid-Alprazolam-Formoterol-ADRB3-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: alendronic acid\nDRUG 1 BACKGROUND INFORMATION: Alendronic acid, sold under the brand name Fosamax among others, is a bisphosphonate medication used to treat osteoporosis and Paget's disease of bone. It is taken by mouth. Use is often recommended together with vitamin D, calcium supplementation, and lifestyle changes.\nCommon side effects (1 to 10% of patients) include constipation, abdominal pain, nausea, and acid reflux. Use is not recommended during pregnancy or in those with poor kidney function. Alendronic acid works by decreasing the activity of cells that break down bone.\nAlendronic acid was first described in 1978 and approved for medical use in the United States in 1995. It is available as a generic medication. In 2022, it was the 103rd most commonly prescribed medication in the United States, with more than 6 million prescriptions.\n\nDRUG 2 NAME: Alprazolam\nDRUG 2 BACKGROUND INFORMATION: Alprazolam is a high-affinity triazolobenzodiazepine functioning as a potent anxiolytic agent through modulation of the GABA_A receptor chloride channel activity, facilitating enhanced inhibitory neurotransmission. Its pharmacodynamic profile encompasses rapid onset and moderate duration of action, predominantly prescribed for anxiety spectrum disorders, including panic disorder and GAD, and adjunctively for chemotherapy-related emesis control. The pharmacokinetic trajectory involves oral administration, exhibiting bioavailability conducive to therapeutic efficacy within a week for GAD. The acute adverse neurological sequelae are characterized by CNS depression manifesting as somnolence, psychomotor impairment, cognitive attenuation, and dose-dependent anterograde amnesia. Tolerance development mitigates some sedative effects over time. Abrupt cessation precipitates benzodiazepine withdrawal symptomatology. As a Schedule IV controlled substance, alprazolam's potential for abuse and dependency necessitates judicious prescription monitoring. Its clinical ubiquity is substantiated by its standing as the 41st most prescribed drug in the US, with significant generic dissemination.\n\nDRUG 3 NAME: Formoterol\nDRUG 3 BACKGROUND INFORMATION: Formoterol, a potent long-acting \u03b22-adrenergic receptor agonist (LABA), functions as a bronchodilator specifically targeting pulmonary smooth muscle to induce bronchodilation, thereby offering therapeutic utility in the management of asthma and chronic obstructive pulmonary disease (COPD). Notably, formoterol distinguishes itself by a prolonged bronchodilatory efficacy of approximately 12 hours post-administration, surpassing the 4-6 hour window typical of short-acting \u03b22 agonists like salbutamol (albuterol). Its pharmacokinetic profile is characterized by a rapid onset of action within 2-3 minutes, setting it apart from other LABAs. According to the 2022 Global Initiative for Asthma guidelines, adult treatment regimens favor a formoterol and inhaled corticosteroid combination for both prophylactic and acute symptom management, whereas pediatric protocols prioritize short-acting \u03b22 adrenergic agonists, such as salbutamol for immediate relief. Formoterol is commercially available both as a standalone generic medication and in synergistic fixed-dose combinations, notably with budesonide and mometasone, to enhance its clinical efficacy in targeted therapeutic strategies.\n\nPROTEIN NAME: ADRB3\nPROTEIN BACKGROUND INFORMATION: The beta-3 adrenergic receptor (\u03b23-adrenoceptor), also known as ADRB3, is a beta-adrenergic receptor, and also denotes the human gene encoding it.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): alendronic acid-cholecystitis-Alprazolam\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Alprazolam-loss of weight-Formoterol\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Formoterol-binding and activation-ADRB3"}]}}
{"custom_id": "Diazepam-Doxazosin-Formoterol-ADRB1-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Diazepam\nDRUG 1 BACKGROUND INFORMATION: Diazepam, a prototypical member of the benzodiazepine pharmacological class, functions primarily as an anxiolytic by potentiation of GABAergic neurotransmission, enhancing the binding affinity of gamma-aminobutyric acid (GABA) at the GABA_A receptor complex. It is employed in the management of a diverse array of conditions, including, but not limited to, generalized anxiety disorder, status epilepticus, alcohol withdrawal delirium, spasticity, insomnia, and restless legs syndrome, with additional utility in procedural amnesia induction. Diazepam exhibits versatile administration routes\u2014oral, rectal, intramuscular, intravenous, and intranasal, with IV administration eliciting rapid onset of action within 1-5 minutes and demonstrating a relatively short duration of clinical efficacy. Oral administration results in peak plasma concentrations within 15 to 60 minutes. While generally well-tolerated, its adverse effect profile includes CNS depression manifesting as sedation and impaired motor coordination, with rare, yet severe risks like respiratory depression, paradoxical excitation, and seizure exacerbation with chronic use. Chronic administration raises the risk of tolerance, physical dependence, and a withdrawal syndrome upon abrupt cessation; cognitive impairments post-discontinuation are well-documented. It is contraindicated in pregnancy and lactation due to teratogenic and neonatal withdrawal potential. Diazepam continues to be a mainstay therapeutic agent on the World Health Organization\u2019s List of Essential Medicines, despite its risk for abuse and dependency, underscoring the necessity for judicious prescribing practice.\n\nDRUG 2 NAME: Doxazosin\nDRUG 2 BACKGROUND INFORMATION: Doxazosin, sold under the brand name Cardura among others, is a medication used to treat symptoms of benign prostatic hyperplasia (enlarged prostate), hypertension (high blood pressure), and post-traumatic stress disorder (PTSD). For high blood pressure, it is a less preferred option. It is taken by mouth.\nCommon side effects include dizziness, sleepiness, swelling, nausea, shortness of breath, and abdominal pain. Severe side effects may include low blood pressure with standing, an irregular heart beat, and priapism. It is a selective \u03b11-adrenergic blocker in the quinazoline class of compounds.\nDoxazosin was patented in 1977 and came into medical use in 1988. It is available as a generic medication. In 2022, it was the 180th most commonly prescribed medication in the United States, with more than 2 million prescriptions.\n\nDRUG 3 NAME: Formoterol\nDRUG 3 BACKGROUND INFORMATION: Formoterol, a potent long-acting \u03b22-adrenergic receptor agonist (LABA), functions as a bronchodilator specifically targeting pulmonary smooth muscle to induce bronchodilation, thereby offering therapeutic utility in the management of asthma and chronic obstructive pulmonary disease (COPD). Notably, formoterol distinguishes itself by a prolonged bronchodilatory efficacy of approximately 12 hours post-administration, surpassing the 4-6 hour window typical of short-acting \u03b22 agonists like salbutamol (albuterol). Its pharmacokinetic profile is characterized by a rapid onset of action within 2-3 minutes, setting it apart from other LABAs. According to the 2022 Global Initiative for Asthma guidelines, adult treatment regimens favor a formoterol and inhaled corticosteroid combination for both prophylactic and acute symptom management, whereas pediatric protocols prioritize short-acting \u03b22 adrenergic agonists, such as salbutamol for immediate relief. Formoterol is commercially available both as a standalone generic medication and in synergistic fixed-dose combinations, notably with budesonide and mometasone, to enhance its clinical efficacy in targeted therapeutic strategies.\n\nPROTEIN NAME: ADRB1\nPROTEIN BACKGROUND INFORMATION: The beta-1 adrenergic receptor (\u03b21 adrenoceptor), also known as ADRB1, can refer to either the protein-encoding gene (gene ADRB1) or one of the four adrenergic receptors. It is a G-protein coupled receptor associated with the Gs heterotrimeric G-protein that is expressed predominantly in cardiac tissue. In addition to cardiac tissue, beta-1 adrenergic receptors are also expressed in the cerebral cortex.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Diazepam-right heart failure-Doxazosin\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Doxazosin-aortic aneurysm-Formoterol\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Formoterol-binding and activation-ADRB1"}]}}
{"custom_id": "Cimetidine-Labetalol-Metoprolol-HRH3-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Cimetidine\nDRUG 1 BACKGROUND INFORMATION: Cimetidine, sold under the brand name Tagamet among others, is a histamine H2 receptor antagonist that inhibits stomach acid production. It is mainly used in the treatment of heartburn and peptic ulcers.\nWith the development of proton pump inhibitors, such as omeprazole, approved for the same indications, cimetidine is available as an over-the-counter formulation to prevent heartburn or acid indigestion, along with the other H2-receptor antagonists.\nCimetidine was developed in 1971 and came into commercial use in 1977. Cimetidine was approved in the United Kingdom in 1976, and was approved in the United States by the Food and Drug Administration in 1979.\n\nDRUG 2 NAME: Labetalol\nDRUG 2 BACKGROUND INFORMATION: Labetalol is a medication used to treat high blood pressure and in long term management of angina. This includes essential hypertension, hypertensive emergencies, and hypertension of pregnancy. In essential hypertension it is generally less preferred than a number of other blood pressure medications. It can be given by mouth or by injection into a vein.\nCommon side effects include low blood pressure with standing, dizziness, feeling tired, and nausea. Serious side effects may include low blood pressure, liver problems, heart failure, and bronchospasm. Use appears safe in the latter part of pregnancy and it is not expected to cause problems during breastfeeding. It works by blocking the activation of \u03b2- and \u03b1-adrenergic receptors.\nLabetalol was patented in 1966 and came into medical use in 1977. It is available as a generic medication. In 2022, it was the 215th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG 3 NAME: Metoprolol\nDRUG 3 BACKGROUND INFORMATION: Metoprolol, a cardioselective \u03b21-adrenergic receptor antagonist, is clinically utilized in the management of angina pectoris, hypertension, tachyarrhythmias, post-myocardial infarction secondary prophylaxis, and migraine prophylaxis. Its therapeutic efficacy is mediated via negative chronotropic and inotropic effects which result in decreased myocardial oxygen demand and improved exercise tolerance. The pharmacokinetics of metoprolol is influenced by hepatic cytochrome P450 2D6 isoenzyme variability leading to significant interpatient variability in drug metabolism, necessitating individualized dosing. Adverse effects prominently include insomnia, asthenia, presyncope, and gastrointestinal disturbances, with higher doses presenting risk for pronounced toxicity. Though teratogenic risk during pregnancy has not been conclusively excluded, its excretion into breast milk is considered clinically insignificant. Metoprolol is widely dispensed, reflecting its inclusion in the WHO's Essential Medicines, and its prescription frequency underscores its pivotal role in cardiovascular therapeutics.\n\nPROTEIN NAME: HRH3\nPROTEIN BACKGROUND INFORMATION: Histamine H3 receptors are expressed in the central nervous system and to a lesser extent the peripheral nervous system, where they act as autoreceptors in presynaptic histaminergic neurons and control histamine turnover by feedback inhibition of histamine synthesis and release. The H3 receptor has also been shown to presynaptically inhibit the release of a number of other neurotransmitters (i.e. it acts as an inhibitory heteroreceptor) including, but probably not limited to dopamine, GABA, acetylcholine, noradrenaline, histamine and serotonin.\nThe gene sequence for H3 receptors expresses only about 22% and 20% homology with both H1 and H2 receptors respectively.\nThere is much interest in the histamine H3 receptor as a potential therapeutic target because of its involvement in the neuronal mechanism behind many cognitive disorders and especially its location in the central nervous system.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Cimetidine-back injury-Labetalol\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Labetalol-apoplexy-Metoprolol\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Metoprolol-binding and activation-HRH3"}]}}
{"custom_id": "Labetalol-Metoprolol-Perphenazine-ADRA1A-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Labetalol\nDRUG 1 BACKGROUND INFORMATION: Labetalol is a medication used to treat high blood pressure and in long term management of angina. This includes essential hypertension, hypertensive emergencies, and hypertension of pregnancy. In essential hypertension it is generally less preferred than a number of other blood pressure medications. It can be given by mouth or by injection into a vein.\nCommon side effects include low blood pressure with standing, dizziness, feeling tired, and nausea. Serious side effects may include low blood pressure, liver problems, heart failure, and bronchospasm. Use appears safe in the latter part of pregnancy and it is not expected to cause problems during breastfeeding. It works by blocking the activation of \u03b2- and \u03b1-adrenergic receptors.\nLabetalol was patented in 1966 and came into medical use in 1977. It is available as a generic medication. In 2022, it was the 215th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG 2 NAME: Metoprolol\nDRUG 2 BACKGROUND INFORMATION: Metoprolol, a cardioselective \u03b21-adrenergic receptor antagonist, is clinically utilized in the management of angina pectoris, hypertension, tachyarrhythmias, post-myocardial infarction secondary prophylaxis, and migraine prophylaxis. Its therapeutic efficacy is mediated via negative chronotropic and inotropic effects which result in decreased myocardial oxygen demand and improved exercise tolerance. The pharmacokinetics of metoprolol is influenced by hepatic cytochrome P450 2D6 isoenzyme variability leading to significant interpatient variability in drug metabolism, necessitating individualized dosing. Adverse effects prominently include insomnia, asthenia, presyncope, and gastrointestinal disturbances, with higher doses presenting risk for pronounced toxicity. Though teratogenic risk during pregnancy has not been conclusively excluded, its excretion into breast milk is considered clinically insignificant. Metoprolol is widely dispensed, reflecting its inclusion in the WHO's Essential Medicines, and its prescription frequency underscores its pivotal role in cardiovascular therapeutics.\n\nDRUG 3 NAME: Perphenazine\nDRUG 3 BACKGROUND INFORMATION: Perphenazine is a typical antipsychotic drug.  Chemically, it is classified as a piperazinyl phenothiazine. Originally marketed in the United States as Trilafon, it has been in clinical use for decades.\nPerphenazine is roughly ten times as potent as chlorpromazine at the dopamine-2 (D2) receptor; thus perphenazine is considered a medium-potency antipsychotic.\n\nPROTEIN NAME: ADRA1A\nPROTEIN BACKGROUND INFORMATION: The alpha-1A adrenergic receptor (\u03b11A adrenoreceptor), also known as ADRA1A, formerly known also as the  alpha-1C adrenergic receptor, is an alpha-1 adrenergic receptor, and also denotes the human gene encoding it. There is no longer a subtype \u03b11C receptor. At one time, there was a subtype known as \u03b11C, but it was found to be identical to the previously discovered \u03b11A receptor subtype. To avoid confusion, the naming convention was continued with the letter D.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Labetalol-apoplexy-Metoprolol\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Metoprolol-insulin dependent diabetes mellitus-Perphenazine\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Perphenazine-binding and inhibition-ADRA1A"}]}}
{"custom_id": "Naproxen-alendronic acid-Salmeterol-ADRB3-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: alendronic acid\nDRUG 2 BACKGROUND INFORMATION: Alendronic acid, sold under the brand name Fosamax among others, is a bisphosphonate medication used to treat osteoporosis and Paget's disease of bone. It is taken by mouth. Use is often recommended together with vitamin D, calcium supplementation, and lifestyle changes.\nCommon side effects (1 to 10% of patients) include constipation, abdominal pain, nausea, and acid reflux. Use is not recommended during pregnancy or in those with poor kidney function. Alendronic acid works by decreasing the activity of cells that break down bone.\nAlendronic acid was first described in 1978 and approved for medical use in the United States in 1995. It is available as a generic medication. In 2022, it was the 103rd most commonly prescribed medication in the United States, with more than 6 million prescriptions.\n\nDRUG 3 NAME: Salmeterol\nDRUG 3 BACKGROUND INFORMATION: Salmeterol is a long-acting \u03b22 adrenergic receptor agonist (LABA) used in the treatment and prevention of asthma symptoms and control of chronic obstructive pulmonary disease (COPD) symptoms. Symptoms of bronchospasm include shortness of breath, wheezing, coughing and chest tightness. It is also used to prevent breathing difficulties during exercise (exercise-induced bronchoconstriction).\nIt was patented in 1983 and came into medical use in 1990. It is marketed as Serevent in the US. It is available as a dry-powder inhaler (DPI) that releases a powdered form of the drug. It was previously available as a metered-dose inhaler (MDI) but was discontinued in the US in 2002. It is available as an MDI in other countries as of 2020.\n\nPROTEIN NAME: ADRB3\nPROTEIN BACKGROUND INFORMATION: The beta-3 adrenergic receptor (\u03b23-adrenoceptor), also known as ADRB3, is a beta-adrenergic receptor, and also denotes the human gene encoding it.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Naproxen-gastric inflammation-alendronic acid\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): alendronic acid-cholecystitis-Salmeterol\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Salmeterol-binding and activation-ADRB3"}]}}
{"custom_id": "Aciclovir-Lidocaine-Metoprolol-ADRB1-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Aciclovir\nDRUG 1 BACKGROUND INFORMATION: Aciclovir, an antiviral guanosine analogue, exhibits its therapeutic efficacy predominantly by inhibiting viral DNA polymerase through its metabolization to aciclovir triphosphate, resulting in the cessation of herpesvirus DNA elongation across Herpes Simplex Virus, varicella-zoster, and CMV prophylaxis post-transplantation. Administerable orally, topically, or intravenously, its pharmacokinetic profile necessitates careful consideration in patients with compromised renal or hepatic function due to potential nephrotoxicity and thrombocytopenia. While demonstrating an acceptable safety margin during gestation and lactation, adverse events such as gastrointestinal discomfort and diarrhea are common. Its inclusion in the WHO's Essential Medicines list underscores its global pivotal role in antiviral therapy, with its generic accessibility enhancing universal healthcare implementation.\n\nDRUG 2 NAME: Lidocaine\nDRUG 2 BACKGROUND INFORMATION: Lidocaine, or lignocaine, is a quintessential amino amide local anesthetic utilized extensively for its neuromodulatory and cardiac electrophysiological properties. As a class Ib antiarrhythmic agent, lidocaine exerts its mechanistic effect via blockade of voltage-gated sodium channels, thereby attenuating myocardial depolarization and stabilizing aberrant conduction pathways responsible for ventricular tachycardia and fibrillation. Its onset of action, contingent upon peripheral nerve administration, is typically rapid, achieving effective anesthesia within minutes, with a duration ranging from 30 minutes to three hours, and efficacy can be potentiated when co-administered with adrenaline due to vasoconstriction and augmented tissue retention. Topical formulations enhance transdermal absorption for sensory blockade across dermal and mucosal surfaces. In systemic circulation, particularly when administered intravenously, lidocaine may induce neurotoxic side effects including CNS agitation, visual disturbances, paresthesia, and emesis, in addition to cardiovascular effects such as hypotension and dysrhythmogenesis. Caution is advised with intra-articular administration due to chondrotoxicity concerns, and dose adjustments are necessary in hepatic insufficiency, yet it remains a favorable option in patients with hypersensitivity to ester-type anesthetics like tetracaine. Due to its obstetric safety profile, lidocaine is deemed viable during gestation and its inclusion in the WHO's List of Essential Medicines underlines its critical therapeutic value and accessibility as a generic formulation.\n\nDRUG 3 NAME: Metoprolol\nDRUG 3 BACKGROUND INFORMATION: Metoprolol, a cardioselective \u03b21-adrenergic receptor antagonist, is clinically utilized in the management of angina pectoris, hypertension, tachyarrhythmias, post-myocardial infarction secondary prophylaxis, and migraine prophylaxis. Its therapeutic efficacy is mediated via negative chronotropic and inotropic effects which result in decreased myocardial oxygen demand and improved exercise tolerance. The pharmacokinetics of metoprolol is influenced by hepatic cytochrome P450 2D6 isoenzyme variability leading to significant interpatient variability in drug metabolism, necessitating individualized dosing. Adverse effects prominently include insomnia, asthenia, presyncope, and gastrointestinal disturbances, with higher doses presenting risk for pronounced toxicity. Though teratogenic risk during pregnancy has not been conclusively excluded, its excretion into breast milk is considered clinically insignificant. Metoprolol is widely dispensed, reflecting its inclusion in the WHO's Essential Medicines, and its prescription frequency underscores its pivotal role in cardiovascular therapeutics.\n\nPROTEIN NAME: ADRB1\nPROTEIN BACKGROUND INFORMATION: The beta-1 adrenergic receptor (\u03b21 adrenoceptor), also known as ADRB1, can refer to either the protein-encoding gene (gene ADRB1) or one of the four adrenergic receptors. It is a G-protein coupled receptor associated with the Gs heterotrimeric G-protein that is expressed predominantly in cardiac tissue. In addition to cardiac tissue, beta-1 adrenergic receptors are also expressed in the cerebral cortex.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Aciclovir-gastric inflammation-Lidocaine\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Lidocaine-cholecystitis-Metoprolol\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Metoprolol-binding and inhibition-ADRB1"}]}}
{"custom_id": "Alprazolam-Doxazosin-Metoprolol-HRH3-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Alprazolam\nDRUG 1 BACKGROUND INFORMATION: Alprazolam is a high-affinity triazolobenzodiazepine functioning as a potent anxiolytic agent through modulation of the GABA_A receptor chloride channel activity, facilitating enhanced inhibitory neurotransmission. Its pharmacodynamic profile encompasses rapid onset and moderate duration of action, predominantly prescribed for anxiety spectrum disorders, including panic disorder and GAD, and adjunctively for chemotherapy-related emesis control. The pharmacokinetic trajectory involves oral administration, exhibiting bioavailability conducive to therapeutic efficacy within a week for GAD. The acute adverse neurological sequelae are characterized by CNS depression manifesting as somnolence, psychomotor impairment, cognitive attenuation, and dose-dependent anterograde amnesia. Tolerance development mitigates some sedative effects over time. Abrupt cessation precipitates benzodiazepine withdrawal symptomatology. As a Schedule IV controlled substance, alprazolam's potential for abuse and dependency necessitates judicious prescription monitoring. Its clinical ubiquity is substantiated by its standing as the 41st most prescribed drug in the US, with significant generic dissemination.\n\nDRUG 2 NAME: Doxazosin\nDRUG 2 BACKGROUND INFORMATION: Doxazosin, sold under the brand name Cardura among others, is a medication used to treat symptoms of benign prostatic hyperplasia (enlarged prostate), hypertension (high blood pressure), and post-traumatic stress disorder (PTSD). For high blood pressure, it is a less preferred option. It is taken by mouth.\nCommon side effects include dizziness, sleepiness, swelling, nausea, shortness of breath, and abdominal pain. Severe side effects may include low blood pressure with standing, an irregular heart beat, and priapism. It is a selective \u03b11-adrenergic blocker in the quinazoline class of compounds.\nDoxazosin was patented in 1977 and came into medical use in 1988. It is available as a generic medication. In 2022, it was the 180th most commonly prescribed medication in the United States, with more than 2 million prescriptions.\n\nDRUG 3 NAME: Metoprolol\nDRUG 3 BACKGROUND INFORMATION: Metoprolol, a cardioselective \u03b21-adrenergic receptor antagonist, is clinically utilized in the management of angina pectoris, hypertension, tachyarrhythmias, post-myocardial infarction secondary prophylaxis, and migraine prophylaxis. Its therapeutic efficacy is mediated via negative chronotropic and inotropic effects which result in decreased myocardial oxygen demand and improved exercise tolerance. The pharmacokinetics of metoprolol is influenced by hepatic cytochrome P450 2D6 isoenzyme variability leading to significant interpatient variability in drug metabolism, necessitating individualized dosing. Adverse effects prominently include insomnia, asthenia, presyncope, and gastrointestinal disturbances, with higher doses presenting risk for pronounced toxicity. Though teratogenic risk during pregnancy has not been conclusively excluded, its excretion into breast milk is considered clinically insignificant. Metoprolol is widely dispensed, reflecting its inclusion in the WHO's Essential Medicines, and its prescription frequency underscores its pivotal role in cardiovascular therapeutics.\n\nPROTEIN NAME: HRH3\nPROTEIN BACKGROUND INFORMATION: Histamine H3 receptors are expressed in the central nervous system and to a lesser extent the peripheral nervous system, where they act as autoreceptors in presynaptic histaminergic neurons and control histamine turnover by feedback inhibition of histamine synthesis and release. The H3 receptor has also been shown to presynaptically inhibit the release of a number of other neurotransmitters (i.e. it acts as an inhibitory heteroreceptor) including, but probably not limited to dopamine, GABA, acetylcholine, noradrenaline, histamine and serotonin.\nThe gene sequence for H3 receptors expresses only about 22% and 20% homology with both H1 and H2 receptors respectively.\nThere is much interest in the histamine H3 receptor as a potential therapeutic target because of its involvement in the neuronal mechanism behind many cognitive disorders and especially its location in the central nervous system.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Alprazolam-myelodysplasia-Doxazosin\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Doxazosin-gastric inflammation-Metoprolol\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Metoprolol-binding and activation-HRH3"}]}}
{"custom_id": "Doxazosin-Metoprolol-Perphenazine-HRH1-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Doxazosin\nDRUG 1 BACKGROUND INFORMATION: Doxazosin, sold under the brand name Cardura among others, is a medication used to treat symptoms of benign prostatic hyperplasia (enlarged prostate), hypertension (high blood pressure), and post-traumatic stress disorder (PTSD). For high blood pressure, it is a less preferred option. It is taken by mouth.\nCommon side effects include dizziness, sleepiness, swelling, nausea, shortness of breath, and abdominal pain. Severe side effects may include low blood pressure with standing, an irregular heart beat, and priapism. It is a selective \u03b11-adrenergic blocker in the quinazoline class of compounds.\nDoxazosin was patented in 1977 and came into medical use in 1988. It is available as a generic medication. In 2022, it was the 180th most commonly prescribed medication in the United States, with more than 2 million prescriptions.\n\nDRUG 2 NAME: Metoprolol\nDRUG 2 BACKGROUND INFORMATION: Metoprolol, a cardioselective \u03b21-adrenergic receptor antagonist, is clinically utilized in the management of angina pectoris, hypertension, tachyarrhythmias, post-myocardial infarction secondary prophylaxis, and migraine prophylaxis. Its therapeutic efficacy is mediated via negative chronotropic and inotropic effects which result in decreased myocardial oxygen demand and improved exercise tolerance. The pharmacokinetics of metoprolol is influenced by hepatic cytochrome P450 2D6 isoenzyme variability leading to significant interpatient variability in drug metabolism, necessitating individualized dosing. Adverse effects prominently include insomnia, asthenia, presyncope, and gastrointestinal disturbances, with higher doses presenting risk for pronounced toxicity. Though teratogenic risk during pregnancy has not been conclusively excluded, its excretion into breast milk is considered clinically insignificant. Metoprolol is widely dispensed, reflecting its inclusion in the WHO's Essential Medicines, and its prescription frequency underscores its pivotal role in cardiovascular therapeutics.\n\nDRUG 3 NAME: Perphenazine\nDRUG 3 BACKGROUND INFORMATION: Perphenazine is a typical antipsychotic drug.  Chemically, it is classified as a piperazinyl phenothiazine. Originally marketed in the United States as Trilafon, it has been in clinical use for decades.\nPerphenazine is roughly ten times as potent as chlorpromazine at the dopamine-2 (D2) receptor; thus perphenazine is considered a medium-potency antipsychotic.\n\nPROTEIN NAME: HRH1\nPROTEIN BACKGROUND INFORMATION: The H1 receptor is a histamine receptor belonging to the family of rhodopsin-like G-protein-coupled receptors. This receptor is activated by the biogenic amine histamine. It is expressed in smooth muscles, on vascular endothelial cells, in the heart, and in the central nervous system. The H1 receptor is linked to an intracellular G-protein (Gq) that activates phospholipase C and the inositol triphosphate (IP3) signalling pathway. Antihistamines, which act on this receptor, are used as anti-allergy drugs. The crystal structure of the receptor has been determined (shown on the right/below) and used to discover new histamine H1 receptor ligands in structure-based virtual screening studies.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Doxazosin-gastric inflammation-Metoprolol\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Metoprolol-insulin dependent diabetes mellitus-Perphenazine\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Perphenazine-binding and inhibition-HRH1"}]}}
{"custom_id": "Naproxen-Dapsone-Pyrimethamine-CHRM1-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: Dapsone\nDRUG 2 BACKGROUND INFORMATION: Dapsone, chemically delineated as 4,4'-sulfonyldianiline or diaminodiphenyl sulfone, operates as a bacteriostatic antimicrobial agent within the sulfone class, frequently co-administered with rifampicin and clofazimine in leprosy management. It serves as an adjunctive therapeutic in pneumocystis pneumonia prophylaxis and toxoplasmosis prevention within immunocompromised cohorts, as well as for dermatological conditions such as acne and dermatitis herpetiformis, available in both oral and topical formulations. Pharmacodynamically, dapsone's modes of action encompass inhibition of bacterial dihydropteroate synthetase, although it is associated with grave hematological adverse effects, notably hemolytic anemia exacerbated by glucose-6-phosphate dehydrogenase deficiency and agranulocytosis, alongside potential hepatotoxicity manifested as hepatic inflammation. Methemoglobinemia and dermatological hypersensitivity reactions, encompassing a variety of rash presentations, constitute additional risk factors. The teratogenic profile remains equivocal; however, continuation during gestation is advised in leprosy cases. Economically accessible as a generic formulation, dapsone retains its inclusion on the WHO Essential Medicines List, underscoring its clinical utility and indispensable status in global health pharmacopeias.\n\nDRUG 3 NAME: Pyrimethamine\nDRUG 3 BACKGROUND INFORMATION: Pyrimethamine, a folic acid antagonist deployed primarily in conjunction with leucovorin to mitigate its hematological toxicity, serves as a therapeutic agent against Toxoplasma gondii and Cystoisospora belli infections. Leveraged as a second-line prophylactic strategy when paired with dapsone, it targets Pneumocystis jiroveci pneumonia in HIV/AIDS cohorts, though its historical anti-malarial application has waned due to resistance. The pharmacological mechanism centers on the inhibition of dihydrofolate reductase, disrupting protozoal DNA synthesis and cell replication. Clinically, the oral administration of pyrimethamine necessitates vigilance due to adverse effects, notably gastrointestinal distress, hypersensitivity reactions, and potential for bone marrow suppression, contraindicating its application in folate-deficient anemia. Oncology concerns persist about its carcinogenic potential, and its teratogenicity risk mandates caution during gestation. Despite these concerns, pyrimethamine retains its status as a World Health Organization Essential Medicine and was ratified as a generic option in the U.S. pharmacopoeia as of early 2020.\n\nPROTEIN NAME: CHRM1\nPROTEIN BACKGROUND INFORMATION: The muscarinic acetylcholine receptor M1, also known as the cholinergic receptor, muscarinic 1, is a muscarinic receptor that in humans is encoded by the CHRM1 gene. It is localized to 11q13.\nThis receptor is found mediating slow EPSP at the ganglion in the postganglionic nerve, is common in exocrine glands and in the CNS.\nIt is predominantly found bound to G proteins of class Gq that use upregulation of phospholipase C and, therefore, inositol trisphosphate and intracellular calcium as a signalling pathway. A receptor so bound would not be susceptible to CTX or PTX. However, Gi (causing a downstream decrease in cAMP) and Gs (causing an increase in cAMP) have also been shown to be involved in interactions in certain tissues, and so would be susceptible to PTX and CTX respectively.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Naproxen-Adenopathy-Dapsone\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Dapsone-neumonia-Pyrimethamine\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Pyrimethamine-binding and inhibition-CHRM1"}]}}
{"custom_id": "Celecoxib-Ibuprofen-Metoprolol-ADRA2A-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Celecoxib\nDRUG 1 BACKGROUND INFORMATION: Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, functions as a nonsteroidal anti-inflammatory drug (NSAID) utilized primarily for its analgesic and anti-inflammatory efficacy in osteoarthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, dysmenorrhea, acute pain management, and juvenile rheumatoid arthritis. Additionally, celecoxib has prophylactic applications in reducing colorectal adenomatous formations in familial adenomatous polyposis due to its COX-2 inhibition, which mitigates pro-inflammatory prostaglandin synthesis while sparing COX-1, ostensibly minimizing gastrointestinal mucosal damage relative to non-selective NSAIDs. The pharmacokinetics permit oral administration, with pharmacodynamic effects commencing typically within one hour post-ingestion. Notable adverse reactions span gastrointestinal disturbances such as abdominal pain, nausea, and diarrhea, with severe risk profiles including cardiovascular thrombotic events, gastrointestinal perforation, renal impairment, and hypersensitivity reactions like anaphylaxis, contraindicating its use in populations with significant cardiovascular risk profiles. The risk profile parallels that of other NSAIDs like ibuprofen and naproxen, and caution is advised during late-stage gestation and lactation. Celecoxib's generic availability and widespread prescription underscore its clinical significance, albeit with requisite consideration of its potential side-effect burden.\n\nDRUG 2 NAME: Ibuprofen\nDRUG 2 BACKGROUND INFORMATION: Ibuprofen, a widely utilized nonsteroidal anti-inflammatory drug (NSAID), exerts its therapeutic effects primarily through the attenuation of cyclooxygenase (COX) enzymatic activity, thereby reducing the biosynthesis of pro-inflammatory prostaglandins. Indicated for alleviating nociceptive and inflammatory perturbations such as dysmenorrhea, migrainous episodes, and inflammatory arthropathies, ibuprofen demonstrates notable pharmacokinetics with onset of action within one hour post administration via oral or parenteral routes. Despite its efficacy, ibuprofen's pharmacodynamic profile correlates with several adverse outcomes, notably gastrointestinal mucosal irritation leading to potential bleeding, renal impairment with prolonged administration, and rare hepatotoxicity. It possesses a variable cardiovascular risk profile, posing increased myocardial infarction risk at higher dosages. Notably, ibuprofen is contraindicated in advanced gestational periods due to its deleterious fetal effects and can exacerbate asthmatic conditions. Although it constitutes a less potent anti-inflammatory than other NSAIDs, its inclusion in the WHO's List of Essential Medicines underscores its clinical utility across various domains. Despite its prevalence, ongoing vigilance is advised due to its side effect spectrum.\n\nDRUG 3 NAME: Metoprolol\nDRUG 3 BACKGROUND INFORMATION: Metoprolol, a cardioselective \u03b21-adrenergic receptor antagonist, is clinically utilized in the management of angina pectoris, hypertension, tachyarrhythmias, post-myocardial infarction secondary prophylaxis, and migraine prophylaxis. Its therapeutic efficacy is mediated via negative chronotropic and inotropic effects which result in decreased myocardial oxygen demand and improved exercise tolerance. The pharmacokinetics of metoprolol is influenced by hepatic cytochrome P450 2D6 isoenzyme variability leading to significant interpatient variability in drug metabolism, necessitating individualized dosing. Adverse effects prominently include insomnia, asthenia, presyncope, and gastrointestinal disturbances, with higher doses presenting risk for pronounced toxicity. Though teratogenic risk during pregnancy has not been conclusively excluded, its excretion into breast milk is considered clinically insignificant. Metoprolol is widely dispensed, reflecting its inclusion in the WHO's Essential Medicines, and its prescription frequency underscores its pivotal role in cardiovascular therapeutics.\n\nPROTEIN NAME: ADRA2A\nPROTEIN BACKGROUND INFORMATION: The alpha-2A adrenergic receptor (\u03b12A adrenoceptor), also known as ADRA2A, is an \u03b12-adrenergic receptor, and also denotes the human gene encoding it.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Celecoxib-gastric inflammation-Ibuprofen\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Ibuprofen-cholecystitis-Metoprolol\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Metoprolol-binding and inhibition-ADRA2A"}]}}
{"custom_id": "acetazolamide-Citalopram-Fluphenazine-ADRA2A-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: acetazolamide\nDRUG 1 BACKGROUND INFORMATION: Acetazolamide, marketed under the trade name Diamox, serves as a versatile pharmaceutical agent within the realm of carbonic anhydrase inhibitors, effectively modulating intraocular pressure via the diminution of aqueous humor production and osmolality. Its clinical utility spans across conditions such as glaucoma\u2014both open-angle and acute angle closure\u2014epilepsy, acute mountain sickness, periodic paralysis, idiopathic intracranial hypertension, and heart failure, with an ancillary role in urinary alkalinization. Therapeutic administration is achievable through oral and intravenous modalities. Mechanistically, acetazolamide exerts its effects by disrupting the equilibria of carbon dioxide hydration and subsequent bicarbonate ion production, thereby reducing intracellular hydrogen ion availability. The pharmacodynamic profile encompasses neuro-sensory side effects like paresthesia and tinnitus, alongside anorexia, emesis, and somnolence. Contraindications are notable in individuals with renal or hepatic impairment, and those with hypersensitivity to sulfonamide derivatives. As a diuretic and enzymatic inhibitor, it holds a position on the WHO's List of Essential Medicines, emphasizing its critical global accessibility as a generic formulation.\n\nDRUG 2 NAME: Citalopram\nDRUG 2 BACKGROUND INFORMATION: Citalopram, a chiral bicyclic phthalane derivative and selective serotonin reuptake inhibitor (SSRI), is primarily employed in the pharmacotherapy of major depressive disorder, obsessive-compulsive disorder, panic disorder, and social phobia through modulation of serotonergic neurotransmission. The therapeutic latency ranges from one to four weeks post-administration. It is predominantly administered orally, though parenteral administration via intravenous injection is utilized in specific regions to expedite therapeutic onset. The pharmacokinetic profile of citalopram encompasses hepatic metabolism predominantly via CYP2C19, CYP3A4, and CYP2D6, yielding demethylated metabolites. It is imperative to monitor for adverse reactions, including, but not limited to, gastrointestinal disturbances, insomnia, sexual dysfunction, tremors, somnolence, hyperhidrosis, serotonin toxicity, and cardiotoxicity as manifested by QT interval prolongation. Contraindications entail concurrent MAO inhibitor therapy due to risk of serotonin syndrome and potential teratogenicity warrants cautious use in pregnancy. The potential for exacerbating suicidality in individuals under 25 necessitates vigilant monitoring. Citalopram's clinical prominence is evidenced by its inclusion in the WHO's List of Essential Medicines and its extensive prescribing frequency in the United States, underscoring its integral role in psychiatric treatment regimens.\n\nDRUG 3 NAME: Fluphenazine\nDRUG 3 BACKGROUND INFORMATION: Fluphenazine is a high-affinity typical antipsychotic of the phenothiazine cohort primarily prescribed for chronic psychotic disorders such as schizophrenia, offering efficacy comparable to chlorpromazine. Administered via oral, intramuscular, subcutaneous routes\u2014or as a long-acting depot, fluphenazine decanoate\u2014this compound exhibits prolonged dopaminergic antagonism with an extended half-life conducive to monthly dosing regimens. Notably contraindicated in severe depressive states, its pharmacological action is ascribed to dopamine receptor blockade, though precision in its mechanism remains indeterminate. The pharmacodynamic profile of fluphenazine entails extrapyramidal symptoms, somnolence, depressive mood alterations, and metabolic side effects, with grave adverse events encompassing neuroleptic malignant syndrome, agranulocytosis, and irreversible tardive dyskinesia. Moreover, in the geriatric cohort with dementia-related psychoses, mortality risk is potentiated. Prolactin secretion perturbations may elicit galactorrhea, gynecomastia, erectile dysfunction, and amenorrhea, with teratogenic safety in gestation unresolved. Chronic administration associates with hepatocellular enzyme elevation in a substantial patient subset. Despite its broad utilization reflected in its inclusion on the World Health Organization's Essential Medicines list, its production cessation in some regions underscores its dynamic availability landscape.\n\nPROTEIN NAME: ADRA2A\nPROTEIN BACKGROUND INFORMATION: The alpha-2A adrenergic receptor (\u03b12A adrenoceptor), also known as ADRA2A, is an \u03b12-adrenergic receptor, and also denotes the human gene encoding it.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): acetazolamide-Back Ache-Citalopram\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Citalopram-cholecystitis-Fluphenazine\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Fluphenazine-binding and inhibition-ADRA2A"}]}}
{"custom_id": "Famotidine-Lamotrigine-oxybutynin-CHRM1-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Famotidine\nDRUG 1 BACKGROUND INFORMATION: Famotidine, sold under the brand name Pepcid among others, is a histamine H2 receptor antagonist medication that decreases stomach acid production. It is used to treat peptic ulcer disease, gastroesophageal reflux disease, and Zollinger\u2013Ellison syndrome. It is taken by mouth or by injection into a vein. It begins working within an hour.\nCommon side effects include headache, abdominal pain, diarrhea or constipation, and dizziness. Serious side effects may include pneumonia and seizures. Use in pregnancy appears safe but has not been well studied, while use during breastfeeding is not recommended.\nFamotidine was patented in 1979 and came into medical use in 1985. It is available as a generic medication. In 2022, it was the 49th most commonly prescribed medication in the United States, with more than 13 million prescriptions.\n\nDRUG 2 NAME: Lamotrigine\nDRUG 2 BACKGROUND INFORMATION: Lamotrigine, a phenyltriazine anticonvulsant, is primarily utilized in the pharmacological management of epilepsy, encompassing focal, tonic-clonic, and Lennox-Gastaut syndrome seizures, as well as serving as a mood-stabilizing agent in bipolar disorder. While it does not consistently ameliorate acute depressive states in bipolar disorders outside of severe depression contexts, it efficaciously mitigates the risk of recurrent depressive episodes in euthymic individuals. Additionally, lamotrigine is prescribed off-label for major depressive disorder and depersonalization-derealization disorder. Its pharmacodynamics are hypothesized to involve the inhibition of excitatory neurotransmitter release through modulation of voltage-sensitive sodium channels and voltage-gated calcium channels. Despite its therapeutic efficacy, lamotrigine's adverse effect profile includes both common side effects such as nausea, somnolence, headache, emesis, ataxia, and dermatological reactions, and serious reactions like hemolytic anemia, suicidality, and potentially fatal Stevens\u2013Johnson syndrome.\n\nDRUG 3 NAME: oxybutynin\nDRUG 3 BACKGROUND INFORMATION: Oxybutynin, marketed as Ditropan, is a quintessential anticholinergic agent employed predominantly for the amelioration of overactive bladder symptoms, capitalizing on its potent antimuscarinic properties that effectively circumvent acetylcholine-mediated smooth muscle contractions. Its pharmacotherapeutic action, analogous to tolterodine, darifenacin, and solifenacin, renders it a superior first-line therapeutic option due to its robust safety and efficacy profile over prolonged usage, despite plausible off-label utilizations in hyperhidrosis management. Contrarily, its application for pediatric nocturnal enuresis has seen diminished prevalence, given its questionable efficacy. Administrable orally or transdermally, oxybutynin's pharmacokinetic profile necessitates vigilance regarding adverse effects such as xerostomia, gastrointestinal hypomotility, and thermoregulatory dysfunction, encompassing severe sequelae like urinary retention and thermophilic impairments manifesting as heat stroke. Its teratogenic and lactogenic safety paradigms remain speculative, underscoring the need for judicious administration during pregnancy and lactation. As a generically available pharmacologic entity, it maintains substantial prescription frequency, embodying a pivotal role in managing cholinergic-mediated urological disorders.\n\nPROTEIN NAME: CHRM1\nPROTEIN BACKGROUND INFORMATION: The muscarinic acetylcholine receptor M1, also known as the cholinergic receptor, muscarinic 1, is a muscarinic receptor that in humans is encoded by the CHRM1 gene. It is localized to 11q13.\nThis receptor is found mediating slow EPSP at the ganglion in the postganglionic nerve, is common in exocrine glands and in the CNS.\nIt is predominantly found bound to G proteins of class Gq that use upregulation of phospholipase C and, therefore, inositol trisphosphate and intracellular calcium as a signalling pathway. A receptor so bound would not be susceptible to CTX or PTX. However, Gi (causing a downstream decrease in cAMP) and Gs (causing an increase in cAMP) have also been shown to be involved in interactions in certain tissues, and so would be susceptible to PTX and CTX respectively.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Famotidine-Adenopathy-Lamotrigine\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Lamotrigine-cholecystitis-oxybutynin\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): oxybutynin-binding and inhibition-CHRM1"}]}}
{"custom_id": "Doxazosin-Metoprolol-Perphenazine-ADRA2C-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Doxazosin\nDRUG 1 BACKGROUND INFORMATION: Doxazosin, sold under the brand name Cardura among others, is a medication used to treat symptoms of benign prostatic hyperplasia (enlarged prostate), hypertension (high blood pressure), and post-traumatic stress disorder (PTSD). For high blood pressure, it is a less preferred option. It is taken by mouth.\nCommon side effects include dizziness, sleepiness, swelling, nausea, shortness of breath, and abdominal pain. Severe side effects may include low blood pressure with standing, an irregular heart beat, and priapism. It is a selective \u03b11-adrenergic blocker in the quinazoline class of compounds.\nDoxazosin was patented in 1977 and came into medical use in 1988. It is available as a generic medication. In 2022, it was the 180th most commonly prescribed medication in the United States, with more than 2 million prescriptions.\n\nDRUG 2 NAME: Metoprolol\nDRUG 2 BACKGROUND INFORMATION: Metoprolol, a cardioselective \u03b21-adrenergic receptor antagonist, is clinically utilized in the management of angina pectoris, hypertension, tachyarrhythmias, post-myocardial infarction secondary prophylaxis, and migraine prophylaxis. Its therapeutic efficacy is mediated via negative chronotropic and inotropic effects which result in decreased myocardial oxygen demand and improved exercise tolerance. The pharmacokinetics of metoprolol is influenced by hepatic cytochrome P450 2D6 isoenzyme variability leading to significant interpatient variability in drug metabolism, necessitating individualized dosing. Adverse effects prominently include insomnia, asthenia, presyncope, and gastrointestinal disturbances, with higher doses presenting risk for pronounced toxicity. Though teratogenic risk during pregnancy has not been conclusively excluded, its excretion into breast milk is considered clinically insignificant. Metoprolol is widely dispensed, reflecting its inclusion in the WHO's Essential Medicines, and its prescription frequency underscores its pivotal role in cardiovascular therapeutics.\n\nDRUG 3 NAME: Perphenazine\nDRUG 3 BACKGROUND INFORMATION: Perphenazine is a typical antipsychotic drug.  Chemically, it is classified as a piperazinyl phenothiazine. Originally marketed in the United States as Trilafon, it has been in clinical use for decades.\nPerphenazine is roughly ten times as potent as chlorpromazine at the dopamine-2 (D2) receptor; thus perphenazine is considered a medium-potency antipsychotic.\n\nPROTEIN NAME: ADRA2C\nPROTEIN BACKGROUND INFORMATION: The alpha-2C adrenergic receptor (\u03b12C adrenoceptor), also known as ADRA2C, is an alpha-2 adrenergic receptor, and also denotes the human gene encoding it.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Doxazosin-gastric inflammation-Metoprolol\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Metoprolol-insulin dependent diabetes mellitus-Perphenazine\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Perphenazine-binding and inhibition-ADRA2C"}]}}
{"custom_id": "Naproxen-Furosemide-Salmeterol-ADRB1-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: Furosemide\nDRUG 2 BACKGROUND INFORMATION: Furosemide, a potent loop diuretic, exerts its pharmacological action by inhibiting the Na-K-2Cl symporter in the thick ascending limb of the loop of Henle, thus profoundly augmenting natriuresis and diuresis, which alleviates conditions of edema secondary to cardiac, hepatic, or renal insufficiencies. Additionally utilized in the management of hypertension, furosemide yields rapid onset of action with intravenous administration effectuating within five minutes, whereas oral ingestion manifests systemic absorption and efficacy within an hour. Adverse effects encompass orthostatic hypotension, tinnitus, and photosensitivity, with severe risks including electrolyte imbalances such as hypokalemia, along with potential nephrotoxicity and ototoxicity. Clinicians are advised to diligently monitor serum electrolytes (notably potassium), bicarbonate, renal indices (creatinine, BUN), and hepatic function parameters. Despite its inclusion on the World Health Organization's List of Essential Medicines, furosemide's utility is tempered by its status on the World Anti-Doping Agency's list of prohibited substances, attributed to its potential misuse for concealing illicit performance-enhancing drug usage, alongside its veterinary application for managing exercise-induced pulmonary hemorrhage in equines.\n\nDRUG 3 NAME: Salmeterol\nDRUG 3 BACKGROUND INFORMATION: Salmeterol is a long-acting \u03b22 adrenergic receptor agonist (LABA) used in the treatment and prevention of asthma symptoms and control of chronic obstructive pulmonary disease (COPD) symptoms. Symptoms of bronchospasm include shortness of breath, wheezing, coughing and chest tightness. It is also used to prevent breathing difficulties during exercise (exercise-induced bronchoconstriction).\nIt was patented in 1983 and came into medical use in 1990. It is marketed as Serevent in the US. It is available as a dry-powder inhaler (DPI) that releases a powdered form of the drug. It was previously available as a metered-dose inhaler (MDI) but was discontinued in the US in 2002. It is available as an MDI in other countries as of 2020.\n\nPROTEIN NAME: ADRB1\nPROTEIN BACKGROUND INFORMATION: The beta-1 adrenergic receptor (\u03b21 adrenoceptor), also known as ADRB1, can refer to either the protein-encoding gene (gene ADRB1) or one of the four adrenergic receptors. It is a G-protein coupled receptor associated with the Gs heterotrimeric G-protein that is expressed predominantly in cardiac tissue. In addition to cardiac tissue, beta-1 adrenergic receptors are also expressed in the cerebral cortex.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Naproxen-adenomyosis-Furosemide\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Furosemide-right heart failure-Salmeterol\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Salmeterol-binding and activation-ADRB1"}]}}
{"custom_id": "Naproxen-Orphenadrine-Trazodone-ADRA2A-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: Orphenadrine\nDRUG 2 BACKGROUND INFORMATION: Orphenadrine (sold under many brand names) is an anticholinergic drug of the ethanolamine antihistamine class; it is closely related to diphenhydramine. It is a muscle relaxant that is used to treat muscle pain and to help with motor control in Parkinson's disease, but has largely been superseded by newer drugs. It is considered a dirty drug due to its multiple mechanisms of action in different pathways. It was discovered and developed in the 1940s.\n\nDRUG 3 NAME: Trazodone\nDRUG 3 BACKGROUND INFORMATION: Trazodone is an antidepressant medication used to treat major depressive disorder, anxiety disorders, and insomnia. It is a phenylpiperazine compound of the serotonin antagonist and reuptake inhibitor (SARI) class. The medication is taken orally.\nCommon side effects include dry mouth, feeling faint, vomiting, and headache. More serious side effects may include suicide, mania, irregular heart rate, and pathologically prolonged erections. It is unclear if use during pregnancy or breastfeeding is safe.  Trazodone also has sedating effects.\nTrazodone was approved for medical use in the United States in 1981. It is available as a generic medication. In 2022, it was the eighteenth most commonly prescribed medication in the United States, with more than 27 million prescriptions.\n\nPROTEIN NAME: ADRA2A\nPROTEIN BACKGROUND INFORMATION: The alpha-2A adrenergic receptor (\u03b12A adrenoceptor), also known as ADRA2A, is an \u03b12-adrenergic receptor, and also denotes the human gene encoding it.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Naproxen-loss of weight-Orphenadrine\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Orphenadrine-Back Ache-Trazodone\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Trazodone-binding and inhibition-ADRA2A"}]}}
{"custom_id": "Amlodipine-Dapsone-Pyrimethamine-CHRM1-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Amlodipine\nDRUG 1 BACKGROUND INFORMATION: Amlodipine, a dihydropyridine-type long-acting calcium channel antagonist, exerts its pharmacological action primarily through vasodilation by impeding calcium ion influx through L-type calcium channels in vascular smooth muscle, which ameliorates hypertension, coronary artery disease, and variant angina. Administered orally, its pharmacokinetic profile necessitates caution in hepatic impairment and geriatric populations, requiring dose modulation. Although the teratogenic risk during gestation or lactation remains indeterminate, its side effect profile encompasses peripheral edema, lethargy, gastrointestinal distress, and potential hypotension or myocardial infarction. This compound's significant therapeutic utility has merited its inclusion on the WHO Essential Medicines List and extensive global prescription prevalence while remaining generically accessible.\n\nDRUG 2 NAME: Dapsone\nDRUG 2 BACKGROUND INFORMATION: Dapsone, chemically delineated as 4,4'-sulfonyldianiline or diaminodiphenyl sulfone, operates as a bacteriostatic antimicrobial agent within the sulfone class, frequently co-administered with rifampicin and clofazimine in leprosy management. It serves as an adjunctive therapeutic in pneumocystis pneumonia prophylaxis and toxoplasmosis prevention within immunocompromised cohorts, as well as for dermatological conditions such as acne and dermatitis herpetiformis, available in both oral and topical formulations. Pharmacodynamically, dapsone's modes of action encompass inhibition of bacterial dihydropteroate synthetase, although it is associated with grave hematological adverse effects, notably hemolytic anemia exacerbated by glucose-6-phosphate dehydrogenase deficiency and agranulocytosis, alongside potential hepatotoxicity manifested as hepatic inflammation. Methemoglobinemia and dermatological hypersensitivity reactions, encompassing a variety of rash presentations, constitute additional risk factors. The teratogenic profile remains equivocal; however, continuation during gestation is advised in leprosy cases. Economically accessible as a generic formulation, dapsone retains its inclusion on the WHO Essential Medicines List, underscoring its clinical utility and indispensable status in global health pharmacopeias.\n\nDRUG 3 NAME: Pyrimethamine\nDRUG 3 BACKGROUND INFORMATION: Pyrimethamine, a folic acid antagonist deployed primarily in conjunction with leucovorin to mitigate its hematological toxicity, serves as a therapeutic agent against Toxoplasma gondii and Cystoisospora belli infections. Leveraged as a second-line prophylactic strategy when paired with dapsone, it targets Pneumocystis jiroveci pneumonia in HIV/AIDS cohorts, though its historical anti-malarial application has waned due to resistance. The pharmacological mechanism centers on the inhibition of dihydrofolate reductase, disrupting protozoal DNA synthesis and cell replication. Clinically, the oral administration of pyrimethamine necessitates vigilance due to adverse effects, notably gastrointestinal distress, hypersensitivity reactions, and potential for bone marrow suppression, contraindicating its application in folate-deficient anemia. Oncology concerns persist about its carcinogenic potential, and its teratogenicity risk mandates caution during gestation. Despite these concerns, pyrimethamine retains its status as a World Health Organization Essential Medicine and was ratified as a generic option in the U.S. pharmacopoeia as of early 2020.\n\nPROTEIN NAME: CHRM1\nPROTEIN BACKGROUND INFORMATION: The muscarinic acetylcholine receptor M1, also known as the cholinergic receptor, muscarinic 1, is a muscarinic receptor that in humans is encoded by the CHRM1 gene. It is localized to 11q13.\nThis receptor is found mediating slow EPSP at the ganglion in the postganglionic nerve, is common in exocrine glands and in the CNS.\nIt is predominantly found bound to G proteins of class Gq that use upregulation of phospholipase C and, therefore, inositol trisphosphate and intracellular calcium as a signalling pathway. A receptor so bound would not be susceptible to CTX or PTX. However, Gi (causing a downstream decrease in cAMP) and Gs (causing an increase in cAMP) have also been shown to be involved in interactions in certain tissues, and so would be susceptible to PTX and CTX respectively.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Amlodipine-cholecystitis-Dapsone\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Dapsone-neumonia-Pyrimethamine\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Pyrimethamine-binding and inhibition-CHRM1"}]}}
{"custom_id": "Naproxen-Ondansetron-Trazodone-ADRA1A-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: Ondansetron\nDRUG 2 BACKGROUND INFORMATION: Ondansetron, a potent antiemetic utilized to mitigate nausea and emesis associated with chemotherapy, radiation, migraine, and surgical procedures, exerts its pharmacological action as a selective serotonin 5-HT3 receptor antagonist. Absence of affinity for dopaminergic and muscarinic acetylcholine receptors precludes extrapyramidal side effects such as akathisia. Administered via oral, intravenous, or intramuscular routes, ondansetron's pharmacokinetic profile is characterized by hepatic metabolism and renal excretion. Adverse effects frequently reported encompass gastrointestinal dysmotility manifesting as diarrhea or constipation, central nervous system manifestations including headache and somnolence, and dermal pruritus, with more severe toxicities including QT interval prolongation on electrocardiographic assessment and anaphylaxis. Although the teratogenic risk is minimal, comprehensive teratological data in gravid populations remain insufficient. Recognized on the WHO's List of Essential Medicines, ondansetron is extensively prescribed, highlighting its clinical utility and incorporation into treatment protocols, with significant utilization confirmed by its high prescription frequency in the United States.\n\nDRUG 3 NAME: Trazodone\nDRUG 3 BACKGROUND INFORMATION: Trazodone is an antidepressant medication used to treat major depressive disorder, anxiety disorders, and insomnia. It is a phenylpiperazine compound of the serotonin antagonist and reuptake inhibitor (SARI) class. The medication is taken orally.\nCommon side effects include dry mouth, feeling faint, vomiting, and headache. More serious side effects may include suicide, mania, irregular heart rate, and pathologically prolonged erections. It is unclear if use during pregnancy or breastfeeding is safe.  Trazodone also has sedating effects.\nTrazodone was approved for medical use in the United States in 1981. It is available as a generic medication. In 2022, it was the eighteenth most commonly prescribed medication in the United States, with more than 27 million prescriptions.\n\nPROTEIN NAME: ADRA1A\nPROTEIN BACKGROUND INFORMATION: The alpha-1A adrenergic receptor (\u03b11A adrenoreceptor), also known as ADRA1A, formerly known also as the  alpha-1C adrenergic receptor, is an alpha-1 adrenergic receptor, and also denotes the human gene encoding it. There is no longer a subtype \u03b11C receptor. At one time, there was a subtype known as \u03b11C, but it was found to be identical to the previously discovered \u03b11A receptor subtype. To avoid confusion, the naming convention was continued with the letter D.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Naproxen-Dyspnea exertional-Ondansetron\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Ondansetron-hepatic neoplasia-Trazodone\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Trazodone-binding and inhibition-ADRA1A"}]}}
{"custom_id": "Aciclovir-Citalopram-Fluphenazine-HRH1-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Aciclovir\nDRUG 1 BACKGROUND INFORMATION: Aciclovir, an antiviral guanosine analogue, exhibits its therapeutic efficacy predominantly by inhibiting viral DNA polymerase through its metabolization to aciclovir triphosphate, resulting in the cessation of herpesvirus DNA elongation across Herpes Simplex Virus, varicella-zoster, and CMV prophylaxis post-transplantation. Administerable orally, topically, or intravenously, its pharmacokinetic profile necessitates careful consideration in patients with compromised renal or hepatic function due to potential nephrotoxicity and thrombocytopenia. While demonstrating an acceptable safety margin during gestation and lactation, adverse events such as gastrointestinal discomfort and diarrhea are common. Its inclusion in the WHO's Essential Medicines list underscores its global pivotal role in antiviral therapy, with its generic accessibility enhancing universal healthcare implementation.\n\nDRUG 2 NAME: Citalopram\nDRUG 2 BACKGROUND INFORMATION: Citalopram, a chiral bicyclic phthalane derivative and selective serotonin reuptake inhibitor (SSRI), is primarily employed in the pharmacotherapy of major depressive disorder, obsessive-compulsive disorder, panic disorder, and social phobia through modulation of serotonergic neurotransmission. The therapeutic latency ranges from one to four weeks post-administration. It is predominantly administered orally, though parenteral administration via intravenous injection is utilized in specific regions to expedite therapeutic onset. The pharmacokinetic profile of citalopram encompasses hepatic metabolism predominantly via CYP2C19, CYP3A4, and CYP2D6, yielding demethylated metabolites. It is imperative to monitor for adverse reactions, including, but not limited to, gastrointestinal disturbances, insomnia, sexual dysfunction, tremors, somnolence, hyperhidrosis, serotonin toxicity, and cardiotoxicity as manifested by QT interval prolongation. Contraindications entail concurrent MAO inhibitor therapy due to risk of serotonin syndrome and potential teratogenicity warrants cautious use in pregnancy. The potential for exacerbating suicidality in individuals under 25 necessitates vigilant monitoring. Citalopram's clinical prominence is evidenced by its inclusion in the WHO's List of Essential Medicines and its extensive prescribing frequency in the United States, underscoring its integral role in psychiatric treatment regimens.\n\nDRUG 3 NAME: Fluphenazine\nDRUG 3 BACKGROUND INFORMATION: Fluphenazine is a high-affinity typical antipsychotic of the phenothiazine cohort primarily prescribed for chronic psychotic disorders such as schizophrenia, offering efficacy comparable to chlorpromazine. Administered via oral, intramuscular, subcutaneous routes\u2014or as a long-acting depot, fluphenazine decanoate\u2014this compound exhibits prolonged dopaminergic antagonism with an extended half-life conducive to monthly dosing regimens. Notably contraindicated in severe depressive states, its pharmacological action is ascribed to dopamine receptor blockade, though precision in its mechanism remains indeterminate. The pharmacodynamic profile of fluphenazine entails extrapyramidal symptoms, somnolence, depressive mood alterations, and metabolic side effects, with grave adverse events encompassing neuroleptic malignant syndrome, agranulocytosis, and irreversible tardive dyskinesia. Moreover, in the geriatric cohort with dementia-related psychoses, mortality risk is potentiated. Prolactin secretion perturbations may elicit galactorrhea, gynecomastia, erectile dysfunction, and amenorrhea, with teratogenic safety in gestation unresolved. Chronic administration associates with hepatocellular enzyme elevation in a substantial patient subset. Despite its broad utilization reflected in its inclusion on the World Health Organization's Essential Medicines list, its production cessation in some regions underscores its dynamic availability landscape.\n\nPROTEIN NAME: HRH1\nPROTEIN BACKGROUND INFORMATION: The H1 receptor is a histamine receptor belonging to the family of rhodopsin-like G-protein-coupled receptors. This receptor is activated by the biogenic amine histamine. It is expressed in smooth muscles, on vascular endothelial cells, in the heart, and in the central nervous system. The H1 receptor is linked to an intracellular G-protein (Gq) that activates phospholipase C and the inositol triphosphate (IP3) signalling pathway. Antihistamines, which act on this receptor, are used as anti-allergy drugs. The crystal structure of the receptor has been determined (shown on the right/below) and used to discover new histamine H1 receptor ligands in structure-based virtual screening studies.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Aciclovir-methaemoglobinaemia-Citalopram\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Citalopram-cholecystitis-Fluphenazine\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Fluphenazine-binding and inhibition-HRH1"}]}}
{"custom_id": "Ibuprofen-Metoprolol-Perphenazine-ADRA2C-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Ibuprofen\nDRUG 1 BACKGROUND INFORMATION: Ibuprofen, a widely utilized nonsteroidal anti-inflammatory drug (NSAID), exerts its therapeutic effects primarily through the attenuation of cyclooxygenase (COX) enzymatic activity, thereby reducing the biosynthesis of pro-inflammatory prostaglandins. Indicated for alleviating nociceptive and inflammatory perturbations such as dysmenorrhea, migrainous episodes, and inflammatory arthropathies, ibuprofen demonstrates notable pharmacokinetics with onset of action within one hour post administration via oral or parenteral routes. Despite its efficacy, ibuprofen's pharmacodynamic profile correlates with several adverse outcomes, notably gastrointestinal mucosal irritation leading to potential bleeding, renal impairment with prolonged administration, and rare hepatotoxicity. It possesses a variable cardiovascular risk profile, posing increased myocardial infarction risk at higher dosages. Notably, ibuprofen is contraindicated in advanced gestational periods due to its deleterious fetal effects and can exacerbate asthmatic conditions. Although it constitutes a less potent anti-inflammatory than other NSAIDs, its inclusion in the WHO's List of Essential Medicines underscores its clinical utility across various domains. Despite its prevalence, ongoing vigilance is advised due to its side effect spectrum.\n\nDRUG 2 NAME: Metoprolol\nDRUG 2 BACKGROUND INFORMATION: Metoprolol, a cardioselective \u03b21-adrenergic receptor antagonist, is clinically utilized in the management of angina pectoris, hypertension, tachyarrhythmias, post-myocardial infarction secondary prophylaxis, and migraine prophylaxis. Its therapeutic efficacy is mediated via negative chronotropic and inotropic effects which result in decreased myocardial oxygen demand and improved exercise tolerance. The pharmacokinetics of metoprolol is influenced by hepatic cytochrome P450 2D6 isoenzyme variability leading to significant interpatient variability in drug metabolism, necessitating individualized dosing. Adverse effects prominently include insomnia, asthenia, presyncope, and gastrointestinal disturbances, with higher doses presenting risk for pronounced toxicity. Though teratogenic risk during pregnancy has not been conclusively excluded, its excretion into breast milk is considered clinically insignificant. Metoprolol is widely dispensed, reflecting its inclusion in the WHO's Essential Medicines, and its prescription frequency underscores its pivotal role in cardiovascular therapeutics.\n\nDRUG 3 NAME: Perphenazine\nDRUG 3 BACKGROUND INFORMATION: Perphenazine is a typical antipsychotic drug.  Chemically, it is classified as a piperazinyl phenothiazine. Originally marketed in the United States as Trilafon, it has been in clinical use for decades.\nPerphenazine is roughly ten times as potent as chlorpromazine at the dopamine-2 (D2) receptor; thus perphenazine is considered a medium-potency antipsychotic.\n\nPROTEIN NAME: ADRA2C\nPROTEIN BACKGROUND INFORMATION: The alpha-2C adrenergic receptor (\u03b12C adrenoceptor), also known as ADRA2C, is an alpha-2 adrenergic receptor, and also denotes the human gene encoding it.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Ibuprofen-cholecystitis-Metoprolol\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Metoprolol-insulin dependent diabetes mellitus-Perphenazine\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Perphenazine-binding and inhibition-ADRA2C"}]}}
{"custom_id": "Aciclovir-Citalopram-Fluphenazine-ADRA2C-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Aciclovir\nDRUG 1 BACKGROUND INFORMATION: Aciclovir, an antiviral guanosine analogue, exhibits its therapeutic efficacy predominantly by inhibiting viral DNA polymerase through its metabolization to aciclovir triphosphate, resulting in the cessation of herpesvirus DNA elongation across Herpes Simplex Virus, varicella-zoster, and CMV prophylaxis post-transplantation. Administerable orally, topically, or intravenously, its pharmacokinetic profile necessitates careful consideration in patients with compromised renal or hepatic function due to potential nephrotoxicity and thrombocytopenia. While demonstrating an acceptable safety margin during gestation and lactation, adverse events such as gastrointestinal discomfort and diarrhea are common. Its inclusion in the WHO's Essential Medicines list underscores its global pivotal role in antiviral therapy, with its generic accessibility enhancing universal healthcare implementation.\n\nDRUG 2 NAME: Citalopram\nDRUG 2 BACKGROUND INFORMATION: Citalopram, a chiral bicyclic phthalane derivative and selective serotonin reuptake inhibitor (SSRI), is primarily employed in the pharmacotherapy of major depressive disorder, obsessive-compulsive disorder, panic disorder, and social phobia through modulation of serotonergic neurotransmission. The therapeutic latency ranges from one to four weeks post-administration. It is predominantly administered orally, though parenteral administration via intravenous injection is utilized in specific regions to expedite therapeutic onset. The pharmacokinetic profile of citalopram encompasses hepatic metabolism predominantly via CYP2C19, CYP3A4, and CYP2D6, yielding demethylated metabolites. It is imperative to monitor for adverse reactions, including, but not limited to, gastrointestinal disturbances, insomnia, sexual dysfunction, tremors, somnolence, hyperhidrosis, serotonin toxicity, and cardiotoxicity as manifested by QT interval prolongation. Contraindications entail concurrent MAO inhibitor therapy due to risk of serotonin syndrome and potential teratogenicity warrants cautious use in pregnancy. The potential for exacerbating suicidality in individuals under 25 necessitates vigilant monitoring. Citalopram's clinical prominence is evidenced by its inclusion in the WHO's List of Essential Medicines and its extensive prescribing frequency in the United States, underscoring its integral role in psychiatric treatment regimens.\n\nDRUG 3 NAME: Fluphenazine\nDRUG 3 BACKGROUND INFORMATION: Fluphenazine is a high-affinity typical antipsychotic of the phenothiazine cohort primarily prescribed for chronic psychotic disorders such as schizophrenia, offering efficacy comparable to chlorpromazine. Administered via oral, intramuscular, subcutaneous routes\u2014or as a long-acting depot, fluphenazine decanoate\u2014this compound exhibits prolonged dopaminergic antagonism with an extended half-life conducive to monthly dosing regimens. Notably contraindicated in severe depressive states, its pharmacological action is ascribed to dopamine receptor blockade, though precision in its mechanism remains indeterminate. The pharmacodynamic profile of fluphenazine entails extrapyramidal symptoms, somnolence, depressive mood alterations, and metabolic side effects, with grave adverse events encompassing neuroleptic malignant syndrome, agranulocytosis, and irreversible tardive dyskinesia. Moreover, in the geriatric cohort with dementia-related psychoses, mortality risk is potentiated. Prolactin secretion perturbations may elicit galactorrhea, gynecomastia, erectile dysfunction, and amenorrhea, with teratogenic safety in gestation unresolved. Chronic administration associates with hepatocellular enzyme elevation in a substantial patient subset. Despite its broad utilization reflected in its inclusion on the World Health Organization's Essential Medicines list, its production cessation in some regions underscores its dynamic availability landscape.\n\nPROTEIN NAME: ADRA2C\nPROTEIN BACKGROUND INFORMATION: The alpha-2C adrenergic receptor (\u03b12C adrenoceptor), also known as ADRA2C, is an alpha-2 adrenergic receptor, and also denotes the human gene encoding it.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Aciclovir-methaemoglobinaemia-Citalopram\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Citalopram-cholecystitis-Fluphenazine\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Fluphenazine-binding and inhibition-ADRA2C"}]}}
{"custom_id": "Naproxen-Capecitabine-Desloratadine-HRH1-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: Capecitabine\nDRUG 2 BACKGROUND INFORMATION: Capecitabine, sold under the brand name Xeloda among others, is a anticancer medication used to treat breast cancer, gastric cancer and colorectal cancer. For breast cancer it is often used together with docetaxel. It is taken by mouth.\nCommon side effects include abdominal pain, vomiting, diarrhea, weakness, and rashes. Other severe side effects include blood clotting problems, allergic reactions, heart problems such as cardiomyopathy, and low blood cell counts. Use during pregnancy may result in harm to the fetus. Capecitabine, inside the body, is converted to 5-fluorouracil (5-FU) through which it acts. It belongs to the class of medications known as fluoropyrimidines, which also includes 5-FU and tegafur.\nCapecitabine was patented in 1992 and approved for medical use in 1998. It is on the World Health Organization's List of Essential Medicines.\n\nDRUG 3 NAME: Desloratadine\nDRUG 3 BACKGROUND INFORMATION: Desloratadine sold under the brand name Aerius among others, is a tricyclic H1 inverse agonist that is used to treat allergies. It is an active metabolite of loratadine.\nIt was patented in 1984 and came into medical use in 2001. It was brought to the market in the US by Schering Corporation, later named Schering-Plough.\n\nPROTEIN NAME: HRH1\nPROTEIN BACKGROUND INFORMATION: The H1 receptor is a histamine receptor belonging to the family of rhodopsin-like G-protein-coupled receptors. This receptor is activated by the biogenic amine histamine. It is expressed in smooth muscles, on vascular endothelial cells, in the heart, and in the central nervous system. The H1 receptor is linked to an intracellular G-protein (Gq) that activates phospholipase C and the inositol triphosphate (IP3) signalling pathway. Antihistamines, which act on this receptor, are used as anti-allergy drugs. The crystal structure of the receptor has been determined (shown on the right/below) and used to discover new histamine H1 receptor ligands in structure-based virtual screening studies.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Naproxen-loss of weight-Capecitabine\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Capecitabine-drug toxicity NOS-Desloratadine\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Desloratadine-binding and inhibition-HRH1"}]}}
{"custom_id": "Naproxen-Cetirizine-Salmeterol-ADRB1-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: Cetirizine\nDRUG 2 BACKGROUND INFORMATION: Cetirizine, a second-generation selective H1 antihistaminergic agent, is primarily administered orally for the amelioration of allergic rhinitis, dermatitis, and urticaria, exerting its pharmacodynamic effects predominantly extracellularly, thereby minimizing central nervous system penetration and consequent sedative effects typical of first-generation antihistamines such as diphenhydramine. Its clinical onset transpires within thirty minutes, maintaining therapeutic efficacy for approximately 24 hours with an adverse effect profile that includes somnolence, xerostomia, cephalalgia, and abdominal discomfort, albeit with a diminished proclivity for sedation compared to its first-generation counterparts due to its peripheral selectivity. Amongst its second-generation analogs, cetirizine exhibits a comparatively higher incidence of somnolence vis-\u00e0-vis fexofenadine and loratadine. It is contraindicated in lactation but permissible during gestation and extends its utility to pediatric cohorts with caution advised regarding potential somnolence. Being generically available and included in the World Health Organization's List of Essential Medicines, cetirizine\u2019s broad prescriptive prevalence, as evidenced by over 13 million US prescriptions in 2022, underscores its efficacy and widespread utilitarian value in allergy management.\n\nDRUG 3 NAME: Salmeterol\nDRUG 3 BACKGROUND INFORMATION: Salmeterol is a long-acting \u03b22 adrenergic receptor agonist (LABA) used in the treatment and prevention of asthma symptoms and control of chronic obstructive pulmonary disease (COPD) symptoms. Symptoms of bronchospasm include shortness of breath, wheezing, coughing and chest tightness. It is also used to prevent breathing difficulties during exercise (exercise-induced bronchoconstriction).\nIt was patented in 1983 and came into medical use in 1990. It is marketed as Serevent in the US. It is available as a dry-powder inhaler (DPI) that releases a powdered form of the drug. It was previously available as a metered-dose inhaler (MDI) but was discontinued in the US in 2002. It is available as an MDI in other countries as of 2020.\n\nPROTEIN NAME: ADRB1\nPROTEIN BACKGROUND INFORMATION: The beta-1 adrenergic receptor (\u03b21 adrenoceptor), also known as ADRB1, can refer to either the protein-encoding gene (gene ADRB1) or one of the four adrenergic receptors. It is a G-protein coupled receptor associated with the Gs heterotrimeric G-protein that is expressed predominantly in cardiac tissue. In addition to cardiac tissue, beta-1 adrenergic receptors are also expressed in the cerebral cortex.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Naproxen-cholecystitis-Cetirizine\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Cetirizine-cholecystitis-Salmeterol\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Salmeterol-binding and activation-ADRB1"}]}}
{"custom_id": "Methylphenidate-Ziprasidone-Desloratadine-HRH1-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Methylphenidate\nDRUG 1 BACKGROUND INFORMATION: Methylphenidate, a CNS stimulant within the phenethylamine and piperidine classes, exerts therapeutic effects in ADHD and narcolepsy predominantly through the inhibition of presynaptic dopamine and norepinephrine transporters, thereby augmenting synaptic monoamine concentrations. Its pharmacodynamics establish a clinical efficacy for enhancing executive functions such as attentional control, inhibitory processes, working memory, and emotional regulation, albeit with a slightly reduced efficacy compared to amphetamines. Pharmacokinetically, methylphenidate is amenable to both oral and transdermal administration with formulation-dependent pharmacokinetics dictating therapeutic windows. Adverse effects span neuropsychiatric and autonomic domains, including, but not limited to, sympathomimetic manifestations such as tachycardia, euphoria, anorexia, and insomnia, while withdrawal is typified by dysphoric and neurovegetative symptoms. Methylphenidate's status as a high-frequency prescription medication is underscored by its extensive dispensation, ranking as the 32nd most prescribed medication in the U.S. as of 2022, available in both branded and generic forms.\n\nDRUG 2 NAME: Ziprasidone\nDRUG 2 BACKGROUND INFORMATION: Ziprasidone, primarily marketed as Geodon, is a second-generation atypical antipsychotic exhibiting therapeutic efficacy in managing both schizophrenia and bipolar disorder, with formulary options for oral and intramuscular (IM) administration. The IM variant, ziprasidone mesylate trihydrate, is particularly leveraged for rapid amelioration of acute agitative states in schizophrenic patients, whereas oral administration utilizes the hydrochloride salt form. The pharmacodynamic profile of ziprasidone suggests a mechanism of action predicated on modulation of serotonergic (5-HT) and dopaminergic (D2) neurotransmitter pathways, although the precise mechanistic underpinnings remain elusive. The adverse effect spectrum spans neuromotor disturbances like tremors and tics, autonomic nervous system effects such as dry mouth and nausea, and characteristic psychotropic-induced sedation. Notably, ziprasidone presents a reduced risk of weight gain compared to its atypical counterparts. Despite its complex pharmacological profile, ziprasidone occupies a significant niche in psychopharmacotherapy, underscored by its prescription prevalence, ranking 282nd in the U.S. pharmaceutical landscape as of 2020 with over a million prescriptions circulated.\n\nDRUG 3 NAME: Desloratadine\nDRUG 3 BACKGROUND INFORMATION: Desloratadine sold under the brand name Aerius among others, is a tricyclic H1 inverse agonist that is used to treat allergies. It is an active metabolite of loratadine.\nIt was patented in 1984 and came into medical use in 2001. It was brought to the market in the US by Schering Corporation, later named Schering-Plough.\n\nPROTEIN NAME: HRH1\nPROTEIN BACKGROUND INFORMATION: The H1 receptor is a histamine receptor belonging to the family of rhodopsin-like G-protein-coupled receptors. This receptor is activated by the biogenic amine histamine. It is expressed in smooth muscles, on vascular endothelial cells, in the heart, and in the central nervous system. The H1 receptor is linked to an intracellular G-protein (Gq) that activates phospholipase C and the inositol triphosphate (IP3) signalling pathway. Antihistamines, which act on this receptor, are used as anti-allergy drugs. The crystal structure of the receptor has been determined (shown on the right/below) and used to discover new histamine H1 receptor ligands in structure-based virtual screening studies.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Methylphenidate-cholecystitis-Ziprasidone\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Ziprasidone-heart rate increased-Desloratadine\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Desloratadine-binding and inhibition-HRH1"}]}}
{"custom_id": "Aciclovir-Dapsone-Pyrimethamine-CHRM1-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Aciclovir\nDRUG 1 BACKGROUND INFORMATION: Aciclovir, an antiviral guanosine analogue, exhibits its therapeutic efficacy predominantly by inhibiting viral DNA polymerase through its metabolization to aciclovir triphosphate, resulting in the cessation of herpesvirus DNA elongation across Herpes Simplex Virus, varicella-zoster, and CMV prophylaxis post-transplantation. Administerable orally, topically, or intravenously, its pharmacokinetic profile necessitates careful consideration in patients with compromised renal or hepatic function due to potential nephrotoxicity and thrombocytopenia. While demonstrating an acceptable safety margin during gestation and lactation, adverse events such as gastrointestinal discomfort and diarrhea are common. Its inclusion in the WHO's Essential Medicines list underscores its global pivotal role in antiviral therapy, with its generic accessibility enhancing universal healthcare implementation.\n\nDRUG 2 NAME: Dapsone\nDRUG 2 BACKGROUND INFORMATION: Dapsone, chemically delineated as 4,4'-sulfonyldianiline or diaminodiphenyl sulfone, operates as a bacteriostatic antimicrobial agent within the sulfone class, frequently co-administered with rifampicin and clofazimine in leprosy management. It serves as an adjunctive therapeutic in pneumocystis pneumonia prophylaxis and toxoplasmosis prevention within immunocompromised cohorts, as well as for dermatological conditions such as acne and dermatitis herpetiformis, available in both oral and topical formulations. Pharmacodynamically, dapsone's modes of action encompass inhibition of bacterial dihydropteroate synthetase, although it is associated with grave hematological adverse effects, notably hemolytic anemia exacerbated by glucose-6-phosphate dehydrogenase deficiency and agranulocytosis, alongside potential hepatotoxicity manifested as hepatic inflammation. Methemoglobinemia and dermatological hypersensitivity reactions, encompassing a variety of rash presentations, constitute additional risk factors. The teratogenic profile remains equivocal; however, continuation during gestation is advised in leprosy cases. Economically accessible as a generic formulation, dapsone retains its inclusion on the WHO Essential Medicines List, underscoring its clinical utility and indispensable status in global health pharmacopeias.\n\nDRUG 3 NAME: Pyrimethamine\nDRUG 3 BACKGROUND INFORMATION: Pyrimethamine, a folic acid antagonist deployed primarily in conjunction with leucovorin to mitigate its hematological toxicity, serves as a therapeutic agent against Toxoplasma gondii and Cystoisospora belli infections. Leveraged as a second-line prophylactic strategy when paired with dapsone, it targets Pneumocystis jiroveci pneumonia in HIV/AIDS cohorts, though its historical anti-malarial application has waned due to resistance. The pharmacological mechanism centers on the inhibition of dihydrofolate reductase, disrupting protozoal DNA synthesis and cell replication. Clinically, the oral administration of pyrimethamine necessitates vigilance due to adverse effects, notably gastrointestinal distress, hypersensitivity reactions, and potential for bone marrow suppression, contraindicating its application in folate-deficient anemia. Oncology concerns persist about its carcinogenic potential, and its teratogenicity risk mandates caution during gestation. Despite these concerns, pyrimethamine retains its status as a World Health Organization Essential Medicine and was ratified as a generic option in the U.S. pharmacopoeia as of early 2020.\n\nPROTEIN NAME: CHRM1\nPROTEIN BACKGROUND INFORMATION: The muscarinic acetylcholine receptor M1, also known as the cholinergic receptor, muscarinic 1, is a muscarinic receptor that in humans is encoded by the CHRM1 gene. It is localized to 11q13.\nThis receptor is found mediating slow EPSP at the ganglion in the postganglionic nerve, is common in exocrine glands and in the CNS.\nIt is predominantly found bound to G proteins of class Gq that use upregulation of phospholipase C and, therefore, inositol trisphosphate and intracellular calcium as a signalling pathway. A receptor so bound would not be susceptible to CTX or PTX. However, Gi (causing a downstream decrease in cAMP) and Gs (causing an increase in cAMP) have also been shown to be involved in interactions in certain tissues, and so would be susceptible to PTX and CTX respectively.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Aciclovir-gastric inflammation-Dapsone\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Dapsone-neumonia-Pyrimethamine\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Pyrimethamine-binding and inhibition-CHRM1"}]}}
{"custom_id": "Cimetidine-Citalopram-Fluphenazine-ADRA1B-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Cimetidine\nDRUG 1 BACKGROUND INFORMATION: Cimetidine, sold under the brand name Tagamet among others, is a histamine H2 receptor antagonist that inhibits stomach acid production. It is mainly used in the treatment of heartburn and peptic ulcers.\nWith the development of proton pump inhibitors, such as omeprazole, approved for the same indications, cimetidine is available as an over-the-counter formulation to prevent heartburn or acid indigestion, along with the other H2-receptor antagonists.\nCimetidine was developed in 1971 and came into commercial use in 1977. Cimetidine was approved in the United Kingdom in 1976, and was approved in the United States by the Food and Drug Administration in 1979.\n\nDRUG 2 NAME: Citalopram\nDRUG 2 BACKGROUND INFORMATION: Citalopram, a chiral bicyclic phthalane derivative and selective serotonin reuptake inhibitor (SSRI), is primarily employed in the pharmacotherapy of major depressive disorder, obsessive-compulsive disorder, panic disorder, and social phobia through modulation of serotonergic neurotransmission. The therapeutic latency ranges from one to four weeks post-administration. It is predominantly administered orally, though parenteral administration via intravenous injection is utilized in specific regions to expedite therapeutic onset. The pharmacokinetic profile of citalopram encompasses hepatic metabolism predominantly via CYP2C19, CYP3A4, and CYP2D6, yielding demethylated metabolites. It is imperative to monitor for adverse reactions, including, but not limited to, gastrointestinal disturbances, insomnia, sexual dysfunction, tremors, somnolence, hyperhidrosis, serotonin toxicity, and cardiotoxicity as manifested by QT interval prolongation. Contraindications entail concurrent MAO inhibitor therapy due to risk of serotonin syndrome and potential teratogenicity warrants cautious use in pregnancy. The potential for exacerbating suicidality in individuals under 25 necessitates vigilant monitoring. Citalopram's clinical prominence is evidenced by its inclusion in the WHO's List of Essential Medicines and its extensive prescribing frequency in the United States, underscoring its integral role in psychiatric treatment regimens.\n\nDRUG 3 NAME: Fluphenazine\nDRUG 3 BACKGROUND INFORMATION: Fluphenazine is a high-affinity typical antipsychotic of the phenothiazine cohort primarily prescribed for chronic psychotic disorders such as schizophrenia, offering efficacy comparable to chlorpromazine. Administered via oral, intramuscular, subcutaneous routes\u2014or as a long-acting depot, fluphenazine decanoate\u2014this compound exhibits prolonged dopaminergic antagonism with an extended half-life conducive to monthly dosing regimens. Notably contraindicated in severe depressive states, its pharmacological action is ascribed to dopamine receptor blockade, though precision in its mechanism remains indeterminate. The pharmacodynamic profile of fluphenazine entails extrapyramidal symptoms, somnolence, depressive mood alterations, and metabolic side effects, with grave adverse events encompassing neuroleptic malignant syndrome, agranulocytosis, and irreversible tardive dyskinesia. Moreover, in the geriatric cohort with dementia-related psychoses, mortality risk is potentiated. Prolactin secretion perturbations may elicit galactorrhea, gynecomastia, erectile dysfunction, and amenorrhea, with teratogenic safety in gestation unresolved. Chronic administration associates with hepatocellular enzyme elevation in a substantial patient subset. Despite its broad utilization reflected in its inclusion on the World Health Organization's Essential Medicines list, its production cessation in some regions underscores its dynamic availability landscape.\n\nPROTEIN NAME: ADRA1B\nPROTEIN BACKGROUND INFORMATION: The alpha-1B adrenergic receptor (\u03b11B-adrenoreceptor), also known as ADRA1B, is an alpha-1 adrenergic receptor, and also denotes the human gene encoding it. The crystal structure of the \u03b11B-adrenergic receptor has been determined in complex with the inverse agonist (+)-cyclazosin.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Cimetidine-gastric inflammation-Citalopram\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Citalopram-cholecystitis-Fluphenazine\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Fluphenazine-binding and inhibition-ADRA1B"}]}}
{"custom_id": "Haloperidol-indometacin-Terazosin-ADRA1D-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Haloperidol\nDRUG 1 BACKGROUND INFORMATION: Haloperidol, a butyrophenone derivative, exerts its therapeutic efficacy as a typical antipsychotic primarily through potent antagonism of central dopaminergic D2 receptors, ameliorating positive psychotic symptoms in conditions such as schizophrenia, Tourette syndrome, acute mania in bipolar disorder, delirium, and alcohol withdrawal-related hallucinations. Exhibiting rapid onset post-oral or parenteral administration, haloperidol can be deployed via bi-weekly intramuscular depot injections for long-term management of schizophrenia spectrum disorders in non-compliant patients. While efficacious, haloperidol is implicated in extrapyramidal side effects, notably irreversible tardive dyskinesia and akathisia, along with the rare but severe neuroleptic malignant syndrome and dose-dependent QT interval prolongation, the latter significantly observed with intravenous routes. Its contraindication in patients with Parkinson's disease and increased mortality risk in dementia-related psychosis underscore the necessity for judicious application. Adverse fetal outcomes restrict its use during pregnancy. Despite these safety concerns, haloperidol maintains its status as an essential medication per the World Health Organization's compendium, continually ranking among the most prescribed antipsychotics in clinical practice.\n\nDRUG 2 NAME: indometacin\nDRUG 2 BACKGROUND INFORMATION: Indometacin, also known as indomethacin, is a nonsteroidal anti-inflammatory drug (NSAID) commonly used as a prescription medication to reduce fever, pain, stiffness, and swelling from inflammation. It works by inhibiting the production of prostaglandins, endogenous signaling molecules known to cause these symptoms. It does this by inhibiting cyclooxygenase, an enzyme that catalyzes the production of prostaglandins.\nIt was patented in 1961 and approved for medical use in 1963. It is on the World Health Organization's List of Essential Medicines. In 2022, it was the 256th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG 3 NAME: Terazosin\nDRUG 3 BACKGROUND INFORMATION: Terazosin, sold under the brand name Hytrin among others, is a medication used to treat symptoms of an enlarged prostate and high blood pressure. For high blood pressure, it is a less preferred option. It is taken by mouth.\nCommon side effects include dizziness, headache, feeling tired, swelling, nausea, and low blood pressure with standing. Severe side effects may include priapism and low blood pressure. Prostate cancer should be ruled out before starting treatment. It is an alpha-1 blocker and works by relaxing blood vessels and the opening of the bladder.\nTerazosin was patented in 1975 and came into medical use in 1985. It is available as a generic medication. In 2021, it was the 234th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nPROTEIN NAME: ADRA1D\nPROTEIN BACKGROUND INFORMATION: The alpha-1D adrenergic receptor (\u03b11D adrenoreceptor), also known as ADRA1D, is an alpha-1 adrenergic receptor, and also denotes the human gene encoding it.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Haloperidol-erythema multiforme-indometacin\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): indometacin-erythema-Terazosin\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Terazosin-binding and inhibition-ADRA1D"}]}}
{"custom_id": "Cimetidine-Citalopram-Salmeterol-ADRB3-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Cimetidine\nDRUG 1 BACKGROUND INFORMATION: Cimetidine, sold under the brand name Tagamet among others, is a histamine H2 receptor antagonist that inhibits stomach acid production. It is mainly used in the treatment of heartburn and peptic ulcers.\nWith the development of proton pump inhibitors, such as omeprazole, approved for the same indications, cimetidine is available as an over-the-counter formulation to prevent heartburn or acid indigestion, along with the other H2-receptor antagonists.\nCimetidine was developed in 1971 and came into commercial use in 1977. Cimetidine was approved in the United Kingdom in 1976, and was approved in the United States by the Food and Drug Administration in 1979.\n\nDRUG 2 NAME: Citalopram\nDRUG 2 BACKGROUND INFORMATION: Citalopram, a chiral bicyclic phthalane derivative and selective serotonin reuptake inhibitor (SSRI), is primarily employed in the pharmacotherapy of major depressive disorder, obsessive-compulsive disorder, panic disorder, and social phobia through modulation of serotonergic neurotransmission. The therapeutic latency ranges from one to four weeks post-administration. It is predominantly administered orally, though parenteral administration via intravenous injection is utilized in specific regions to expedite therapeutic onset. The pharmacokinetic profile of citalopram encompasses hepatic metabolism predominantly via CYP2C19, CYP3A4, and CYP2D6, yielding demethylated metabolites. It is imperative to monitor for adverse reactions, including, but not limited to, gastrointestinal disturbances, insomnia, sexual dysfunction, tremors, somnolence, hyperhidrosis, serotonin toxicity, and cardiotoxicity as manifested by QT interval prolongation. Contraindications entail concurrent MAO inhibitor therapy due to risk of serotonin syndrome and potential teratogenicity warrants cautious use in pregnancy. The potential for exacerbating suicidality in individuals under 25 necessitates vigilant monitoring. Citalopram's clinical prominence is evidenced by its inclusion in the WHO's List of Essential Medicines and its extensive prescribing frequency in the United States, underscoring its integral role in psychiatric treatment regimens.\n\nDRUG 3 NAME: Salmeterol\nDRUG 3 BACKGROUND INFORMATION: Salmeterol is a long-acting \u03b22 adrenergic receptor agonist (LABA) used in the treatment and prevention of asthma symptoms and control of chronic obstructive pulmonary disease (COPD) symptoms. Symptoms of bronchospasm include shortness of breath, wheezing, coughing and chest tightness. It is also used to prevent breathing difficulties during exercise (exercise-induced bronchoconstriction).\nIt was patented in 1983 and came into medical use in 1990. It is marketed as Serevent in the US. It is available as a dry-powder inhaler (DPI) that releases a powdered form of the drug. It was previously available as a metered-dose inhaler (MDI) but was discontinued in the US in 2002. It is available as an MDI in other countries as of 2020.\n\nPROTEIN NAME: ADRB3\nPROTEIN BACKGROUND INFORMATION: The beta-3 adrenergic receptor (\u03b23-adrenoceptor), also known as ADRB3, is a beta-adrenergic receptor, and also denotes the human gene encoding it.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Cimetidine-gastric inflammation-Citalopram\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Citalopram-cholecystitis-Salmeterol\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Salmeterol-binding and activation-ADRB3"}]}}
{"custom_id": "Citalopram-Dapsone-Pyrimethamine-CHRM1-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Citalopram\nDRUG 1 BACKGROUND INFORMATION: Citalopram, a chiral bicyclic phthalane derivative and selective serotonin reuptake inhibitor (SSRI), is primarily employed in the pharmacotherapy of major depressive disorder, obsessive-compulsive disorder, panic disorder, and social phobia through modulation of serotonergic neurotransmission. The therapeutic latency ranges from one to four weeks post-administration. It is predominantly administered orally, though parenteral administration via intravenous injection is utilized in specific regions to expedite therapeutic onset. The pharmacokinetic profile of citalopram encompasses hepatic metabolism predominantly via CYP2C19, CYP3A4, and CYP2D6, yielding demethylated metabolites. It is imperative to monitor for adverse reactions, including, but not limited to, gastrointestinal disturbances, insomnia, sexual dysfunction, tremors, somnolence, hyperhidrosis, serotonin toxicity, and cardiotoxicity as manifested by QT interval prolongation. Contraindications entail concurrent MAO inhibitor therapy due to risk of serotonin syndrome and potential teratogenicity warrants cautious use in pregnancy. The potential for exacerbating suicidality in individuals under 25 necessitates vigilant monitoring. Citalopram's clinical prominence is evidenced by its inclusion in the WHO's List of Essential Medicines and its extensive prescribing frequency in the United States, underscoring its integral role in psychiatric treatment regimens.\n\nDRUG 2 NAME: Dapsone\nDRUG 2 BACKGROUND INFORMATION: Dapsone, chemically delineated as 4,4'-sulfonyldianiline or diaminodiphenyl sulfone, operates as a bacteriostatic antimicrobial agent within the sulfone class, frequently co-administered with rifampicin and clofazimine in leprosy management. It serves as an adjunctive therapeutic in pneumocystis pneumonia prophylaxis and toxoplasmosis prevention within immunocompromised cohorts, as well as for dermatological conditions such as acne and dermatitis herpetiformis, available in both oral and topical formulations. Pharmacodynamically, dapsone's modes of action encompass inhibition of bacterial dihydropteroate synthetase, although it is associated with grave hematological adverse effects, notably hemolytic anemia exacerbated by glucose-6-phosphate dehydrogenase deficiency and agranulocytosis, alongside potential hepatotoxicity manifested as hepatic inflammation. Methemoglobinemia and dermatological hypersensitivity reactions, encompassing a variety of rash presentations, constitute additional risk factors. The teratogenic profile remains equivocal; however, continuation during gestation is advised in leprosy cases. Economically accessible as a generic formulation, dapsone retains its inclusion on the WHO Essential Medicines List, underscoring its clinical utility and indispensable status in global health pharmacopeias.\n\nDRUG 3 NAME: Pyrimethamine\nDRUG 3 BACKGROUND INFORMATION: Pyrimethamine, a folic acid antagonist deployed primarily in conjunction with leucovorin to mitigate its hematological toxicity, serves as a therapeutic agent against Toxoplasma gondii and Cystoisospora belli infections. Leveraged as a second-line prophylactic strategy when paired with dapsone, it targets Pneumocystis jiroveci pneumonia in HIV/AIDS cohorts, though its historical anti-malarial application has waned due to resistance. The pharmacological mechanism centers on the inhibition of dihydrofolate reductase, disrupting protozoal DNA synthesis and cell replication. Clinically, the oral administration of pyrimethamine necessitates vigilance due to adverse effects, notably gastrointestinal distress, hypersensitivity reactions, and potential for bone marrow suppression, contraindicating its application in folate-deficient anemia. Oncology concerns persist about its carcinogenic potential, and its teratogenicity risk mandates caution during gestation. Despite these concerns, pyrimethamine retains its status as a World Health Organization Essential Medicine and was ratified as a generic option in the U.S. pharmacopoeia as of early 2020.\n\nPROTEIN NAME: CHRM1\nPROTEIN BACKGROUND INFORMATION: The muscarinic acetylcholine receptor M1, also known as the cholinergic receptor, muscarinic 1, is a muscarinic receptor that in humans is encoded by the CHRM1 gene. It is localized to 11q13.\nThis receptor is found mediating slow EPSP at the ganglion in the postganglionic nerve, is common in exocrine glands and in the CNS.\nIt is predominantly found bound to G proteins of class Gq that use upregulation of phospholipase C and, therefore, inositol trisphosphate and intracellular calcium as a signalling pathway. A receptor so bound would not be susceptible to CTX or PTX. However, Gi (causing a downstream decrease in cAMP) and Gs (causing an increase in cAMP) have also been shown to be involved in interactions in certain tissues, and so would be susceptible to PTX and CTX respectively.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Citalopram-Adenopathy-Dapsone\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Dapsone-neumonia-Pyrimethamine\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Pyrimethamine-binding and inhibition-CHRM1"}]}}
{"custom_id": "Fentanyl-Ondansetron-Trazodone-HRH1-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Fentanyl\nDRUG 1 BACKGROUND INFORMATION: Fentanyl, a synthetic piperidine opioid agonist, demonstrates exceptional analgesic efficacy, with \u03bc-opioid receptor affinity rendering it 50-100 times more potent than morphine. Clinically, it is indispensable for managing severe pain in oncologic contexts and post-operative recovery, administered under brand names such as Actiq, Duragesic, and Sublimaze. The pharmacokinetic profile facilitates rapid onset across administration routes, thus posing significant overdose risk even at minimal doses. Adverse pharmacodynamics encompass addiction potential, central nervous system depression leading to respiratory compromise, and a range of neuropsychiatric disturbances, including narcotic delirium and hypotensive coma, exacerbated synergistically by concurrent alcohol or co-ingestants like cocaine and heroin. Although opioid antagonists such as naloxone are efficacious in overdose scenarios, fentanyl\u2019s high receptor occupancy and potency often necessitate multiple reversal attempts. Epidemiologically, fentanyl supersedes other synthetic opioids, catalyzing an overdose epidemic exacerbated by clandestine synthesis and poly-drug formulations, complicating therapeutic interventions and forensic investigations. Proactive measures, including test kits and advanced analytical protocols, are critical in mitigating rampant illicit distribution, underpinned by fentanyl\u2019s streamlined synthesis and distribution adaptability.\n\nDRUG 2 NAME: Ondansetron\nDRUG 2 BACKGROUND INFORMATION: Ondansetron, a potent antiemetic utilized to mitigate nausea and emesis associated with chemotherapy, radiation, migraine, and surgical procedures, exerts its pharmacological action as a selective serotonin 5-HT3 receptor antagonist. Absence of affinity for dopaminergic and muscarinic acetylcholine receptors precludes extrapyramidal side effects such as akathisia. Administered via oral, intravenous, or intramuscular routes, ondansetron's pharmacokinetic profile is characterized by hepatic metabolism and renal excretion. Adverse effects frequently reported encompass gastrointestinal dysmotility manifesting as diarrhea or constipation, central nervous system manifestations including headache and somnolence, and dermal pruritus, with more severe toxicities including QT interval prolongation on electrocardiographic assessment and anaphylaxis. Although the teratogenic risk is minimal, comprehensive teratological data in gravid populations remain insufficient. Recognized on the WHO's List of Essential Medicines, ondansetron is extensively prescribed, highlighting its clinical utility and incorporation into treatment protocols, with significant utilization confirmed by its high prescription frequency in the United States.\n\nDRUG 3 NAME: Trazodone\nDRUG 3 BACKGROUND INFORMATION: Trazodone is an antidepressant medication used to treat major depressive disorder, anxiety disorders, and insomnia. It is a phenylpiperazine compound of the serotonin antagonist and reuptake inhibitor (SARI) class. The medication is taken orally.\nCommon side effects include dry mouth, feeling faint, vomiting, and headache. More serious side effects may include suicide, mania, irregular heart rate, and pathologically prolonged erections. It is unclear if use during pregnancy or breastfeeding is safe.  Trazodone also has sedating effects.\nTrazodone was approved for medical use in the United States in 1981. It is available as a generic medication. In 2022, it was the eighteenth most commonly prescribed medication in the United States, with more than 27 million prescriptions.\n\nPROTEIN NAME: HRH1\nPROTEIN BACKGROUND INFORMATION: The H1 receptor is a histamine receptor belonging to the family of rhodopsin-like G-protein-coupled receptors. This receptor is activated by the biogenic amine histamine. It is expressed in smooth muscles, on vascular endothelial cells, in the heart, and in the central nervous system. The H1 receptor is linked to an intracellular G-protein (Gq) that activates phospholipase C and the inositol triphosphate (IP3) signalling pathway. Antihistamines, which act on this receptor, are used as anti-allergy drugs. The crystal structure of the receptor has been determined (shown on the right/below) and used to discover new histamine H1 receptor ligands in structure-based virtual screening studies.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Fentanyl-Adenopathy-Ondansetron\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Ondansetron-hepatic neoplasia-Trazodone\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Trazodone-binding and inhibition-HRH1"}]}}
{"custom_id": "Gabapentin-Ziprasidone-Desloratadine-HRH1-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Gabapentin\nDRUG 1 BACKGROUND INFORMATION: Gabapentin, a prototypical member of the gabapentinoid class, is extensively utilized in the management of neuropathic pain syndromes, including diabetic neuropathy and postherpetic neuralgia, as well as partial epileptic seizures. Its mechanism of action predominantly involves high-affinity binding to the \u03b12\u03b4-1 subunit of voltage-gated calcium channels, encoded by the CACNA2D1 gene, thereby attenuating the synaptic release of glutamate and consequent hyperexcitability within central neuronal circuits. Although effective in approximately 30-40% of patients with neuropathic pain, the pharmacodynamic profile necessitates cautious administration, particularly in patients with renal impairment, due to its propensity to induce sedation, dizziness, potential for respiratory depression, and a heightened suicidality risk as classified by the FDA. Gabapentin's pharmacokinetic traits and adverse event profile require vigilant therapeutic monitoring to mitigate risks and optimize clinical outcomes. It continues to be a staple in therapeutic regimens, as evidenced by its status as one of the most prescribed medications in the United States, albeit historical controversies concerning its marketing strategies by the originating pharmaceutical entities.\n\nDRUG 2 NAME: Ziprasidone\nDRUG 2 BACKGROUND INFORMATION: Ziprasidone, primarily marketed as Geodon, is a second-generation atypical antipsychotic exhibiting therapeutic efficacy in managing both schizophrenia and bipolar disorder, with formulary options for oral and intramuscular (IM) administration. The IM variant, ziprasidone mesylate trihydrate, is particularly leveraged for rapid amelioration of acute agitative states in schizophrenic patients, whereas oral administration utilizes the hydrochloride salt form. The pharmacodynamic profile of ziprasidone suggests a mechanism of action predicated on modulation of serotonergic (5-HT) and dopaminergic (D2) neurotransmitter pathways, although the precise mechanistic underpinnings remain elusive. The adverse effect spectrum spans neuromotor disturbances like tremors and tics, autonomic nervous system effects such as dry mouth and nausea, and characteristic psychotropic-induced sedation. Notably, ziprasidone presents a reduced risk of weight gain compared to its atypical counterparts. Despite its complex pharmacological profile, ziprasidone occupies a significant niche in psychopharmacotherapy, underscored by its prescription prevalence, ranking 282nd in the U.S. pharmaceutical landscape as of 2020 with over a million prescriptions circulated.\n\nDRUG 3 NAME: Desloratadine\nDRUG 3 BACKGROUND INFORMATION: Desloratadine sold under the brand name Aerius among others, is a tricyclic H1 inverse agonist that is used to treat allergies. It is an active metabolite of loratadine.\nIt was patented in 1984 and came into medical use in 2001. It was brought to the market in the US by Schering Corporation, later named Schering-Plough.\n\nPROTEIN NAME: HRH1\nPROTEIN BACKGROUND INFORMATION: The H1 receptor is a histamine receptor belonging to the family of rhodopsin-like G-protein-coupled receptors. This receptor is activated by the biogenic amine histamine. It is expressed in smooth muscles, on vascular endothelial cells, in the heart, and in the central nervous system. The H1 receptor is linked to an intracellular G-protein (Gq) that activates phospholipase C and the inositol triphosphate (IP3) signalling pathway. Antihistamines, which act on this receptor, are used as anti-allergy drugs. The crystal structure of the receptor has been determined (shown on the right/below) and used to discover new histamine H1 receptor ligands in structure-based virtual screening studies.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Gabapentin-loss of weight-Ziprasidone\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Ziprasidone-heart rate increased-Desloratadine\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Desloratadine-binding and inhibition-HRH1"}]}}
{"custom_id": "Alfuzosin-Benazepril-Terazosin-ADRA1B-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Alfuzosin\nDRUG 1 BACKGROUND INFORMATION: Alfuzosin, sold under the brand name Uroxatral among others, is a medication of the \u03b11 blocker class. It is used to treat benign prostatic hyperplasia (BPH).\nAs an antagonist of the \u03b11-adrenergic receptor, it works by relaxing the muscles in the prostate and bladder neck, making urination easier. \nAlfuzosin was patented in 1978 and approved for medical use in 1988. It was approved in the US for benign prostatic hyperplasia in 2003. In 2020, it was the 336th-most commonly prescribed medication in the United States, with more than 700 thousand prescriptions.\n\nDRUG 2 NAME: Benazepril\nDRUG 2 BACKGROUND INFORMATION: Benazepril, an ACE inhibitor marketed as Lotensin, is administered orally for the management of hypertension, heart failure, and diabetic nephropathy by attenuating the renin-angiotensin-aldosterone system activity. Formulations include benazepril/hydrochlorothiazide and benazepril/amlodipine combinations, targeting synergistic pathways for antihypertensive efficacy. The pharmacodynamic profile includes adverse reactions such as asthenia, orthostatic dizziness, and cough, while severe adverse events consist of potential nephrotoxicity, hypotension, hyperkalemia, and angioedema. Teratogenic risks disallow its use during gestation, contrasting with permissible lactational use. Its pharmacokinetic properties have secured its status as a widely prescribed, generic therapeutic, illustrated by over three million prescriptions in the U.S. in 2022.\n\nDRUG 3 NAME: Terazosin\nDRUG 3 BACKGROUND INFORMATION: Terazosin, sold under the brand name Hytrin among others, is a medication used to treat symptoms of an enlarged prostate and high blood pressure. For high blood pressure, it is a less preferred option. It is taken by mouth.\nCommon side effects include dizziness, headache, feeling tired, swelling, nausea, and low blood pressure with standing. Severe side effects may include priapism and low blood pressure. Prostate cancer should be ruled out before starting treatment. It is an alpha-1 blocker and works by relaxing blood vessels and the opening of the bladder.\nTerazosin was patented in 1975 and came into medical use in 1985. It is available as a generic medication. In 2021, it was the 234th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nPROTEIN NAME: ADRA1B\nPROTEIN BACKGROUND INFORMATION: The alpha-1B adrenergic receptor (\u03b11B-adrenoreceptor), also known as ADRA1B, is an alpha-1 adrenergic receptor, and also denotes the human gene encoding it. The crystal structure of the \u03b11B-adrenergic receptor has been determined in complex with the inverse agonist (+)-cyclazosin.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Alfuzosin-Decreased Libido-Benazepril\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Benazepril-apoplexy-Terazosin\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Terazosin-binding and inhibition-ADRA1B"}]}}
{"custom_id": "acetazolamide-Celecoxib-Labetalol-ADRB1-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: acetazolamide\nDRUG 1 BACKGROUND INFORMATION: Acetazolamide, marketed under the trade name Diamox, serves as a versatile pharmaceutical agent within the realm of carbonic anhydrase inhibitors, effectively modulating intraocular pressure via the diminution of aqueous humor production and osmolality. Its clinical utility spans across conditions such as glaucoma\u2014both open-angle and acute angle closure\u2014epilepsy, acute mountain sickness, periodic paralysis, idiopathic intracranial hypertension, and heart failure, with an ancillary role in urinary alkalinization. Therapeutic administration is achievable through oral and intravenous modalities. Mechanistically, acetazolamide exerts its effects by disrupting the equilibria of carbon dioxide hydration and subsequent bicarbonate ion production, thereby reducing intracellular hydrogen ion availability. The pharmacodynamic profile encompasses neuro-sensory side effects like paresthesia and tinnitus, alongside anorexia, emesis, and somnolence. Contraindications are notable in individuals with renal or hepatic impairment, and those with hypersensitivity to sulfonamide derivatives. As a diuretic and enzymatic inhibitor, it holds a position on the WHO's List of Essential Medicines, emphasizing its critical global accessibility as a generic formulation.\n\nDRUG 2 NAME: Celecoxib\nDRUG 2 BACKGROUND INFORMATION: Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, functions as a nonsteroidal anti-inflammatory drug (NSAID) utilized primarily for its analgesic and anti-inflammatory efficacy in osteoarthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, dysmenorrhea, acute pain management, and juvenile rheumatoid arthritis. Additionally, celecoxib has prophylactic applications in reducing colorectal adenomatous formations in familial adenomatous polyposis due to its COX-2 inhibition, which mitigates pro-inflammatory prostaglandin synthesis while sparing COX-1, ostensibly minimizing gastrointestinal mucosal damage relative to non-selective NSAIDs. The pharmacokinetics permit oral administration, with pharmacodynamic effects commencing typically within one hour post-ingestion. Notable adverse reactions span gastrointestinal disturbances such as abdominal pain, nausea, and diarrhea, with severe risk profiles including cardiovascular thrombotic events, gastrointestinal perforation, renal impairment, and hypersensitivity reactions like anaphylaxis, contraindicating its use in populations with significant cardiovascular risk profiles. The risk profile parallels that of other NSAIDs like ibuprofen and naproxen, and caution is advised during late-stage gestation and lactation. Celecoxib's generic availability and widespread prescription underscore its clinical significance, albeit with requisite consideration of its potential side-effect burden.\n\nDRUG 3 NAME: Labetalol\nDRUG 3 BACKGROUND INFORMATION: Labetalol is a medication used to treat high blood pressure and in long term management of angina. This includes essential hypertension, hypertensive emergencies, and hypertension of pregnancy. In essential hypertension it is generally less preferred than a number of other blood pressure medications. It can be given by mouth or by injection into a vein.\nCommon side effects include low blood pressure with standing, dizziness, feeling tired, and nausea. Serious side effects may include low blood pressure, liver problems, heart failure, and bronchospasm. Use appears safe in the latter part of pregnancy and it is not expected to cause problems during breastfeeding. It works by blocking the activation of \u03b2- and \u03b1-adrenergic receptors.\nLabetalol was patented in 1966 and came into medical use in 1977. It is available as a generic medication. In 2022, it was the 215th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nPROTEIN NAME: ADRB1\nPROTEIN BACKGROUND INFORMATION: The beta-1 adrenergic receptor (\u03b21 adrenoceptor), also known as ADRB1, can refer to either the protein-encoding gene (gene ADRB1) or one of the four adrenergic receptors. It is a G-protein coupled receptor associated with the Gs heterotrimeric G-protein that is expressed predominantly in cardiac tissue. In addition to cardiac tissue, beta-1 adrenergic receptors are also expressed in the cerebral cortex.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): acetazolamide-Pain-Celecoxib\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Celecoxib-Back Ache-Labetalol\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Labetalol-binding and inhibition-ADRB1"}]}}
{"custom_id": "Celecoxib-Ibuprofen-Metoprolol-ADRB1-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Celecoxib\nDRUG 1 BACKGROUND INFORMATION: Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, functions as a nonsteroidal anti-inflammatory drug (NSAID) utilized primarily for its analgesic and anti-inflammatory efficacy in osteoarthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, dysmenorrhea, acute pain management, and juvenile rheumatoid arthritis. Additionally, celecoxib has prophylactic applications in reducing colorectal adenomatous formations in familial adenomatous polyposis due to its COX-2 inhibition, which mitigates pro-inflammatory prostaglandin synthesis while sparing COX-1, ostensibly minimizing gastrointestinal mucosal damage relative to non-selective NSAIDs. The pharmacokinetics permit oral administration, with pharmacodynamic effects commencing typically within one hour post-ingestion. Notable adverse reactions span gastrointestinal disturbances such as abdominal pain, nausea, and diarrhea, with severe risk profiles including cardiovascular thrombotic events, gastrointestinal perforation, renal impairment, and hypersensitivity reactions like anaphylaxis, contraindicating its use in populations with significant cardiovascular risk profiles. The risk profile parallels that of other NSAIDs like ibuprofen and naproxen, and caution is advised during late-stage gestation and lactation. Celecoxib's generic availability and widespread prescription underscore its clinical significance, albeit with requisite consideration of its potential side-effect burden.\n\nDRUG 2 NAME: Ibuprofen\nDRUG 2 BACKGROUND INFORMATION: Ibuprofen, a widely utilized nonsteroidal anti-inflammatory drug (NSAID), exerts its therapeutic effects primarily through the attenuation of cyclooxygenase (COX) enzymatic activity, thereby reducing the biosynthesis of pro-inflammatory prostaglandins. Indicated for alleviating nociceptive and inflammatory perturbations such as dysmenorrhea, migrainous episodes, and inflammatory arthropathies, ibuprofen demonstrates notable pharmacokinetics with onset of action within one hour post administration via oral or parenteral routes. Despite its efficacy, ibuprofen's pharmacodynamic profile correlates with several adverse outcomes, notably gastrointestinal mucosal irritation leading to potential bleeding, renal impairment with prolonged administration, and rare hepatotoxicity. It possesses a variable cardiovascular risk profile, posing increased myocardial infarction risk at higher dosages. Notably, ibuprofen is contraindicated in advanced gestational periods due to its deleterious fetal effects and can exacerbate asthmatic conditions. Although it constitutes a less potent anti-inflammatory than other NSAIDs, its inclusion in the WHO's List of Essential Medicines underscores its clinical utility across various domains. Despite its prevalence, ongoing vigilance is advised due to its side effect spectrum.\n\nDRUG 3 NAME: Metoprolol\nDRUG 3 BACKGROUND INFORMATION: Metoprolol, a cardioselective \u03b21-adrenergic receptor antagonist, is clinically utilized in the management of angina pectoris, hypertension, tachyarrhythmias, post-myocardial infarction secondary prophylaxis, and migraine prophylaxis. Its therapeutic efficacy is mediated via negative chronotropic and inotropic effects which result in decreased myocardial oxygen demand and improved exercise tolerance. The pharmacokinetics of metoprolol is influenced by hepatic cytochrome P450 2D6 isoenzyme variability leading to significant interpatient variability in drug metabolism, necessitating individualized dosing. Adverse effects prominently include insomnia, asthenia, presyncope, and gastrointestinal disturbances, with higher doses presenting risk for pronounced toxicity. Though teratogenic risk during pregnancy has not been conclusively excluded, its excretion into breast milk is considered clinically insignificant. Metoprolol is widely dispensed, reflecting its inclusion in the WHO's Essential Medicines, and its prescription frequency underscores its pivotal role in cardiovascular therapeutics.\n\nPROTEIN NAME: ADRB1\nPROTEIN BACKGROUND INFORMATION: The beta-1 adrenergic receptor (\u03b21 adrenoceptor), also known as ADRB1, can refer to either the protein-encoding gene (gene ADRB1) or one of the four adrenergic receptors. It is a G-protein coupled receptor associated with the Gs heterotrimeric G-protein that is expressed predominantly in cardiac tissue. In addition to cardiac tissue, beta-1 adrenergic receptors are also expressed in the cerebral cortex.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Celecoxib-gastric inflammation-Ibuprofen\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Ibuprofen-cholecystitis-Metoprolol\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Metoprolol-binding and inhibition-ADRB1"}]}}
{"custom_id": "Famotidine-Lamivudine-Metoprolol-ADRA2A-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Famotidine\nDRUG 1 BACKGROUND INFORMATION: Famotidine, sold under the brand name Pepcid among others, is a histamine H2 receptor antagonist medication that decreases stomach acid production. It is used to treat peptic ulcer disease, gastroesophageal reflux disease, and Zollinger\u2013Ellison syndrome. It is taken by mouth or by injection into a vein. It begins working within an hour.\nCommon side effects include headache, abdominal pain, diarrhea or constipation, and dizziness. Serious side effects may include pneumonia and seizures. Use in pregnancy appears safe but has not been well studied, while use during breastfeeding is not recommended.\nFamotidine was patented in 1979 and came into medical use in 1985. It is available as a generic medication. In 2022, it was the 49th most commonly prescribed medication in the United States, with more than 13 million prescriptions.\n\nDRUG 2 NAME: Lamivudine\nDRUG 2 BACKGROUND INFORMATION: Lamivudine, or 3TC, is a nucleoside reverse transcriptase inhibitor with efficacy against HIV-1, HIV-2, and chronic hepatitis B virus. It functions by competitive inhibition of HIV reverse transcriptase and hepatitis B virus polymerase, disrupting viral DNA synthesis. Clinically, lamivudine is integral to combination antiretroviral therapy, often co-administered with agents such as zidovudine, dolutegravir, and abacavir, and forms part of post-exposure prophylactic regimens. It is available for oral administration as liquid or tablet formulations, maintaining therapeutic flexibility through its dosing independence from food intake. While generally well-tolerated, adverse effects can include gastrointestinal disturbances, cephalalgia, asthenia, and respiratory symptoms; however, clinicians must vigilantly monitor for hepatotoxicity, lactic acidosis, and hepatitis B exacerbations. Suitable for patients over three months and deemed safe in pregnancy, lamivudine is recognized as an essential medicine, underscoring its pivotal role in antiretroviral pharmacotherapy despite potential genotypic resistance mutations.\n\nDRUG 3 NAME: Metoprolol\nDRUG 3 BACKGROUND INFORMATION: Metoprolol, a cardioselective \u03b21-adrenergic receptor antagonist, is clinically utilized in the management of angina pectoris, hypertension, tachyarrhythmias, post-myocardial infarction secondary prophylaxis, and migraine prophylaxis. Its therapeutic efficacy is mediated via negative chronotropic and inotropic effects which result in decreased myocardial oxygen demand and improved exercise tolerance. The pharmacokinetics of metoprolol is influenced by hepatic cytochrome P450 2D6 isoenzyme variability leading to significant interpatient variability in drug metabolism, necessitating individualized dosing. Adverse effects prominently include insomnia, asthenia, presyncope, and gastrointestinal disturbances, with higher doses presenting risk for pronounced toxicity. Though teratogenic risk during pregnancy has not been conclusively excluded, its excretion into breast milk is considered clinically insignificant. Metoprolol is widely dispensed, reflecting its inclusion in the WHO's Essential Medicines, and its prescription frequency underscores its pivotal role in cardiovascular therapeutics.\n\nPROTEIN NAME: ADRA2A\nPROTEIN BACKGROUND INFORMATION: The alpha-2A adrenergic receptor (\u03b12A adrenoceptor), also known as ADRA2A, is an \u03b12-adrenergic receptor, and also denotes the human gene encoding it.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Famotidine-Adenopathy-Lamivudine\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Lamivudine-dysarthria-Metoprolol\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Metoprolol-binding and inhibition-ADRA2A"}]}}
{"custom_id": "acetazolamide-Citalopram-Fluphenazine-HRH1-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: acetazolamide\nDRUG 1 BACKGROUND INFORMATION: Acetazolamide, marketed under the trade name Diamox, serves as a versatile pharmaceutical agent within the realm of carbonic anhydrase inhibitors, effectively modulating intraocular pressure via the diminution of aqueous humor production and osmolality. Its clinical utility spans across conditions such as glaucoma\u2014both open-angle and acute angle closure\u2014epilepsy, acute mountain sickness, periodic paralysis, idiopathic intracranial hypertension, and heart failure, with an ancillary role in urinary alkalinization. Therapeutic administration is achievable through oral and intravenous modalities. Mechanistically, acetazolamide exerts its effects by disrupting the equilibria of carbon dioxide hydration and subsequent bicarbonate ion production, thereby reducing intracellular hydrogen ion availability. The pharmacodynamic profile encompasses neuro-sensory side effects like paresthesia and tinnitus, alongside anorexia, emesis, and somnolence. Contraindications are notable in individuals with renal or hepatic impairment, and those with hypersensitivity to sulfonamide derivatives. As a diuretic and enzymatic inhibitor, it holds a position on the WHO's List of Essential Medicines, emphasizing its critical global accessibility as a generic formulation.\n\nDRUG 2 NAME: Citalopram\nDRUG 2 BACKGROUND INFORMATION: Citalopram, a chiral bicyclic phthalane derivative and selective serotonin reuptake inhibitor (SSRI), is primarily employed in the pharmacotherapy of major depressive disorder, obsessive-compulsive disorder, panic disorder, and social phobia through modulation of serotonergic neurotransmission. The therapeutic latency ranges from one to four weeks post-administration. It is predominantly administered orally, though parenteral administration via intravenous injection is utilized in specific regions to expedite therapeutic onset. The pharmacokinetic profile of citalopram encompasses hepatic metabolism predominantly via CYP2C19, CYP3A4, and CYP2D6, yielding demethylated metabolites. It is imperative to monitor for adverse reactions, including, but not limited to, gastrointestinal disturbances, insomnia, sexual dysfunction, tremors, somnolence, hyperhidrosis, serotonin toxicity, and cardiotoxicity as manifested by QT interval prolongation. Contraindications entail concurrent MAO inhibitor therapy due to risk of serotonin syndrome and potential teratogenicity warrants cautious use in pregnancy. The potential for exacerbating suicidality in individuals under 25 necessitates vigilant monitoring. Citalopram's clinical prominence is evidenced by its inclusion in the WHO's List of Essential Medicines and its extensive prescribing frequency in the United States, underscoring its integral role in psychiatric treatment regimens.\n\nDRUG 3 NAME: Fluphenazine\nDRUG 3 BACKGROUND INFORMATION: Fluphenazine is a high-affinity typical antipsychotic of the phenothiazine cohort primarily prescribed for chronic psychotic disorders such as schizophrenia, offering efficacy comparable to chlorpromazine. Administered via oral, intramuscular, subcutaneous routes\u2014or as a long-acting depot, fluphenazine decanoate\u2014this compound exhibits prolonged dopaminergic antagonism with an extended half-life conducive to monthly dosing regimens. Notably contraindicated in severe depressive states, its pharmacological action is ascribed to dopamine receptor blockade, though precision in its mechanism remains indeterminate. The pharmacodynamic profile of fluphenazine entails extrapyramidal symptoms, somnolence, depressive mood alterations, and metabolic side effects, with grave adverse events encompassing neuroleptic malignant syndrome, agranulocytosis, and irreversible tardive dyskinesia. Moreover, in the geriatric cohort with dementia-related psychoses, mortality risk is potentiated. Prolactin secretion perturbations may elicit galactorrhea, gynecomastia, erectile dysfunction, and amenorrhea, with teratogenic safety in gestation unresolved. Chronic administration associates with hepatocellular enzyme elevation in a substantial patient subset. Despite its broad utilization reflected in its inclusion on the World Health Organization's Essential Medicines list, its production cessation in some regions underscores its dynamic availability landscape.\n\nPROTEIN NAME: HRH1\nPROTEIN BACKGROUND INFORMATION: The H1 receptor is a histamine receptor belonging to the family of rhodopsin-like G-protein-coupled receptors. This receptor is activated by the biogenic amine histamine. It is expressed in smooth muscles, on vascular endothelial cells, in the heart, and in the central nervous system. The H1 receptor is linked to an intracellular G-protein (Gq) that activates phospholipase C and the inositol triphosphate (IP3) signalling pathway. Antihistamines, which act on this receptor, are used as anti-allergy drugs. The crystal structure of the receptor has been determined (shown on the right/below) and used to discover new histamine H1 receptor ligands in structure-based virtual screening studies.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): acetazolamide-Back Ache-Citalopram\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Citalopram-cholecystitis-Fluphenazine\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Fluphenazine-binding and inhibition-HRH1"}]}}
{"custom_id": "Naproxen-Risedronic acid-Terazosin-ADRA1B-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: Risedronic acid\nDRUG 2 BACKGROUND INFORMATION: Risedronic acid, often used as its sodium salt risedronate sodium, is a bisphosphonate. It slows down the cells which break down bone. It's used to treat or prevent osteoporosis, and treat Paget's disease of bone. It is taken by mouth.\nIt was patented in 1984 and approved for medical use in 1998.\n\nDRUG 3 NAME: Terazosin\nDRUG 3 BACKGROUND INFORMATION: Terazosin, sold under the brand name Hytrin among others, is a medication used to treat symptoms of an enlarged prostate and high blood pressure. For high blood pressure, it is a less preferred option. It is taken by mouth.\nCommon side effects include dizziness, headache, feeling tired, swelling, nausea, and low blood pressure with standing. Severe side effects may include priapism and low blood pressure. Prostate cancer should be ruled out before starting treatment. It is an alpha-1 blocker and works by relaxing blood vessels and the opening of the bladder.\nTerazosin was patented in 1975 and came into medical use in 1985. It is available as a generic medication. In 2021, it was the 234th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nPROTEIN NAME: ADRA1B\nPROTEIN BACKGROUND INFORMATION: The alpha-1B adrenergic receptor (\u03b11B-adrenoreceptor), also known as ADRA1B, is an alpha-1 adrenergic receptor, and also denotes the human gene encoding it. The crystal structure of the \u03b11B-adrenergic receptor has been determined in complex with the inverse agonist (+)-cyclazosin.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Naproxen-erythema-Risedronic acid\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Risedronic acid-Adenopathy-Terazosin\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Terazosin-binding and inhibition-ADRA1B"}]}}
{"custom_id": "Carvedilol-Metolazone-Metoprolol-ADRA2A-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Carvedilol\nDRUG 1 BACKGROUND INFORMATION: Carvedilol, a nonselective beta-adrenergic blocker with alpha-1 adrenergic receptor antagonism, is clinically utilized for managing hypertension and chronic heart failure with reduced ejection fraction (HFrEF), often despite beta-blockers not being preferred first-line antihypertensives due to inferior cardiovascular outcomes and safety profiles relative to alternative hypertensives. While its pharmacodynamic mechanisms contributing to therapeutic efficacy in HFrEF remain incompletely elucidated, vasodilation resultant from alpha-1 blockade may play a role. Adverse reactions encompass orthostatic hypotension, asthenia, arthralgia, nausea, and dyspnea, with bronchospasm as a potential severe manifestation. The drug's pharmacokinetics necessitate cautious use during gestation and lactation and contraindicate administration in hepatic impairment cases. Despite exhibiting a broad safety spectrum, carvedilol's utilization extends to over 17 million annual prescriptions in the U.S., affirming its presence on the WHO's List of Essential Medicines and availability in generic formulations.\n\nDRUG 2 NAME: Metolazone\nDRUG 2 BACKGROUND INFORMATION: Metolazone is a thiazide-like diuretic marketed under the brand names Zytanix, Metoz, Zaroxolyn, and Mykrox. It is primarily used to treat congestive heart failure and high blood pressure. Metolazone indirectly decreases the amount of water reabsorbed into the bloodstream by the kidney, so that blood volume decreases and urine volume increases. This lowers blood pressure and prevents excess fluid accumulation in heart failure. Metolazone is sometimes used together with loop diuretics such as furosemide or bumetanide, but these highly effective combinations can lead to dehydration and electrolyte abnormalities.\nIt was patented in 1966 and approved for medical use in 1974.\n\nDRUG 3 NAME: Metoprolol\nDRUG 3 BACKGROUND INFORMATION: Metoprolol, a cardioselective \u03b21-adrenergic receptor antagonist, is clinically utilized in the management of angina pectoris, hypertension, tachyarrhythmias, post-myocardial infarction secondary prophylaxis, and migraine prophylaxis. Its therapeutic efficacy is mediated via negative chronotropic and inotropic effects which result in decreased myocardial oxygen demand and improved exercise tolerance. The pharmacokinetics of metoprolol is influenced by hepatic cytochrome P450 2D6 isoenzyme variability leading to significant interpatient variability in drug metabolism, necessitating individualized dosing. Adverse effects prominently include insomnia, asthenia, presyncope, and gastrointestinal disturbances, with higher doses presenting risk for pronounced toxicity. Though teratogenic risk during pregnancy has not been conclusively excluded, its excretion into breast milk is considered clinically insignificant. Metoprolol is widely dispensed, reflecting its inclusion in the WHO's Essential Medicines, and its prescription frequency underscores its pivotal role in cardiovascular therapeutics.\n\nPROTEIN NAME: ADRA2A\nPROTEIN BACKGROUND INFORMATION: The alpha-2A adrenergic receptor (\u03b12A adrenoceptor), also known as ADRA2A, is an \u03b12-adrenergic receptor, and also denotes the human gene encoding it.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Carvedilol-erythema-Metolazone\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Metolazone-cholecystitis-Metoprolol\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Metoprolol-binding and inhibition-ADRA2A"}]}}
{"custom_id": "Alprazolam-Benazepril-Terazosin-ADRA1D-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Alprazolam\nDRUG 1 BACKGROUND INFORMATION: Alprazolam is a high-affinity triazolobenzodiazepine functioning as a potent anxiolytic agent through modulation of the GABA_A receptor chloride channel activity, facilitating enhanced inhibitory neurotransmission. Its pharmacodynamic profile encompasses rapid onset and moderate duration of action, predominantly prescribed for anxiety spectrum disorders, including panic disorder and GAD, and adjunctively for chemotherapy-related emesis control. The pharmacokinetic trajectory involves oral administration, exhibiting bioavailability conducive to therapeutic efficacy within a week for GAD. The acute adverse neurological sequelae are characterized by CNS depression manifesting as somnolence, psychomotor impairment, cognitive attenuation, and dose-dependent anterograde amnesia. Tolerance development mitigates some sedative effects over time. Abrupt cessation precipitates benzodiazepine withdrawal symptomatology. As a Schedule IV controlled substance, alprazolam's potential for abuse and dependency necessitates judicious prescription monitoring. Its clinical ubiquity is substantiated by its standing as the 41st most prescribed drug in the US, with significant generic dissemination.\n\nDRUG 2 NAME: Benazepril\nDRUG 2 BACKGROUND INFORMATION: Benazepril, an ACE inhibitor marketed as Lotensin, is administered orally for the management of hypertension, heart failure, and diabetic nephropathy by attenuating the renin-angiotensin-aldosterone system activity. Formulations include benazepril/hydrochlorothiazide and benazepril/amlodipine combinations, targeting synergistic pathways for antihypertensive efficacy. The pharmacodynamic profile includes adverse reactions such as asthenia, orthostatic dizziness, and cough, while severe adverse events consist of potential nephrotoxicity, hypotension, hyperkalemia, and angioedema. Teratogenic risks disallow its use during gestation, contrasting with permissible lactational use. Its pharmacokinetic properties have secured its status as a widely prescribed, generic therapeutic, illustrated by over three million prescriptions in the U.S. in 2022.\n\nDRUG 3 NAME: Terazosin\nDRUG 3 BACKGROUND INFORMATION: Terazosin, sold under the brand name Hytrin among others, is a medication used to treat symptoms of an enlarged prostate and high blood pressure. For high blood pressure, it is a less preferred option. It is taken by mouth.\nCommon side effects include dizziness, headache, feeling tired, swelling, nausea, and low blood pressure with standing. Severe side effects may include priapism and low blood pressure. Prostate cancer should be ruled out before starting treatment. It is an alpha-1 blocker and works by relaxing blood vessels and the opening of the bladder.\nTerazosin was patented in 1975 and came into medical use in 1985. It is available as a generic medication. In 2021, it was the 234th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nPROTEIN NAME: ADRA1D\nPROTEIN BACKGROUND INFORMATION: The alpha-1D adrenergic receptor (\u03b11D adrenoreceptor), also known as ADRA1D, is an alpha-1 adrenergic receptor, and also denotes the human gene encoding it.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Alprazolam-gastric inflammation-Benazepril\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Benazepril-apoplexy-Terazosin\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Terazosin-binding and inhibition-ADRA1D"}]}}
{"custom_id": "acetazolamide-Celecoxib-Labetalol-ADRA2A-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: acetazolamide\nDRUG 1 BACKGROUND INFORMATION: Acetazolamide, marketed under the trade name Diamox, serves as a versatile pharmaceutical agent within the realm of carbonic anhydrase inhibitors, effectively modulating intraocular pressure via the diminution of aqueous humor production and osmolality. Its clinical utility spans across conditions such as glaucoma\u2014both open-angle and acute angle closure\u2014epilepsy, acute mountain sickness, periodic paralysis, idiopathic intracranial hypertension, and heart failure, with an ancillary role in urinary alkalinization. Therapeutic administration is achievable through oral and intravenous modalities. Mechanistically, acetazolamide exerts its effects by disrupting the equilibria of carbon dioxide hydration and subsequent bicarbonate ion production, thereby reducing intracellular hydrogen ion availability. The pharmacodynamic profile encompasses neuro-sensory side effects like paresthesia and tinnitus, alongside anorexia, emesis, and somnolence. Contraindications are notable in individuals with renal or hepatic impairment, and those with hypersensitivity to sulfonamide derivatives. As a diuretic and enzymatic inhibitor, it holds a position on the WHO's List of Essential Medicines, emphasizing its critical global accessibility as a generic formulation.\n\nDRUG 2 NAME: Celecoxib\nDRUG 2 BACKGROUND INFORMATION: Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, functions as a nonsteroidal anti-inflammatory drug (NSAID) utilized primarily for its analgesic and anti-inflammatory efficacy in osteoarthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, dysmenorrhea, acute pain management, and juvenile rheumatoid arthritis. Additionally, celecoxib has prophylactic applications in reducing colorectal adenomatous formations in familial adenomatous polyposis due to its COX-2 inhibition, which mitigates pro-inflammatory prostaglandin synthesis while sparing COX-1, ostensibly minimizing gastrointestinal mucosal damage relative to non-selective NSAIDs. The pharmacokinetics permit oral administration, with pharmacodynamic effects commencing typically within one hour post-ingestion. Notable adverse reactions span gastrointestinal disturbances such as abdominal pain, nausea, and diarrhea, with severe risk profiles including cardiovascular thrombotic events, gastrointestinal perforation, renal impairment, and hypersensitivity reactions like anaphylaxis, contraindicating its use in populations with significant cardiovascular risk profiles. The risk profile parallels that of other NSAIDs like ibuprofen and naproxen, and caution is advised during late-stage gestation and lactation. Celecoxib's generic availability and widespread prescription underscore its clinical significance, albeit with requisite consideration of its potential side-effect burden.\n\nDRUG 3 NAME: Labetalol\nDRUG 3 BACKGROUND INFORMATION: Labetalol is a medication used to treat high blood pressure and in long term management of angina. This includes essential hypertension, hypertensive emergencies, and hypertension of pregnancy. In essential hypertension it is generally less preferred than a number of other blood pressure medications. It can be given by mouth or by injection into a vein.\nCommon side effects include low blood pressure with standing, dizziness, feeling tired, and nausea. Serious side effects may include low blood pressure, liver problems, heart failure, and bronchospasm. Use appears safe in the latter part of pregnancy and it is not expected to cause problems during breastfeeding. It works by blocking the activation of \u03b2- and \u03b1-adrenergic receptors.\nLabetalol was patented in 1966 and came into medical use in 1977. It is available as a generic medication. In 2022, it was the 215th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nPROTEIN NAME: ADRA2A\nPROTEIN BACKGROUND INFORMATION: The alpha-2A adrenergic receptor (\u03b12A adrenoceptor), also known as ADRA2A, is an \u03b12-adrenergic receptor, and also denotes the human gene encoding it.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): acetazolamide-Pain-Celecoxib\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Celecoxib-Back Ache-Labetalol\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Labetalol-binding and inhibition-ADRA2A"}]}}
{"custom_id": "Orphenadrine-Temazepam-Trimipramine-HRH1-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Orphenadrine\nDRUG 1 BACKGROUND INFORMATION: Orphenadrine (sold under many brand names) is an anticholinergic drug of the ethanolamine antihistamine class; it is closely related to diphenhydramine. It is a muscle relaxant that is used to treat muscle pain and to help with motor control in Parkinson's disease, but has largely been superseded by newer drugs. It is considered a dirty drug due to its multiple mechanisms of action in different pathways. It was discovered and developed in the 1940s.\n\nDRUG 2 NAME: Temazepam\nDRUG 2 BACKGROUND INFORMATION: Temazepam is a benzodiazepine class hypnotic agent indicated primarily for the management of severe insomnia, characterized by its rapid oral absorption with clinically significant hypnotic and anxiolytic actions initiating within 30 minutes and persisting for approximately eight hours. The pharmacodynamic efficacy is mediated via positive allosteric modulation of the GABA-A receptor, enhancing GABAergic neurotransmission and inducing sedative-hypnotic outcomes. Despite its historical utilization, the prescription prevalence has diminished, supplanted by z-drugs and certain atypical antidepressants due to a more favorable side effect profile. Temazepam\u2019s pharmacokinetic and safety concerns include side effects such as ataxia, cognitive dysfunction, and in severe cases, can escalate to hallucinations, hypotension, and potential respiratory depression, particularly when co-administered with CNS depressants like alcohol or opioids. The withdrawal syndrome poses a significant risk upon rapid cessation following prolonged use. Teratogenic concerns contraindicate use during pregnancy and lactation. Despite its historical ubiquity as evidenced by over two million prescriptions in 2021, the clinical positioning of temazepam now leans towards refractory insomnia cases where alternative pharmacotherapy has been deemed inadequate.\n\nDRUG 3 NAME: Trimipramine\nDRUG 3 BACKGROUND INFORMATION: Trimipramine, sold under the brand name Surmontil among others, is a tricyclic antidepressant (TCA) which is used to treat depression. It has also been used for its sedative, anxiolytic, and weak antipsychotic effects in the treatment of insomnia, anxiety disorders, and psychosis, respectively. The drug is described as an atypical or \"second-generation\" TCA because, unlike other TCAs, it seems to be a fairly weak monoamine reuptake inhibitor. Similarly to other TCAs, however, trimipramine does have antihistamine, antiserotonergic, antiadrenergic, antidopaminergic, and anticholinergic activities.\n\nPROTEIN NAME: HRH1\nPROTEIN BACKGROUND INFORMATION: The H1 receptor is a histamine receptor belonging to the family of rhodopsin-like G-protein-coupled receptors. This receptor is activated by the biogenic amine histamine. It is expressed in smooth muscles, on vascular endothelial cells, in the heart, and in the central nervous system. The H1 receptor is linked to an intracellular G-protein (Gq) that activates phospholipase C and the inositol triphosphate (IP3) signalling pathway. Antihistamines, which act on this receptor, are used as anti-allergy drugs. The crystal structure of the receptor has been determined (shown on the right/below) and used to discover new histamine H1 receptor ligands in structure-based virtual screening studies.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Orphenadrine-Back Ache-Temazepam\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Temazepam-constipated-Trimipramine\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Trimipramine-binding and inhibition-HRH1"}]}}
{"custom_id": "Naproxen-Temazepam-Trimipramine-HRH1-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: Temazepam\nDRUG 2 BACKGROUND INFORMATION: Temazepam is a benzodiazepine class hypnotic agent indicated primarily for the management of severe insomnia, characterized by its rapid oral absorption with clinically significant hypnotic and anxiolytic actions initiating within 30 minutes and persisting for approximately eight hours. The pharmacodynamic efficacy is mediated via positive allosteric modulation of the GABA-A receptor, enhancing GABAergic neurotransmission and inducing sedative-hypnotic outcomes. Despite its historical utilization, the prescription prevalence has diminished, supplanted by z-drugs and certain atypical antidepressants due to a more favorable side effect profile. Temazepam\u2019s pharmacokinetic and safety concerns include side effects such as ataxia, cognitive dysfunction, and in severe cases, can escalate to hallucinations, hypotension, and potential respiratory depression, particularly when co-administered with CNS depressants like alcohol or opioids. The withdrawal syndrome poses a significant risk upon rapid cessation following prolonged use. Teratogenic concerns contraindicate use during pregnancy and lactation. Despite its historical ubiquity as evidenced by over two million prescriptions in 2021, the clinical positioning of temazepam now leans towards refractory insomnia cases where alternative pharmacotherapy has been deemed inadequate.\n\nDRUG 3 NAME: Trimipramine\nDRUG 3 BACKGROUND INFORMATION: Trimipramine, sold under the brand name Surmontil among others, is a tricyclic antidepressant (TCA) which is used to treat depression. It has also been used for its sedative, anxiolytic, and weak antipsychotic effects in the treatment of insomnia, anxiety disorders, and psychosis, respectively. The drug is described as an atypical or \"second-generation\" TCA because, unlike other TCAs, it seems to be a fairly weak monoamine reuptake inhibitor. Similarly to other TCAs, however, trimipramine does have antihistamine, antiserotonergic, antiadrenergic, antidopaminergic, and anticholinergic activities.\n\nPROTEIN NAME: HRH1\nPROTEIN BACKGROUND INFORMATION: The H1 receptor is a histamine receptor belonging to the family of rhodopsin-like G-protein-coupled receptors. This receptor is activated by the biogenic amine histamine. It is expressed in smooth muscles, on vascular endothelial cells, in the heart, and in the central nervous system. The H1 receptor is linked to an intracellular G-protein (Gq) that activates phospholipase C and the inositol triphosphate (IP3) signalling pathway. Antihistamines, which act on this receptor, are used as anti-allergy drugs. The crystal structure of the receptor has been determined (shown on the right/below) and used to discover new histamine H1 receptor ligands in structure-based virtual screening studies.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Naproxen-Acne-Temazepam\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Temazepam-constipated-Trimipramine\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Trimipramine-binding and inhibition-HRH1"}]}}
{"custom_id": "acetazolamide-Diazepam-Doxazosin-ADRA1B-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: acetazolamide\nDRUG 1 BACKGROUND INFORMATION: Acetazolamide, marketed under the trade name Diamox, serves as a versatile pharmaceutical agent within the realm of carbonic anhydrase inhibitors, effectively modulating intraocular pressure via the diminution of aqueous humor production and osmolality. Its clinical utility spans across conditions such as glaucoma\u2014both open-angle and acute angle closure\u2014epilepsy, acute mountain sickness, periodic paralysis, idiopathic intracranial hypertension, and heart failure, with an ancillary role in urinary alkalinization. Therapeutic administration is achievable through oral and intravenous modalities. Mechanistically, acetazolamide exerts its effects by disrupting the equilibria of carbon dioxide hydration and subsequent bicarbonate ion production, thereby reducing intracellular hydrogen ion availability. The pharmacodynamic profile encompasses neuro-sensory side effects like paresthesia and tinnitus, alongside anorexia, emesis, and somnolence. Contraindications are notable in individuals with renal or hepatic impairment, and those with hypersensitivity to sulfonamide derivatives. As a diuretic and enzymatic inhibitor, it holds a position on the WHO's List of Essential Medicines, emphasizing its critical global accessibility as a generic formulation.\n\nDRUG 2 NAME: Diazepam\nDRUG 2 BACKGROUND INFORMATION: Diazepam, a prototypical member of the benzodiazepine pharmacological class, functions primarily as an anxiolytic by potentiation of GABAergic neurotransmission, enhancing the binding affinity of gamma-aminobutyric acid (GABA) at the GABA_A receptor complex. It is employed in the management of a diverse array of conditions, including, but not limited to, generalized anxiety disorder, status epilepticus, alcohol withdrawal delirium, spasticity, insomnia, and restless legs syndrome, with additional utility in procedural amnesia induction. Diazepam exhibits versatile administration routes\u2014oral, rectal, intramuscular, intravenous, and intranasal, with IV administration eliciting rapid onset of action within 1-5 minutes and demonstrating a relatively short duration of clinical efficacy. Oral administration results in peak plasma concentrations within 15 to 60 minutes. While generally well-tolerated, its adverse effect profile includes CNS depression manifesting as sedation and impaired motor coordination, with rare, yet severe risks like respiratory depression, paradoxical excitation, and seizure exacerbation with chronic use. Chronic administration raises the risk of tolerance, physical dependence, and a withdrawal syndrome upon abrupt cessation; cognitive impairments post-discontinuation are well-documented. It is contraindicated in pregnancy and lactation due to teratogenic and neonatal withdrawal potential. Diazepam continues to be a mainstay therapeutic agent on the World Health Organization\u2019s List of Essential Medicines, despite its risk for abuse and dependency, underscoring the necessity for judicious prescribing practice.\n\nDRUG 3 NAME: Doxazosin\nDRUG 3 BACKGROUND INFORMATION: Doxazosin, sold under the brand name Cardura among others, is a medication used to treat symptoms of benign prostatic hyperplasia (enlarged prostate), hypertension (high blood pressure), and post-traumatic stress disorder (PTSD). For high blood pressure, it is a less preferred option. It is taken by mouth.\nCommon side effects include dizziness, sleepiness, swelling, nausea, shortness of breath, and abdominal pain. Severe side effects may include low blood pressure with standing, an irregular heart beat, and priapism. It is a selective \u03b11-adrenergic blocker in the quinazoline class of compounds.\nDoxazosin was patented in 1977 and came into medical use in 1988. It is available as a generic medication. In 2022, it was the 180th most commonly prescribed medication in the United States, with more than 2 million prescriptions.\n\nPROTEIN NAME: ADRA1B\nPROTEIN BACKGROUND INFORMATION: The alpha-1B adrenergic receptor (\u03b11B-adrenoreceptor), also known as ADRA1B, is an alpha-1 adrenergic receptor, and also denotes the human gene encoding it. The crystal structure of the \u03b11B-adrenergic receptor has been determined in complex with the inverse agonist (+)-cyclazosin.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): acetazolamide-Pain-Diazepam\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Diazepam-right heart failure-Doxazosin\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Doxazosin-binding and inhibition-ADRA1B"}]}}
{"custom_id": "Naproxen-Lamotrigine-oxybutynin-CHRM1-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: Lamotrigine\nDRUG 2 BACKGROUND INFORMATION: Lamotrigine, a phenyltriazine anticonvulsant, is primarily utilized in the pharmacological management of epilepsy, encompassing focal, tonic-clonic, and Lennox-Gastaut syndrome seizures, as well as serving as a mood-stabilizing agent in bipolar disorder. While it does not consistently ameliorate acute depressive states in bipolar disorders outside of severe depression contexts, it efficaciously mitigates the risk of recurrent depressive episodes in euthymic individuals. Additionally, lamotrigine is prescribed off-label for major depressive disorder and depersonalization-derealization disorder. Its pharmacodynamics are hypothesized to involve the inhibition of excitatory neurotransmitter release through modulation of voltage-sensitive sodium channels and voltage-gated calcium channels. Despite its therapeutic efficacy, lamotrigine's adverse effect profile includes both common side effects such as nausea, somnolence, headache, emesis, ataxia, and dermatological reactions, and serious reactions like hemolytic anemia, suicidality, and potentially fatal Stevens\u2013Johnson syndrome.\n\nDRUG 3 NAME: oxybutynin\nDRUG 3 BACKGROUND INFORMATION: Oxybutynin, marketed as Ditropan, is a quintessential anticholinergic agent employed predominantly for the amelioration of overactive bladder symptoms, capitalizing on its potent antimuscarinic properties that effectively circumvent acetylcholine-mediated smooth muscle contractions. Its pharmacotherapeutic action, analogous to tolterodine, darifenacin, and solifenacin, renders it a superior first-line therapeutic option due to its robust safety and efficacy profile over prolonged usage, despite plausible off-label utilizations in hyperhidrosis management. Contrarily, its application for pediatric nocturnal enuresis has seen diminished prevalence, given its questionable efficacy. Administrable orally or transdermally, oxybutynin's pharmacokinetic profile necessitates vigilance regarding adverse effects such as xerostomia, gastrointestinal hypomotility, and thermoregulatory dysfunction, encompassing severe sequelae like urinary retention and thermophilic impairments manifesting as heat stroke. Its teratogenic and lactogenic safety paradigms remain speculative, underscoring the need for judicious administration during pregnancy and lactation. As a generically available pharmacologic entity, it maintains substantial prescription frequency, embodying a pivotal role in managing cholinergic-mediated urological disorders.\n\nPROTEIN NAME: CHRM1\nPROTEIN BACKGROUND INFORMATION: The muscarinic acetylcholine receptor M1, also known as the cholinergic receptor, muscarinic 1, is a muscarinic receptor that in humans is encoded by the CHRM1 gene. It is localized to 11q13.\nThis receptor is found mediating slow EPSP at the ganglion in the postganglionic nerve, is common in exocrine glands and in the CNS.\nIt is predominantly found bound to G proteins of class Gq that use upregulation of phospholipase C and, therefore, inositol trisphosphate and intracellular calcium as a signalling pathway. A receptor so bound would not be susceptible to CTX or PTX. However, Gi (causing a downstream decrease in cAMP) and Gs (causing an increase in cAMP) have also been shown to be involved in interactions in certain tissues, and so would be susceptible to PTX and CTX respectively.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Naproxen-abnormal EEG-Lamotrigine\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Lamotrigine-cholecystitis-oxybutynin\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): oxybutynin-binding and inhibition-CHRM1"}]}}
{"custom_id": "Labetalol-Metoprolol-Perphenazine-ADRA2C-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Labetalol\nDRUG 1 BACKGROUND INFORMATION: Labetalol is a medication used to treat high blood pressure and in long term management of angina. This includes essential hypertension, hypertensive emergencies, and hypertension of pregnancy. In essential hypertension it is generally less preferred than a number of other blood pressure medications. It can be given by mouth or by injection into a vein.\nCommon side effects include low blood pressure with standing, dizziness, feeling tired, and nausea. Serious side effects may include low blood pressure, liver problems, heart failure, and bronchospasm. Use appears safe in the latter part of pregnancy and it is not expected to cause problems during breastfeeding. It works by blocking the activation of \u03b2- and \u03b1-adrenergic receptors.\nLabetalol was patented in 1966 and came into medical use in 1977. It is available as a generic medication. In 2022, it was the 215th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG 2 NAME: Metoprolol\nDRUG 2 BACKGROUND INFORMATION: Metoprolol, a cardioselective \u03b21-adrenergic receptor antagonist, is clinically utilized in the management of angina pectoris, hypertension, tachyarrhythmias, post-myocardial infarction secondary prophylaxis, and migraine prophylaxis. Its therapeutic efficacy is mediated via negative chronotropic and inotropic effects which result in decreased myocardial oxygen demand and improved exercise tolerance. The pharmacokinetics of metoprolol is influenced by hepatic cytochrome P450 2D6 isoenzyme variability leading to significant interpatient variability in drug metabolism, necessitating individualized dosing. Adverse effects prominently include insomnia, asthenia, presyncope, and gastrointestinal disturbances, with higher doses presenting risk for pronounced toxicity. Though teratogenic risk during pregnancy has not been conclusively excluded, its excretion into breast milk is considered clinically insignificant. Metoprolol is widely dispensed, reflecting its inclusion in the WHO's Essential Medicines, and its prescription frequency underscores its pivotal role in cardiovascular therapeutics.\n\nDRUG 3 NAME: Perphenazine\nDRUG 3 BACKGROUND INFORMATION: Perphenazine is a typical antipsychotic drug.  Chemically, it is classified as a piperazinyl phenothiazine. Originally marketed in the United States as Trilafon, it has been in clinical use for decades.\nPerphenazine is roughly ten times as potent as chlorpromazine at the dopamine-2 (D2) receptor; thus perphenazine is considered a medium-potency antipsychotic.\n\nPROTEIN NAME: ADRA2C\nPROTEIN BACKGROUND INFORMATION: The alpha-2C adrenergic receptor (\u03b12C adrenoceptor), also known as ADRA2C, is an alpha-2 adrenergic receptor, and also denotes the human gene encoding it.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Labetalol-apoplexy-Metoprolol\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Metoprolol-insulin dependent diabetes mellitus-Perphenazine\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Perphenazine-binding and inhibition-ADRA2C"}]}}
{"custom_id": "Aciclovir-Citalopram-Fluphenazine-ADRA1B-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Aciclovir\nDRUG 1 BACKGROUND INFORMATION: Aciclovir, an antiviral guanosine analogue, exhibits its therapeutic efficacy predominantly by inhibiting viral DNA polymerase through its metabolization to aciclovir triphosphate, resulting in the cessation of herpesvirus DNA elongation across Herpes Simplex Virus, varicella-zoster, and CMV prophylaxis post-transplantation. Administerable orally, topically, or intravenously, its pharmacokinetic profile necessitates careful consideration in patients with compromised renal or hepatic function due to potential nephrotoxicity and thrombocytopenia. While demonstrating an acceptable safety margin during gestation and lactation, adverse events such as gastrointestinal discomfort and diarrhea are common. Its inclusion in the WHO's Essential Medicines list underscores its global pivotal role in antiviral therapy, with its generic accessibility enhancing universal healthcare implementation.\n\nDRUG 2 NAME: Citalopram\nDRUG 2 BACKGROUND INFORMATION: Citalopram, a chiral bicyclic phthalane derivative and selective serotonin reuptake inhibitor (SSRI), is primarily employed in the pharmacotherapy of major depressive disorder, obsessive-compulsive disorder, panic disorder, and social phobia through modulation of serotonergic neurotransmission. The therapeutic latency ranges from one to four weeks post-administration. It is predominantly administered orally, though parenteral administration via intravenous injection is utilized in specific regions to expedite therapeutic onset. The pharmacokinetic profile of citalopram encompasses hepatic metabolism predominantly via CYP2C19, CYP3A4, and CYP2D6, yielding demethylated metabolites. It is imperative to monitor for adverse reactions, including, but not limited to, gastrointestinal disturbances, insomnia, sexual dysfunction, tremors, somnolence, hyperhidrosis, serotonin toxicity, and cardiotoxicity as manifested by QT interval prolongation. Contraindications entail concurrent MAO inhibitor therapy due to risk of serotonin syndrome and potential teratogenicity warrants cautious use in pregnancy. The potential for exacerbating suicidality in individuals under 25 necessitates vigilant monitoring. Citalopram's clinical prominence is evidenced by its inclusion in the WHO's List of Essential Medicines and its extensive prescribing frequency in the United States, underscoring its integral role in psychiatric treatment regimens.\n\nDRUG 3 NAME: Fluphenazine\nDRUG 3 BACKGROUND INFORMATION: Fluphenazine is a high-affinity typical antipsychotic of the phenothiazine cohort primarily prescribed for chronic psychotic disorders such as schizophrenia, offering efficacy comparable to chlorpromazine. Administered via oral, intramuscular, subcutaneous routes\u2014or as a long-acting depot, fluphenazine decanoate\u2014this compound exhibits prolonged dopaminergic antagonism with an extended half-life conducive to monthly dosing regimens. Notably contraindicated in severe depressive states, its pharmacological action is ascribed to dopamine receptor blockade, though precision in its mechanism remains indeterminate. The pharmacodynamic profile of fluphenazine entails extrapyramidal symptoms, somnolence, depressive mood alterations, and metabolic side effects, with grave adverse events encompassing neuroleptic malignant syndrome, agranulocytosis, and irreversible tardive dyskinesia. Moreover, in the geriatric cohort with dementia-related psychoses, mortality risk is potentiated. Prolactin secretion perturbations may elicit galactorrhea, gynecomastia, erectile dysfunction, and amenorrhea, with teratogenic safety in gestation unresolved. Chronic administration associates with hepatocellular enzyme elevation in a substantial patient subset. Despite its broad utilization reflected in its inclusion on the World Health Organization's Essential Medicines list, its production cessation in some regions underscores its dynamic availability landscape.\n\nPROTEIN NAME: ADRA1B\nPROTEIN BACKGROUND INFORMATION: The alpha-1B adrenergic receptor (\u03b11B-adrenoreceptor), also known as ADRA1B, is an alpha-1 adrenergic receptor, and also denotes the human gene encoding it. The crystal structure of the \u03b11B-adrenergic receptor has been determined in complex with the inverse agonist (+)-cyclazosin.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Aciclovir-methaemoglobinaemia-Citalopram\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Citalopram-cholecystitis-Fluphenazine\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Fluphenazine-binding and inhibition-ADRA1B"}]}}
{"custom_id": "Aciclovir-Doxazosin-Metoprolol-PTGIR-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Aciclovir\nDRUG 1 BACKGROUND INFORMATION: Aciclovir, an antiviral guanosine analogue, exhibits its therapeutic efficacy predominantly by inhibiting viral DNA polymerase through its metabolization to aciclovir triphosphate, resulting in the cessation of herpesvirus DNA elongation across Herpes Simplex Virus, varicella-zoster, and CMV prophylaxis post-transplantation. Administerable orally, topically, or intravenously, its pharmacokinetic profile necessitates careful consideration in patients with compromised renal or hepatic function due to potential nephrotoxicity and thrombocytopenia. While demonstrating an acceptable safety margin during gestation and lactation, adverse events such as gastrointestinal discomfort and diarrhea are common. Its inclusion in the WHO's Essential Medicines list underscores its global pivotal role in antiviral therapy, with its generic accessibility enhancing universal healthcare implementation.\n\nDRUG 2 NAME: Doxazosin\nDRUG 2 BACKGROUND INFORMATION: Doxazosin, sold under the brand name Cardura among others, is a medication used to treat symptoms of benign prostatic hyperplasia (enlarged prostate), hypertension (high blood pressure), and post-traumatic stress disorder (PTSD). For high blood pressure, it is a less preferred option. It is taken by mouth.\nCommon side effects include dizziness, sleepiness, swelling, nausea, shortness of breath, and abdominal pain. Severe side effects may include low blood pressure with standing, an irregular heart beat, and priapism. It is a selective \u03b11-adrenergic blocker in the quinazoline class of compounds.\nDoxazosin was patented in 1977 and came into medical use in 1988. It is available as a generic medication. In 2022, it was the 180th most commonly prescribed medication in the United States, with more than 2 million prescriptions.\n\nDRUG 3 NAME: Metoprolol\nDRUG 3 BACKGROUND INFORMATION: Metoprolol, a cardioselective \u03b21-adrenergic receptor antagonist, is clinically utilized in the management of angina pectoris, hypertension, tachyarrhythmias, post-myocardial infarction secondary prophylaxis, and migraine prophylaxis. Its therapeutic efficacy is mediated via negative chronotropic and inotropic effects which result in decreased myocardial oxygen demand and improved exercise tolerance. The pharmacokinetics of metoprolol is influenced by hepatic cytochrome P450 2D6 isoenzyme variability leading to significant interpatient variability in drug metabolism, necessitating individualized dosing. Adverse effects prominently include insomnia, asthenia, presyncope, and gastrointestinal disturbances, with higher doses presenting risk for pronounced toxicity. Though teratogenic risk during pregnancy has not been conclusively excluded, its excretion into breast milk is considered clinically insignificant. Metoprolol is widely dispensed, reflecting its inclusion in the WHO's Essential Medicines, and its prescription frequency underscores its pivotal role in cardiovascular therapeutics.\n\nPROTEIN NAME: PTGIR\nPROTEIN BACKGROUND INFORMATION: The prostacyclin receptor, also termed the prostaglandin I2 receptor or just IP, is a receptor belonging to the prostaglandin (PG) group of receptors. IP binds to and mediates the biological actions of prostacyclin (also termed prostaglandin I2, PGI2, or when used as a drug, epoprostenol). IP is encoded in humans by the PTGIR gene. While possessing many functions as defined in animal model studies, the major clinical relevancy of IP is as a powerful vasodilator: stimulators of IP are used to treat severe and even life-threatening diseases involving pathological vasoconstriction.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Aciclovir-gastric inflammation-Doxazosin\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Doxazosin-gastric inflammation-Metoprolol\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Metoprolol-binding and activation-PTGIR"}]}}
{"custom_id": "Orphenadrine-Temazepam-Zafirlukast-CYSLTR1-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Orphenadrine\nDRUG 1 BACKGROUND INFORMATION: Orphenadrine (sold under many brand names) is an anticholinergic drug of the ethanolamine antihistamine class; it is closely related to diphenhydramine. It is a muscle relaxant that is used to treat muscle pain and to help with motor control in Parkinson's disease, but has largely been superseded by newer drugs. It is considered a dirty drug due to its multiple mechanisms of action in different pathways. It was discovered and developed in the 1940s.\n\nDRUG 2 NAME: Temazepam\nDRUG 2 BACKGROUND INFORMATION: Temazepam is a benzodiazepine class hypnotic agent indicated primarily for the management of severe insomnia, characterized by its rapid oral absorption with clinically significant hypnotic and anxiolytic actions initiating within 30 minutes and persisting for approximately eight hours. The pharmacodynamic efficacy is mediated via positive allosteric modulation of the GABA-A receptor, enhancing GABAergic neurotransmission and inducing sedative-hypnotic outcomes. Despite its historical utilization, the prescription prevalence has diminished, supplanted by z-drugs and certain atypical antidepressants due to a more favorable side effect profile. Temazepam\u2019s pharmacokinetic and safety concerns include side effects such as ataxia, cognitive dysfunction, and in severe cases, can escalate to hallucinations, hypotension, and potential respiratory depression, particularly when co-administered with CNS depressants like alcohol or opioids. The withdrawal syndrome poses a significant risk upon rapid cessation following prolonged use. Teratogenic concerns contraindicate use during pregnancy and lactation. Despite its historical ubiquity as evidenced by over two million prescriptions in 2021, the clinical positioning of temazepam now leans towards refractory insomnia cases where alternative pharmacotherapy has been deemed inadequate.\n\nDRUG 3 NAME: Zafirlukast\nDRUG 3 BACKGROUND INFORMATION: Zafirlukast, an orally bioavailable leukotriene receptor antagonist, targets the cysteinyl leukotriene receptor subtypes CysLT1, thereby attenuating leukotriene-mediated bronchoconstriction, microvascular permeability, and airway inflammation pivotal in the asthma pathophysiology. While generally well tolerated, adverse reactions include cephalalgia and gastrointestinal disturbances; however, hepatotoxicity such as fulminant hepatic failure and eosinophilic granulomatosis with polyangiitis have been sporadically reported, though the latter lacks a definitive causal linkage. Zafirlukast undergoes extensive hepatic biotransformation via the cytochrome P450 2C9 isoenzyme, with consequential inhibition of CYP3A4, delineating a potential for pharmacokinetic drug-drug interactions. Polymorphisms in LTC4 synthase and cytochrome P450 2C9 may modulate individual response variability to this pharmacotherapy.\n\nPROTEIN NAME: CYSLTR1\nPROTEIN BACKGROUND INFORMATION: Cysteinyl leukotriene receptor 1, also termed CYSLTR1, is a receptor for cysteinyl leukotrienes (LT) (see  cysteinyl leukotrienes). CYSLTR1, by binding these cysteinyl LTs (CysLTs; viz, LTC4, LTD4, and to a much lesser extent, LTE4) contributes to mediating various allergic and hypersensitivity reactions in humans as well as models of the reactions in other animals.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Orphenadrine-Back Ache-Temazepam\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Temazepam-dysarthria-Zafirlukast\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Zafirlukast-binding and inhibition-CYSLTR1"}]}}
{"custom_id": "Naproxen-Furosemide-Salmeterol-ADRB3-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: Furosemide\nDRUG 2 BACKGROUND INFORMATION: Furosemide, a potent loop diuretic, exerts its pharmacological action by inhibiting the Na-K-2Cl symporter in the thick ascending limb of the loop of Henle, thus profoundly augmenting natriuresis and diuresis, which alleviates conditions of edema secondary to cardiac, hepatic, or renal insufficiencies. Additionally utilized in the management of hypertension, furosemide yields rapid onset of action with intravenous administration effectuating within five minutes, whereas oral ingestion manifests systemic absorption and efficacy within an hour. Adverse effects encompass orthostatic hypotension, tinnitus, and photosensitivity, with severe risks including electrolyte imbalances such as hypokalemia, along with potential nephrotoxicity and ototoxicity. Clinicians are advised to diligently monitor serum electrolytes (notably potassium), bicarbonate, renal indices (creatinine, BUN), and hepatic function parameters. Despite its inclusion on the World Health Organization's List of Essential Medicines, furosemide's utility is tempered by its status on the World Anti-Doping Agency's list of prohibited substances, attributed to its potential misuse for concealing illicit performance-enhancing drug usage, alongside its veterinary application for managing exercise-induced pulmonary hemorrhage in equines.\n\nDRUG 3 NAME: Salmeterol\nDRUG 3 BACKGROUND INFORMATION: Salmeterol is a long-acting \u03b22 adrenergic receptor agonist (LABA) used in the treatment and prevention of asthma symptoms and control of chronic obstructive pulmonary disease (COPD) symptoms. Symptoms of bronchospasm include shortness of breath, wheezing, coughing and chest tightness. It is also used to prevent breathing difficulties during exercise (exercise-induced bronchoconstriction).\nIt was patented in 1983 and came into medical use in 1990. It is marketed as Serevent in the US. It is available as a dry-powder inhaler (DPI) that releases a powdered form of the drug. It was previously available as a metered-dose inhaler (MDI) but was discontinued in the US in 2002. It is available as an MDI in other countries as of 2020.\n\nPROTEIN NAME: ADRB3\nPROTEIN BACKGROUND INFORMATION: The beta-3 adrenergic receptor (\u03b23-adrenoceptor), also known as ADRB3, is a beta-adrenergic receptor, and also denotes the human gene encoding it.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Naproxen-adenomyosis-Furosemide\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Furosemide-right heart failure-Salmeterol\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Salmeterol-binding and activation-ADRB3"}]}}
{"custom_id": "Naproxen-Temazepam-Zafirlukast-CYSLTR1-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: Temazepam\nDRUG 2 BACKGROUND INFORMATION: Temazepam is a benzodiazepine class hypnotic agent indicated primarily for the management of severe insomnia, characterized by its rapid oral absorption with clinically significant hypnotic and anxiolytic actions initiating within 30 minutes and persisting for approximately eight hours. The pharmacodynamic efficacy is mediated via positive allosteric modulation of the GABA-A receptor, enhancing GABAergic neurotransmission and inducing sedative-hypnotic outcomes. Despite its historical utilization, the prescription prevalence has diminished, supplanted by z-drugs and certain atypical antidepressants due to a more favorable side effect profile. Temazepam\u2019s pharmacokinetic and safety concerns include side effects such as ataxia, cognitive dysfunction, and in severe cases, can escalate to hallucinations, hypotension, and potential respiratory depression, particularly when co-administered with CNS depressants like alcohol or opioids. The withdrawal syndrome poses a significant risk upon rapid cessation following prolonged use. Teratogenic concerns contraindicate use during pregnancy and lactation. Despite its historical ubiquity as evidenced by over two million prescriptions in 2021, the clinical positioning of temazepam now leans towards refractory insomnia cases where alternative pharmacotherapy has been deemed inadequate.\n\nDRUG 3 NAME: Zafirlukast\nDRUG 3 BACKGROUND INFORMATION: Zafirlukast, an orally bioavailable leukotriene receptor antagonist, targets the cysteinyl leukotriene receptor subtypes CysLT1, thereby attenuating leukotriene-mediated bronchoconstriction, microvascular permeability, and airway inflammation pivotal in the asthma pathophysiology. While generally well tolerated, adverse reactions include cephalalgia and gastrointestinal disturbances; however, hepatotoxicity such as fulminant hepatic failure and eosinophilic granulomatosis with polyangiitis have been sporadically reported, though the latter lacks a definitive causal linkage. Zafirlukast undergoes extensive hepatic biotransformation via the cytochrome P450 2C9 isoenzyme, with consequential inhibition of CYP3A4, delineating a potential for pharmacokinetic drug-drug interactions. Polymorphisms in LTC4 synthase and cytochrome P450 2C9 may modulate individual response variability to this pharmacotherapy.\n\nPROTEIN NAME: CYSLTR1\nPROTEIN BACKGROUND INFORMATION: Cysteinyl leukotriene receptor 1, also termed CYSLTR1, is a receptor for cysteinyl leukotrienes (LT) (see  cysteinyl leukotrienes). CYSLTR1, by binding these cysteinyl LTs (CysLTs; viz, LTC4, LTD4, and to a much lesser extent, LTE4) contributes to mediating various allergic and hypersensitivity reactions in humans as well as models of the reactions in other animals.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Naproxen-Acne-Temazepam\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Temazepam-dysarthria-Zafirlukast\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Zafirlukast-binding and inhibition-CYSLTR1"}]}}
{"custom_id": "Alprazolam-Doxazosin-Formoterol-ADRB3-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Alprazolam\nDRUG 1 BACKGROUND INFORMATION: Alprazolam is a high-affinity triazolobenzodiazepine functioning as a potent anxiolytic agent through modulation of the GABA_A receptor chloride channel activity, facilitating enhanced inhibitory neurotransmission. Its pharmacodynamic profile encompasses rapid onset and moderate duration of action, predominantly prescribed for anxiety spectrum disorders, including panic disorder and GAD, and adjunctively for chemotherapy-related emesis control. The pharmacokinetic trajectory involves oral administration, exhibiting bioavailability conducive to therapeutic efficacy within a week for GAD. The acute adverse neurological sequelae are characterized by CNS depression manifesting as somnolence, psychomotor impairment, cognitive attenuation, and dose-dependent anterograde amnesia. Tolerance development mitigates some sedative effects over time. Abrupt cessation precipitates benzodiazepine withdrawal symptomatology. As a Schedule IV controlled substance, alprazolam's potential for abuse and dependency necessitates judicious prescription monitoring. Its clinical ubiquity is substantiated by its standing as the 41st most prescribed drug in the US, with significant generic dissemination.\n\nDRUG 2 NAME: Doxazosin\nDRUG 2 BACKGROUND INFORMATION: Doxazosin, sold under the brand name Cardura among others, is a medication used to treat symptoms of benign prostatic hyperplasia (enlarged prostate), hypertension (high blood pressure), and post-traumatic stress disorder (PTSD). For high blood pressure, it is a less preferred option. It is taken by mouth.\nCommon side effects include dizziness, sleepiness, swelling, nausea, shortness of breath, and abdominal pain. Severe side effects may include low blood pressure with standing, an irregular heart beat, and priapism. It is a selective \u03b11-adrenergic blocker in the quinazoline class of compounds.\nDoxazosin was patented in 1977 and came into medical use in 1988. It is available as a generic medication. In 2022, it was the 180th most commonly prescribed medication in the United States, with more than 2 million prescriptions.\n\nDRUG 3 NAME: Formoterol\nDRUG 3 BACKGROUND INFORMATION: Formoterol, a potent long-acting \u03b22-adrenergic receptor agonist (LABA), functions as a bronchodilator specifically targeting pulmonary smooth muscle to induce bronchodilation, thereby offering therapeutic utility in the management of asthma and chronic obstructive pulmonary disease (COPD). Notably, formoterol distinguishes itself by a prolonged bronchodilatory efficacy of approximately 12 hours post-administration, surpassing the 4-6 hour window typical of short-acting \u03b22 agonists like salbutamol (albuterol). Its pharmacokinetic profile is characterized by a rapid onset of action within 2-3 minutes, setting it apart from other LABAs. According to the 2022 Global Initiative for Asthma guidelines, adult treatment regimens favor a formoterol and inhaled corticosteroid combination for both prophylactic and acute symptom management, whereas pediatric protocols prioritize short-acting \u03b22 adrenergic agonists, such as salbutamol for immediate relief. Formoterol is commercially available both as a standalone generic medication and in synergistic fixed-dose combinations, notably with budesonide and mometasone, to enhance its clinical efficacy in targeted therapeutic strategies.\n\nPROTEIN NAME: ADRB3\nPROTEIN BACKGROUND INFORMATION: The beta-3 adrenergic receptor (\u03b23-adrenoceptor), also known as ADRB3, is a beta-adrenergic receptor, and also denotes the human gene encoding it.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Alprazolam-myelodysplasia-Doxazosin\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Doxazosin-aortic aneurysm-Formoterol\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Formoterol-binding and activation-ADRB3"}]}}
{"custom_id": "Naproxen-Lamotrigine-Salmeterol-ADRB1-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: Lamotrigine\nDRUG 2 BACKGROUND INFORMATION: Lamotrigine, a phenyltriazine anticonvulsant, is primarily utilized in the pharmacological management of epilepsy, encompassing focal, tonic-clonic, and Lennox-Gastaut syndrome seizures, as well as serving as a mood-stabilizing agent in bipolar disorder. While it does not consistently ameliorate acute depressive states in bipolar disorders outside of severe depression contexts, it efficaciously mitigates the risk of recurrent depressive episodes in euthymic individuals. Additionally, lamotrigine is prescribed off-label for major depressive disorder and depersonalization-derealization disorder. Its pharmacodynamics are hypothesized to involve the inhibition of excitatory neurotransmitter release through modulation of voltage-sensitive sodium channels and voltage-gated calcium channels. Despite its therapeutic efficacy, lamotrigine's adverse effect profile includes both common side effects such as nausea, somnolence, headache, emesis, ataxia, and dermatological reactions, and serious reactions like hemolytic anemia, suicidality, and potentially fatal Stevens\u2013Johnson syndrome.\n\nDRUG 3 NAME: Salmeterol\nDRUG 3 BACKGROUND INFORMATION: Salmeterol is a long-acting \u03b22 adrenergic receptor agonist (LABA) used in the treatment and prevention of asthma symptoms and control of chronic obstructive pulmonary disease (COPD) symptoms. Symptoms of bronchospasm include shortness of breath, wheezing, coughing and chest tightness. It is also used to prevent breathing difficulties during exercise (exercise-induced bronchoconstriction).\nIt was patented in 1983 and came into medical use in 1990. It is marketed as Serevent in the US. It is available as a dry-powder inhaler (DPI) that releases a powdered form of the drug. It was previously available as a metered-dose inhaler (MDI) but was discontinued in the US in 2002. It is available as an MDI in other countries as of 2020.\n\nPROTEIN NAME: ADRB1\nPROTEIN BACKGROUND INFORMATION: The beta-1 adrenergic receptor (\u03b21 adrenoceptor), also known as ADRB1, can refer to either the protein-encoding gene (gene ADRB1) or one of the four adrenergic receptors. It is a G-protein coupled receptor associated with the Gs heterotrimeric G-protein that is expressed predominantly in cardiac tissue. In addition to cardiac tissue, beta-1 adrenergic receptors are also expressed in the cerebral cortex.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Naproxen-abnormal EEG-Lamotrigine\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Lamotrigine-erythema-Salmeterol\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Salmeterol-binding and activation-ADRB1"}]}}
{"custom_id": "acetazolamide-Diazepam-Desloratadine-HRH1-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: acetazolamide\nDRUG 1 BACKGROUND INFORMATION: Acetazolamide, marketed under the trade name Diamox, serves as a versatile pharmaceutical agent within the realm of carbonic anhydrase inhibitors, effectively modulating intraocular pressure via the diminution of aqueous humor production and osmolality. Its clinical utility spans across conditions such as glaucoma\u2014both open-angle and acute angle closure\u2014epilepsy, acute mountain sickness, periodic paralysis, idiopathic intracranial hypertension, and heart failure, with an ancillary role in urinary alkalinization. Therapeutic administration is achievable through oral and intravenous modalities. Mechanistically, acetazolamide exerts its effects by disrupting the equilibria of carbon dioxide hydration and subsequent bicarbonate ion production, thereby reducing intracellular hydrogen ion availability. The pharmacodynamic profile encompasses neuro-sensory side effects like paresthesia and tinnitus, alongside anorexia, emesis, and somnolence. Contraindications are notable in individuals with renal or hepatic impairment, and those with hypersensitivity to sulfonamide derivatives. As a diuretic and enzymatic inhibitor, it holds a position on the WHO's List of Essential Medicines, emphasizing its critical global accessibility as a generic formulation.\n\nDRUG 2 NAME: Diazepam\nDRUG 2 BACKGROUND INFORMATION: Diazepam, a prototypical member of the benzodiazepine pharmacological class, functions primarily as an anxiolytic by potentiation of GABAergic neurotransmission, enhancing the binding affinity of gamma-aminobutyric acid (GABA) at the GABA_A receptor complex. It is employed in the management of a diverse array of conditions, including, but not limited to, generalized anxiety disorder, status epilepticus, alcohol withdrawal delirium, spasticity, insomnia, and restless legs syndrome, with additional utility in procedural amnesia induction. Diazepam exhibits versatile administration routes\u2014oral, rectal, intramuscular, intravenous, and intranasal, with IV administration eliciting rapid onset of action within 1-5 minutes and demonstrating a relatively short duration of clinical efficacy. Oral administration results in peak plasma concentrations within 15 to 60 minutes. While generally well-tolerated, its adverse effect profile includes CNS depression manifesting as sedation and impaired motor coordination, with rare, yet severe risks like respiratory depression, paradoxical excitation, and seizure exacerbation with chronic use. Chronic administration raises the risk of tolerance, physical dependence, and a withdrawal syndrome upon abrupt cessation; cognitive impairments post-discontinuation are well-documented. It is contraindicated in pregnancy and lactation due to teratogenic and neonatal withdrawal potential. Diazepam continues to be a mainstay therapeutic agent on the World Health Organization\u2019s List of Essential Medicines, despite its risk for abuse and dependency, underscoring the necessity for judicious prescribing practice.\n\nDRUG 3 NAME: Desloratadine\nDRUG 3 BACKGROUND INFORMATION: Desloratadine sold under the brand name Aerius among others, is a tricyclic H1 inverse agonist that is used to treat allergies. It is an active metabolite of loratadine.\nIt was patented in 1984 and came into medical use in 2001. It was brought to the market in the US by Schering Corporation, later named Schering-Plough.\n\nPROTEIN NAME: HRH1\nPROTEIN BACKGROUND INFORMATION: The H1 receptor is a histamine receptor belonging to the family of rhodopsin-like G-protein-coupled receptors. This receptor is activated by the biogenic amine histamine. It is expressed in smooth muscles, on vascular endothelial cells, in the heart, and in the central nervous system. The H1 receptor is linked to an intracellular G-protein (Gq) that activates phospholipase C and the inositol triphosphate (IP3) signalling pathway. Antihistamines, which act on this receptor, are used as anti-allergy drugs. The crystal structure of the receptor has been determined (shown on the right/below) and used to discover new histamine H1 receptor ligands in structure-based virtual screening studies.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): acetazolamide-Pain-Diazepam\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Diazepam-cholecystitis-Desloratadine\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Desloratadine-binding and inhibition-HRH1"}]}}
{"custom_id": "Cimetidine-Labetalol-Metoprolol-PTGIR-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Cimetidine\nDRUG 1 BACKGROUND INFORMATION: Cimetidine, sold under the brand name Tagamet among others, is a histamine H2 receptor antagonist that inhibits stomach acid production. It is mainly used in the treatment of heartburn and peptic ulcers.\nWith the development of proton pump inhibitors, such as omeprazole, approved for the same indications, cimetidine is available as an over-the-counter formulation to prevent heartburn or acid indigestion, along with the other H2-receptor antagonists.\nCimetidine was developed in 1971 and came into commercial use in 1977. Cimetidine was approved in the United Kingdom in 1976, and was approved in the United States by the Food and Drug Administration in 1979.\n\nDRUG 2 NAME: Labetalol\nDRUG 2 BACKGROUND INFORMATION: Labetalol is a medication used to treat high blood pressure and in long term management of angina. This includes essential hypertension, hypertensive emergencies, and hypertension of pregnancy. In essential hypertension it is generally less preferred than a number of other blood pressure medications. It can be given by mouth or by injection into a vein.\nCommon side effects include low blood pressure with standing, dizziness, feeling tired, and nausea. Serious side effects may include low blood pressure, liver problems, heart failure, and bronchospasm. Use appears safe in the latter part of pregnancy and it is not expected to cause problems during breastfeeding. It works by blocking the activation of \u03b2- and \u03b1-adrenergic receptors.\nLabetalol was patented in 1966 and came into medical use in 1977. It is available as a generic medication. In 2022, it was the 215th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG 3 NAME: Metoprolol\nDRUG 3 BACKGROUND INFORMATION: Metoprolol, a cardioselective \u03b21-adrenergic receptor antagonist, is clinically utilized in the management of angina pectoris, hypertension, tachyarrhythmias, post-myocardial infarction secondary prophylaxis, and migraine prophylaxis. Its therapeutic efficacy is mediated via negative chronotropic and inotropic effects which result in decreased myocardial oxygen demand and improved exercise tolerance. The pharmacokinetics of metoprolol is influenced by hepatic cytochrome P450 2D6 isoenzyme variability leading to significant interpatient variability in drug metabolism, necessitating individualized dosing. Adverse effects prominently include insomnia, asthenia, presyncope, and gastrointestinal disturbances, with higher doses presenting risk for pronounced toxicity. Though teratogenic risk during pregnancy has not been conclusively excluded, its excretion into breast milk is considered clinically insignificant. Metoprolol is widely dispensed, reflecting its inclusion in the WHO's Essential Medicines, and its prescription frequency underscores its pivotal role in cardiovascular therapeutics.\n\nPROTEIN NAME: PTGIR\nPROTEIN BACKGROUND INFORMATION: The prostacyclin receptor, also termed the prostaglandin I2 receptor or just IP, is a receptor belonging to the prostaglandin (PG) group of receptors. IP binds to and mediates the biological actions of prostacyclin (also termed prostaglandin I2, PGI2, or when used as a drug, epoprostenol). IP is encoded in humans by the PTGIR gene. While possessing many functions as defined in animal model studies, the major clinical relevancy of IP is as a powerful vasodilator: stimulators of IP are used to treat severe and even life-threatening diseases involving pathological vasoconstriction.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Cimetidine-back injury-Labetalol\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Labetalol-apoplexy-Metoprolol\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Metoprolol-binding and activation-PTGIR"}]}}
{"custom_id": "Aciclovir-Citalopram-Terazosin-ADRA1B-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Aciclovir\nDRUG 1 BACKGROUND INFORMATION: Aciclovir, an antiviral guanosine analogue, exhibits its therapeutic efficacy predominantly by inhibiting viral DNA polymerase through its metabolization to aciclovir triphosphate, resulting in the cessation of herpesvirus DNA elongation across Herpes Simplex Virus, varicella-zoster, and CMV prophylaxis post-transplantation. Administerable orally, topically, or intravenously, its pharmacokinetic profile necessitates careful consideration in patients with compromised renal or hepatic function due to potential nephrotoxicity and thrombocytopenia. While demonstrating an acceptable safety margin during gestation and lactation, adverse events such as gastrointestinal discomfort and diarrhea are common. Its inclusion in the WHO's Essential Medicines list underscores its global pivotal role in antiviral therapy, with its generic accessibility enhancing universal healthcare implementation.\n\nDRUG 2 NAME: Citalopram\nDRUG 2 BACKGROUND INFORMATION: Citalopram, a chiral bicyclic phthalane derivative and selective serotonin reuptake inhibitor (SSRI), is primarily employed in the pharmacotherapy of major depressive disorder, obsessive-compulsive disorder, panic disorder, and social phobia through modulation of serotonergic neurotransmission. The therapeutic latency ranges from one to four weeks post-administration. It is predominantly administered orally, though parenteral administration via intravenous injection is utilized in specific regions to expedite therapeutic onset. The pharmacokinetic profile of citalopram encompasses hepatic metabolism predominantly via CYP2C19, CYP3A4, and CYP2D6, yielding demethylated metabolites. It is imperative to monitor for adverse reactions, including, but not limited to, gastrointestinal disturbances, insomnia, sexual dysfunction, tremors, somnolence, hyperhidrosis, serotonin toxicity, and cardiotoxicity as manifested by QT interval prolongation. Contraindications entail concurrent MAO inhibitor therapy due to risk of serotonin syndrome and potential teratogenicity warrants cautious use in pregnancy. The potential for exacerbating suicidality in individuals under 25 necessitates vigilant monitoring. Citalopram's clinical prominence is evidenced by its inclusion in the WHO's List of Essential Medicines and its extensive prescribing frequency in the United States, underscoring its integral role in psychiatric treatment regimens.\n\nDRUG 3 NAME: Terazosin\nDRUG 3 BACKGROUND INFORMATION: Terazosin, sold under the brand name Hytrin among others, is a medication used to treat symptoms of an enlarged prostate and high blood pressure. For high blood pressure, it is a less preferred option. It is taken by mouth.\nCommon side effects include dizziness, headache, feeling tired, swelling, nausea, and low blood pressure with standing. Severe side effects may include priapism and low blood pressure. Prostate cancer should be ruled out before starting treatment. It is an alpha-1 blocker and works by relaxing blood vessels and the opening of the bladder.\nTerazosin was patented in 1975 and came into medical use in 1985. It is available as a generic medication. In 2021, it was the 234th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nPROTEIN NAME: ADRA1B\nPROTEIN BACKGROUND INFORMATION: The alpha-1B adrenergic receptor (\u03b11B-adrenoreceptor), also known as ADRA1B, is an alpha-1 adrenergic receptor, and also denotes the human gene encoding it. The crystal structure of the \u03b11B-adrenergic receptor has been determined in complex with the inverse agonist (+)-cyclazosin.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Aciclovir-methaemoglobinaemia-Citalopram\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Citalopram-gastric inflammation-Terazosin\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Terazosin-binding and inhibition-ADRA1B"}]}}
{"custom_id": "alendronic acid-Lamivudine-Metoprolol-HRH3-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: alendronic acid\nDRUG 1 BACKGROUND INFORMATION: Alendronic acid, sold under the brand name Fosamax among others, is a bisphosphonate medication used to treat osteoporosis and Paget's disease of bone. It is taken by mouth. Use is often recommended together with vitamin D, calcium supplementation, and lifestyle changes.\nCommon side effects (1 to 10% of patients) include constipation, abdominal pain, nausea, and acid reflux. Use is not recommended during pregnancy or in those with poor kidney function. Alendronic acid works by decreasing the activity of cells that break down bone.\nAlendronic acid was first described in 1978 and approved for medical use in the United States in 1995. It is available as a generic medication. In 2022, it was the 103rd most commonly prescribed medication in the United States, with more than 6 million prescriptions.\n\nDRUG 2 NAME: Lamivudine\nDRUG 2 BACKGROUND INFORMATION: Lamivudine, or 3TC, is a nucleoside reverse transcriptase inhibitor with efficacy against HIV-1, HIV-2, and chronic hepatitis B virus. It functions by competitive inhibition of HIV reverse transcriptase and hepatitis B virus polymerase, disrupting viral DNA synthesis. Clinically, lamivudine is integral to combination antiretroviral therapy, often co-administered with agents such as zidovudine, dolutegravir, and abacavir, and forms part of post-exposure prophylactic regimens. It is available for oral administration as liquid or tablet formulations, maintaining therapeutic flexibility through its dosing independence from food intake. While generally well-tolerated, adverse effects can include gastrointestinal disturbances, cephalalgia, asthenia, and respiratory symptoms; however, clinicians must vigilantly monitor for hepatotoxicity, lactic acidosis, and hepatitis B exacerbations. Suitable for patients over three months and deemed safe in pregnancy, lamivudine is recognized as an essential medicine, underscoring its pivotal role in antiretroviral pharmacotherapy despite potential genotypic resistance mutations.\n\nDRUG 3 NAME: Metoprolol\nDRUG 3 BACKGROUND INFORMATION: Metoprolol, a cardioselective \u03b21-adrenergic receptor antagonist, is clinically utilized in the management of angina pectoris, hypertension, tachyarrhythmias, post-myocardial infarction secondary prophylaxis, and migraine prophylaxis. Its therapeutic efficacy is mediated via negative chronotropic and inotropic effects which result in decreased myocardial oxygen demand and improved exercise tolerance. The pharmacokinetics of metoprolol is influenced by hepatic cytochrome P450 2D6 isoenzyme variability leading to significant interpatient variability in drug metabolism, necessitating individualized dosing. Adverse effects prominently include insomnia, asthenia, presyncope, and gastrointestinal disturbances, with higher doses presenting risk for pronounced toxicity. Though teratogenic risk during pregnancy has not been conclusively excluded, its excretion into breast milk is considered clinically insignificant. Metoprolol is widely dispensed, reflecting its inclusion in the WHO's Essential Medicines, and its prescription frequency underscores its pivotal role in cardiovascular therapeutics.\n\nPROTEIN NAME: HRH3\nPROTEIN BACKGROUND INFORMATION: Histamine H3 receptors are expressed in the central nervous system and to a lesser extent the peripheral nervous system, where they act as autoreceptors in presynaptic histaminergic neurons and control histamine turnover by feedback inhibition of histamine synthesis and release. The H3 receptor has also been shown to presynaptically inhibit the release of a number of other neurotransmitters (i.e. it acts as an inhibitory heteroreceptor) including, but probably not limited to dopamine, GABA, acetylcholine, noradrenaline, histamine and serotonin.\nThe gene sequence for H3 receptors expresses only about 22% and 20% homology with both H1 and H2 receptors respectively.\nThere is much interest in the histamine H3 receptor as a potential therapeutic target because of its involvement in the neuronal mechanism behind many cognitive disorders and especially its location in the central nervous system.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): alendronic acid-Adenopathy-Lamivudine\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Lamivudine-dysarthria-Metoprolol\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Metoprolol-binding and activation-HRH3"}]}}
{"custom_id": "Metolazone-Metoprolol-Perphenazine-ADRA1A-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Metolazone\nDRUG 1 BACKGROUND INFORMATION: Metolazone is a thiazide-like diuretic marketed under the brand names Zytanix, Metoz, Zaroxolyn, and Mykrox. It is primarily used to treat congestive heart failure and high blood pressure. Metolazone indirectly decreases the amount of water reabsorbed into the bloodstream by the kidney, so that blood volume decreases and urine volume increases. This lowers blood pressure and prevents excess fluid accumulation in heart failure. Metolazone is sometimes used together with loop diuretics such as furosemide or bumetanide, but these highly effective combinations can lead to dehydration and electrolyte abnormalities.\nIt was patented in 1966 and approved for medical use in 1974.\n\nDRUG 2 NAME: Metoprolol\nDRUG 2 BACKGROUND INFORMATION: Metoprolol, a cardioselective \u03b21-adrenergic receptor antagonist, is clinically utilized in the management of angina pectoris, hypertension, tachyarrhythmias, post-myocardial infarction secondary prophylaxis, and migraine prophylaxis. Its therapeutic efficacy is mediated via negative chronotropic and inotropic effects which result in decreased myocardial oxygen demand and improved exercise tolerance. The pharmacokinetics of metoprolol is influenced by hepatic cytochrome P450 2D6 isoenzyme variability leading to significant interpatient variability in drug metabolism, necessitating individualized dosing. Adverse effects prominently include insomnia, asthenia, presyncope, and gastrointestinal disturbances, with higher doses presenting risk for pronounced toxicity. Though teratogenic risk during pregnancy has not been conclusively excluded, its excretion into breast milk is considered clinically insignificant. Metoprolol is widely dispensed, reflecting its inclusion in the WHO's Essential Medicines, and its prescription frequency underscores its pivotal role in cardiovascular therapeutics.\n\nDRUG 3 NAME: Perphenazine\nDRUG 3 BACKGROUND INFORMATION: Perphenazine is a typical antipsychotic drug.  Chemically, it is classified as a piperazinyl phenothiazine. Originally marketed in the United States as Trilafon, it has been in clinical use for decades.\nPerphenazine is roughly ten times as potent as chlorpromazine at the dopamine-2 (D2) receptor; thus perphenazine is considered a medium-potency antipsychotic.\n\nPROTEIN NAME: ADRA1A\nPROTEIN BACKGROUND INFORMATION: The alpha-1A adrenergic receptor (\u03b11A adrenoreceptor), also known as ADRA1A, formerly known also as the  alpha-1C adrenergic receptor, is an alpha-1 adrenergic receptor, and also denotes the human gene encoding it. There is no longer a subtype \u03b11C receptor. At one time, there was a subtype known as \u03b11C, but it was found to be identical to the previously discovered \u03b11A receptor subtype. To avoid confusion, the naming convention was continued with the letter D.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Metolazone-cholecystitis-Metoprolol\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Metoprolol-insulin dependent diabetes mellitus-Perphenazine\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Perphenazine-binding and inhibition-ADRA1A"}]}}
{"custom_id": "Naproxen-Ondansetron-Trazodone-HRH1-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: Ondansetron\nDRUG 2 BACKGROUND INFORMATION: Ondansetron, a potent antiemetic utilized to mitigate nausea and emesis associated with chemotherapy, radiation, migraine, and surgical procedures, exerts its pharmacological action as a selective serotonin 5-HT3 receptor antagonist. Absence of affinity for dopaminergic and muscarinic acetylcholine receptors precludes extrapyramidal side effects such as akathisia. Administered via oral, intravenous, or intramuscular routes, ondansetron's pharmacokinetic profile is characterized by hepatic metabolism and renal excretion. Adverse effects frequently reported encompass gastrointestinal dysmotility manifesting as diarrhea or constipation, central nervous system manifestations including headache and somnolence, and dermal pruritus, with more severe toxicities including QT interval prolongation on electrocardiographic assessment and anaphylaxis. Although the teratogenic risk is minimal, comprehensive teratological data in gravid populations remain insufficient. Recognized on the WHO's List of Essential Medicines, ondansetron is extensively prescribed, highlighting its clinical utility and incorporation into treatment protocols, with significant utilization confirmed by its high prescription frequency in the United States.\n\nDRUG 3 NAME: Trazodone\nDRUG 3 BACKGROUND INFORMATION: Trazodone is an antidepressant medication used to treat major depressive disorder, anxiety disorders, and insomnia. It is a phenylpiperazine compound of the serotonin antagonist and reuptake inhibitor (SARI) class. The medication is taken orally.\nCommon side effects include dry mouth, feeling faint, vomiting, and headache. More serious side effects may include suicide, mania, irregular heart rate, and pathologically prolonged erections. It is unclear if use during pregnancy or breastfeeding is safe.  Trazodone also has sedating effects.\nTrazodone was approved for medical use in the United States in 1981. It is available as a generic medication. In 2022, it was the eighteenth most commonly prescribed medication in the United States, with more than 27 million prescriptions.\n\nPROTEIN NAME: HRH1\nPROTEIN BACKGROUND INFORMATION: The H1 receptor is a histamine receptor belonging to the family of rhodopsin-like G-protein-coupled receptors. This receptor is activated by the biogenic amine histamine. It is expressed in smooth muscles, on vascular endothelial cells, in the heart, and in the central nervous system. The H1 receptor is linked to an intracellular G-protein (Gq) that activates phospholipase C and the inositol triphosphate (IP3) signalling pathway. Antihistamines, which act on this receptor, are used as anti-allergy drugs. The crystal structure of the receptor has been determined (shown on the right/below) and used to discover new histamine H1 receptor ligands in structure-based virtual screening studies.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Naproxen-Dyspnea exertional-Ondansetron\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Ondansetron-hepatic neoplasia-Trazodone\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Trazodone-binding and inhibition-HRH1"}]}}
{"custom_id": "Naproxen-Cetirizine-Salmeterol-ADRB3-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: Cetirizine\nDRUG 2 BACKGROUND INFORMATION: Cetirizine, a second-generation selective H1 antihistaminergic agent, is primarily administered orally for the amelioration of allergic rhinitis, dermatitis, and urticaria, exerting its pharmacodynamic effects predominantly extracellularly, thereby minimizing central nervous system penetration and consequent sedative effects typical of first-generation antihistamines such as diphenhydramine. Its clinical onset transpires within thirty minutes, maintaining therapeutic efficacy for approximately 24 hours with an adverse effect profile that includes somnolence, xerostomia, cephalalgia, and abdominal discomfort, albeit with a diminished proclivity for sedation compared to its first-generation counterparts due to its peripheral selectivity. Amongst its second-generation analogs, cetirizine exhibits a comparatively higher incidence of somnolence vis-\u00e0-vis fexofenadine and loratadine. It is contraindicated in lactation but permissible during gestation and extends its utility to pediatric cohorts with caution advised regarding potential somnolence. Being generically available and included in the World Health Organization's List of Essential Medicines, cetirizine\u2019s broad prescriptive prevalence, as evidenced by over 13 million US prescriptions in 2022, underscores its efficacy and widespread utilitarian value in allergy management.\n\nDRUG 3 NAME: Salmeterol\nDRUG 3 BACKGROUND INFORMATION: Salmeterol is a long-acting \u03b22 adrenergic receptor agonist (LABA) used in the treatment and prevention of asthma symptoms and control of chronic obstructive pulmonary disease (COPD) symptoms. Symptoms of bronchospasm include shortness of breath, wheezing, coughing and chest tightness. It is also used to prevent breathing difficulties during exercise (exercise-induced bronchoconstriction).\nIt was patented in 1983 and came into medical use in 1990. It is marketed as Serevent in the US. It is available as a dry-powder inhaler (DPI) that releases a powdered form of the drug. It was previously available as a metered-dose inhaler (MDI) but was discontinued in the US in 2002. It is available as an MDI in other countries as of 2020.\n\nPROTEIN NAME: ADRB3\nPROTEIN BACKGROUND INFORMATION: The beta-3 adrenergic receptor (\u03b23-adrenoceptor), also known as ADRB3, is a beta-adrenergic receptor, and also denotes the human gene encoding it.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Naproxen-cholecystitis-Cetirizine\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Cetirizine-cholecystitis-Salmeterol\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Salmeterol-binding and activation-ADRB3"}]}}
{"custom_id": "Methylphenidate-Metronidazole-Terazosin-ADRA1D-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Methylphenidate\nDRUG 1 BACKGROUND INFORMATION: Methylphenidate, a CNS stimulant within the phenethylamine and piperidine classes, exerts therapeutic effects in ADHD and narcolepsy predominantly through the inhibition of presynaptic dopamine and norepinephrine transporters, thereby augmenting synaptic monoamine concentrations. Its pharmacodynamics establish a clinical efficacy for enhancing executive functions such as attentional control, inhibitory processes, working memory, and emotional regulation, albeit with a slightly reduced efficacy compared to amphetamines. Pharmacokinetically, methylphenidate is amenable to both oral and transdermal administration with formulation-dependent pharmacokinetics dictating therapeutic windows. Adverse effects span neuropsychiatric and autonomic domains, including, but not limited to, sympathomimetic manifestations such as tachycardia, euphoria, anorexia, and insomnia, while withdrawal is typified by dysphoric and neurovegetative symptoms. Methylphenidate's status as a high-frequency prescription medication is underscored by its extensive dispensation, ranking as the 32nd most prescribed medication in the U.S. as of 2022, available in both branded and generic forms.\n\nDRUG 2 NAME: Metronidazole\nDRUG 2 BACKGROUND INFORMATION: Metronidazole, a nitroimidazole antimicrobial agent, exerts its therapeutic efficacy through the reductive activation of its nitro group under anaerobic conditions, leading to the generation of radical intermediates that disrupt nucleic acid synthesis and result in microbial cell death. This antimicrobial exhibits a broad spectrum of antiprotozoal and antibacterial activity, making it efficacious in treating a variety of conditions, including pelvic inflammatory disease, bacterial vaginosis, and anaerobic infections such as Clostridioides difficile colitis, particularly when first-line options like vancomycin are unavailable. Pharmacodynamically, metronidazole can be administered via oral, topical, or intravenous routes, allowing flexibility in clinical application. However, its use is occasionally accompanied by adverse reactions such as gastrointestinal disturbances, neurotoxicity including seizures, and hypersensitivity responses, necessitating cautious application, particularly in pregnant populations where teratogenic potential is debated, though generally compatible with lactation. Despite these considerations, metronidazole remains a cornerstone in antimicrobial treatment paradigms, reflected by its inclusion in the WHO's List of Essential Medicines and high prescription rates globally.\n\nDRUG 3 NAME: Terazosin\nDRUG 3 BACKGROUND INFORMATION: Terazosin, sold under the brand name Hytrin among others, is a medication used to treat symptoms of an enlarged prostate and high blood pressure. For high blood pressure, it is a less preferred option. It is taken by mouth.\nCommon side effects include dizziness, headache, feeling tired, swelling, nausea, and low blood pressure with standing. Severe side effects may include priapism and low blood pressure. Prostate cancer should be ruled out before starting treatment. It is an alpha-1 blocker and works by relaxing blood vessels and the opening of the bladder.\nTerazosin was patented in 1975 and came into medical use in 1985. It is available as a generic medication. In 2021, it was the 234th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nPROTEIN NAME: ADRA1D\nPROTEIN BACKGROUND INFORMATION: The alpha-1D adrenergic receptor (\u03b11D adrenoreceptor), also known as ADRA1D, is an alpha-1 adrenergic receptor, and also denotes the human gene encoding it.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Methylphenidate-subarachnoid haemorrhage-Metronidazole\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Metronidazole-drug toxicity NOS-Terazosin\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Terazosin-binding and inhibition-ADRA1D"}]}}
{"custom_id": "Naproxen-Cetirizine-Terazosin-ADRA1B-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: Cetirizine\nDRUG 2 BACKGROUND INFORMATION: Cetirizine, a second-generation selective H1 antihistaminergic agent, is primarily administered orally for the amelioration of allergic rhinitis, dermatitis, and urticaria, exerting its pharmacodynamic effects predominantly extracellularly, thereby minimizing central nervous system penetration and consequent sedative effects typical of first-generation antihistamines such as diphenhydramine. Its clinical onset transpires within thirty minutes, maintaining therapeutic efficacy for approximately 24 hours with an adverse effect profile that includes somnolence, xerostomia, cephalalgia, and abdominal discomfort, albeit with a diminished proclivity for sedation compared to its first-generation counterparts due to its peripheral selectivity. Amongst its second-generation analogs, cetirizine exhibits a comparatively higher incidence of somnolence vis-\u00e0-vis fexofenadine and loratadine. It is contraindicated in lactation but permissible during gestation and extends its utility to pediatric cohorts with caution advised regarding potential somnolence. Being generically available and included in the World Health Organization's List of Essential Medicines, cetirizine\u2019s broad prescriptive prevalence, as evidenced by over 13 million US prescriptions in 2022, underscores its efficacy and widespread utilitarian value in allergy management.\n\nDRUG 3 NAME: Terazosin\nDRUG 3 BACKGROUND INFORMATION: Terazosin, sold under the brand name Hytrin among others, is a medication used to treat symptoms of an enlarged prostate and high blood pressure. For high blood pressure, it is a less preferred option. It is taken by mouth.\nCommon side effects include dizziness, headache, feeling tired, swelling, nausea, and low blood pressure with standing. Severe side effects may include priapism and low blood pressure. Prostate cancer should be ruled out before starting treatment. It is an alpha-1 blocker and works by relaxing blood vessels and the opening of the bladder.\nTerazosin was patented in 1975 and came into medical use in 1985. It is available as a generic medication. In 2021, it was the 234th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nPROTEIN NAME: ADRA1B\nPROTEIN BACKGROUND INFORMATION: The alpha-1B adrenergic receptor (\u03b11B-adrenoreceptor), also known as ADRA1B, is an alpha-1 adrenergic receptor, and also denotes the human gene encoding it. The crystal structure of the \u03b11B-adrenergic receptor has been determined in complex with the inverse agonist (+)-cyclazosin.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Naproxen-cholecystitis-Cetirizine\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Cetirizine-elevated erythrocyte sedimentation rate-Terazosin\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Terazosin-binding and inhibition-ADRA1B"}]}}
{"custom_id": "Fentanyl-Ketorolac-Trazodone-HRH1-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Fentanyl\nDRUG 1 BACKGROUND INFORMATION: Fentanyl, a synthetic piperidine opioid agonist, demonstrates exceptional analgesic efficacy, with \u03bc-opioid receptor affinity rendering it 50-100 times more potent than morphine. Clinically, it is indispensable for managing severe pain in oncologic contexts and post-operative recovery, administered under brand names such as Actiq, Duragesic, and Sublimaze. The pharmacokinetic profile facilitates rapid onset across administration routes, thus posing significant overdose risk even at minimal doses. Adverse pharmacodynamics encompass addiction potential, central nervous system depression leading to respiratory compromise, and a range of neuropsychiatric disturbances, including narcotic delirium and hypotensive coma, exacerbated synergistically by concurrent alcohol or co-ingestants like cocaine and heroin. Although opioid antagonists such as naloxone are efficacious in overdose scenarios, fentanyl\u2019s high receptor occupancy and potency often necessitate multiple reversal attempts. Epidemiologically, fentanyl supersedes other synthetic opioids, catalyzing an overdose epidemic exacerbated by clandestine synthesis and poly-drug formulations, complicating therapeutic interventions and forensic investigations. Proactive measures, including test kits and advanced analytical protocols, are critical in mitigating rampant illicit distribution, underpinned by fentanyl\u2019s streamlined synthesis and distribution adaptability.\n\nDRUG 2 NAME: Ketorolac\nDRUG 2 BACKGROUND INFORMATION: Ketorolac, marketed under names such as Toradol, Acular, and Sprix, is a potent nonsteroidal anti-inflammatory drug (NSAID) indicated for the management of moderate to severe nociceptive pain with a treatment limitation not exceeding six to seven days, varying by country guidelines. Administration routes include oral, nasal, intravenous, intramuscular, and ophthalmic, with onset of analgesia within one hour and duration of efficacy up to eight hours. Its mechanism of action involves the inhibition of cyclooxygenase enzymes 1 and 2 (COX-1 and COX-2), resulting in the attenuation of prostaglandin synthesis, and it possesses ancillary antipyretic properties. Common adverse reactions encompass sedation, vertigo, gastrointestinal discomfort, and emesis, while severe complications may involve gastrointestinal hemorrhage, nephrotoxicity, myocardial infarction, bronchospasm, heart failure, and hypersensitivity reactions. It is contraindicated in later stages of gestation and lactation due to potential fetal and neonatal risks. Despite its initial appeal as a non-opioid analgesic alternative with lower addictive potential, its correlation with significant adverse outcomes such as gastrointestinal and renal sequelae led to market withdrawal in specific regions like Germany. As a robust prostaglandin synthesis inhibitor, ketorolac compromises renal autoregulation under conditions of hemodynamic stress or elevated catecholamine states, limiting its utilization in those with underlying renal or cardiovascular vulnerabilities.\n\nDRUG 3 NAME: Trazodone\nDRUG 3 BACKGROUND INFORMATION: Trazodone is an antidepressant medication used to treat major depressive disorder, anxiety disorders, and insomnia. It is a phenylpiperazine compound of the serotonin antagonist and reuptake inhibitor (SARI) class. The medication is taken orally.\nCommon side effects include dry mouth, feeling faint, vomiting, and headache. More serious side effects may include suicide, mania, irregular heart rate, and pathologically prolonged erections. It is unclear if use during pregnancy or breastfeeding is safe.  Trazodone also has sedating effects.\nTrazodone was approved for medical use in the United States in 1981. It is available as a generic medication. In 2022, it was the eighteenth most commonly prescribed medication in the United States, with more than 27 million prescriptions.\n\nPROTEIN NAME: HRH1\nPROTEIN BACKGROUND INFORMATION: The H1 receptor is a histamine receptor belonging to the family of rhodopsin-like G-protein-coupled receptors. This receptor is activated by the biogenic amine histamine. It is expressed in smooth muscles, on vascular endothelial cells, in the heart, and in the central nervous system. The H1 receptor is linked to an intracellular G-protein (Gq) that activates phospholipase C and the inositol triphosphate (IP3) signalling pathway. Antihistamines, which act on this receptor, are used as anti-allergy drugs. The crystal structure of the receptor has been determined (shown on the right/below) and used to discover new histamine H1 receptor ligands in structure-based virtual screening studies.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Fentanyl-Adenopathy-Ketorolac\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Ketorolac-cholecystitis-Trazodone\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Trazodone-binding and inhibition-HRH1"}]}}
{"custom_id": "acetazolamide-Citalopram-Fluphenazine-ADRA1B-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: acetazolamide\nDRUG 1 BACKGROUND INFORMATION: Acetazolamide, marketed under the trade name Diamox, serves as a versatile pharmaceutical agent within the realm of carbonic anhydrase inhibitors, effectively modulating intraocular pressure via the diminution of aqueous humor production and osmolality. Its clinical utility spans across conditions such as glaucoma\u2014both open-angle and acute angle closure\u2014epilepsy, acute mountain sickness, periodic paralysis, idiopathic intracranial hypertension, and heart failure, with an ancillary role in urinary alkalinization. Therapeutic administration is achievable through oral and intravenous modalities. Mechanistically, acetazolamide exerts its effects by disrupting the equilibria of carbon dioxide hydration and subsequent bicarbonate ion production, thereby reducing intracellular hydrogen ion availability. The pharmacodynamic profile encompasses neuro-sensory side effects like paresthesia and tinnitus, alongside anorexia, emesis, and somnolence. Contraindications are notable in individuals with renal or hepatic impairment, and those with hypersensitivity to sulfonamide derivatives. As a diuretic and enzymatic inhibitor, it holds a position on the WHO's List of Essential Medicines, emphasizing its critical global accessibility as a generic formulation.\n\nDRUG 2 NAME: Citalopram\nDRUG 2 BACKGROUND INFORMATION: Citalopram, a chiral bicyclic phthalane derivative and selective serotonin reuptake inhibitor (SSRI), is primarily employed in the pharmacotherapy of major depressive disorder, obsessive-compulsive disorder, panic disorder, and social phobia through modulation of serotonergic neurotransmission. The therapeutic latency ranges from one to four weeks post-administration. It is predominantly administered orally, though parenteral administration via intravenous injection is utilized in specific regions to expedite therapeutic onset. The pharmacokinetic profile of citalopram encompasses hepatic metabolism predominantly via CYP2C19, CYP3A4, and CYP2D6, yielding demethylated metabolites. It is imperative to monitor for adverse reactions, including, but not limited to, gastrointestinal disturbances, insomnia, sexual dysfunction, tremors, somnolence, hyperhidrosis, serotonin toxicity, and cardiotoxicity as manifested by QT interval prolongation. Contraindications entail concurrent MAO inhibitor therapy due to risk of serotonin syndrome and potential teratogenicity warrants cautious use in pregnancy. The potential for exacerbating suicidality in individuals under 25 necessitates vigilant monitoring. Citalopram's clinical prominence is evidenced by its inclusion in the WHO's List of Essential Medicines and its extensive prescribing frequency in the United States, underscoring its integral role in psychiatric treatment regimens.\n\nDRUG 3 NAME: Fluphenazine\nDRUG 3 BACKGROUND INFORMATION: Fluphenazine is a high-affinity typical antipsychotic of the phenothiazine cohort primarily prescribed for chronic psychotic disorders such as schizophrenia, offering efficacy comparable to chlorpromazine. Administered via oral, intramuscular, subcutaneous routes\u2014or as a long-acting depot, fluphenazine decanoate\u2014this compound exhibits prolonged dopaminergic antagonism with an extended half-life conducive to monthly dosing regimens. Notably contraindicated in severe depressive states, its pharmacological action is ascribed to dopamine receptor blockade, though precision in its mechanism remains indeterminate. The pharmacodynamic profile of fluphenazine entails extrapyramidal symptoms, somnolence, depressive mood alterations, and metabolic side effects, with grave adverse events encompassing neuroleptic malignant syndrome, agranulocytosis, and irreversible tardive dyskinesia. Moreover, in the geriatric cohort with dementia-related psychoses, mortality risk is potentiated. Prolactin secretion perturbations may elicit galactorrhea, gynecomastia, erectile dysfunction, and amenorrhea, with teratogenic safety in gestation unresolved. Chronic administration associates with hepatocellular enzyme elevation in a substantial patient subset. Despite its broad utilization reflected in its inclusion on the World Health Organization's Essential Medicines list, its production cessation in some regions underscores its dynamic availability landscape.\n\nPROTEIN NAME: ADRA1B\nPROTEIN BACKGROUND INFORMATION: The alpha-1B adrenergic receptor (\u03b11B-adrenoreceptor), also known as ADRA1B, is an alpha-1 adrenergic receptor, and also denotes the human gene encoding it. The crystal structure of the \u03b11B-adrenergic receptor has been determined in complex with the inverse agonist (+)-cyclazosin.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): acetazolamide-Back Ache-Citalopram\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Citalopram-cholecystitis-Fluphenazine\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Fluphenazine-binding and inhibition-ADRA1B"}]}}
{"custom_id": "acetazolamide-Diazepam-Formoterol-ADRB1-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: acetazolamide\nDRUG 1 BACKGROUND INFORMATION: Acetazolamide, marketed under the trade name Diamox, serves as a versatile pharmaceutical agent within the realm of carbonic anhydrase inhibitors, effectively modulating intraocular pressure via the diminution of aqueous humor production and osmolality. Its clinical utility spans across conditions such as glaucoma\u2014both open-angle and acute angle closure\u2014epilepsy, acute mountain sickness, periodic paralysis, idiopathic intracranial hypertension, and heart failure, with an ancillary role in urinary alkalinization. Therapeutic administration is achievable through oral and intravenous modalities. Mechanistically, acetazolamide exerts its effects by disrupting the equilibria of carbon dioxide hydration and subsequent bicarbonate ion production, thereby reducing intracellular hydrogen ion availability. The pharmacodynamic profile encompasses neuro-sensory side effects like paresthesia and tinnitus, alongside anorexia, emesis, and somnolence. Contraindications are notable in individuals with renal or hepatic impairment, and those with hypersensitivity to sulfonamide derivatives. As a diuretic and enzymatic inhibitor, it holds a position on the WHO's List of Essential Medicines, emphasizing its critical global accessibility as a generic formulation.\n\nDRUG 2 NAME: Diazepam\nDRUG 2 BACKGROUND INFORMATION: Diazepam, a prototypical member of the benzodiazepine pharmacological class, functions primarily as an anxiolytic by potentiation of GABAergic neurotransmission, enhancing the binding affinity of gamma-aminobutyric acid (GABA) at the GABA_A receptor complex. It is employed in the management of a diverse array of conditions, including, but not limited to, generalized anxiety disorder, status epilepticus, alcohol withdrawal delirium, spasticity, insomnia, and restless legs syndrome, with additional utility in procedural amnesia induction. Diazepam exhibits versatile administration routes\u2014oral, rectal, intramuscular, intravenous, and intranasal, with IV administration eliciting rapid onset of action within 1-5 minutes and demonstrating a relatively short duration of clinical efficacy. Oral administration results in peak plasma concentrations within 15 to 60 minutes. While generally well-tolerated, its adverse effect profile includes CNS depression manifesting as sedation and impaired motor coordination, with rare, yet severe risks like respiratory depression, paradoxical excitation, and seizure exacerbation with chronic use. Chronic administration raises the risk of tolerance, physical dependence, and a withdrawal syndrome upon abrupt cessation; cognitive impairments post-discontinuation are well-documented. It is contraindicated in pregnancy and lactation due to teratogenic and neonatal withdrawal potential. Diazepam continues to be a mainstay therapeutic agent on the World Health Organization\u2019s List of Essential Medicines, despite its risk for abuse and dependency, underscoring the necessity for judicious prescribing practice.\n\nDRUG 3 NAME: Formoterol\nDRUG 3 BACKGROUND INFORMATION: Formoterol, a potent long-acting \u03b22-adrenergic receptor agonist (LABA), functions as a bronchodilator specifically targeting pulmonary smooth muscle to induce bronchodilation, thereby offering therapeutic utility in the management of asthma and chronic obstructive pulmonary disease (COPD). Notably, formoterol distinguishes itself by a prolonged bronchodilatory efficacy of approximately 12 hours post-administration, surpassing the 4-6 hour window typical of short-acting \u03b22 agonists like salbutamol (albuterol). Its pharmacokinetic profile is characterized by a rapid onset of action within 2-3 minutes, setting it apart from other LABAs. According to the 2022 Global Initiative for Asthma guidelines, adult treatment regimens favor a formoterol and inhaled corticosteroid combination for both prophylactic and acute symptom management, whereas pediatric protocols prioritize short-acting \u03b22 adrenergic agonists, such as salbutamol for immediate relief. Formoterol is commercially available both as a standalone generic medication and in synergistic fixed-dose combinations, notably with budesonide and mometasone, to enhance its clinical efficacy in targeted therapeutic strategies.\n\nPROTEIN NAME: ADRB1\nPROTEIN BACKGROUND INFORMATION: The beta-1 adrenergic receptor (\u03b21 adrenoceptor), also known as ADRB1, can refer to either the protein-encoding gene (gene ADRB1) or one of the four adrenergic receptors. It is a G-protein coupled receptor associated with the Gs heterotrimeric G-protein that is expressed predominantly in cardiac tissue. In addition to cardiac tissue, beta-1 adrenergic receptors are also expressed in the cerebral cortex.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): acetazolamide-Pain-Diazepam\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Diazepam-loss of weight-Formoterol\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Formoterol-binding and activation-ADRB1"}]}}
{"custom_id": "Lamivudine-Metoprolol-Perphenazine-ADRA2A-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Lamivudine\nDRUG 1 BACKGROUND INFORMATION: Lamivudine, or 3TC, is a nucleoside reverse transcriptase inhibitor with efficacy against HIV-1, HIV-2, and chronic hepatitis B virus. It functions by competitive inhibition of HIV reverse transcriptase and hepatitis B virus polymerase, disrupting viral DNA synthesis. Clinically, lamivudine is integral to combination antiretroviral therapy, often co-administered with agents such as zidovudine, dolutegravir, and abacavir, and forms part of post-exposure prophylactic regimens. It is available for oral administration as liquid or tablet formulations, maintaining therapeutic flexibility through its dosing independence from food intake. While generally well-tolerated, adverse effects can include gastrointestinal disturbances, cephalalgia, asthenia, and respiratory symptoms; however, clinicians must vigilantly monitor for hepatotoxicity, lactic acidosis, and hepatitis B exacerbations. Suitable for patients over three months and deemed safe in pregnancy, lamivudine is recognized as an essential medicine, underscoring its pivotal role in antiretroviral pharmacotherapy despite potential genotypic resistance mutations.\n\nDRUG 2 NAME: Metoprolol\nDRUG 2 BACKGROUND INFORMATION: Metoprolol, a cardioselective \u03b21-adrenergic receptor antagonist, is clinically utilized in the management of angina pectoris, hypertension, tachyarrhythmias, post-myocardial infarction secondary prophylaxis, and migraine prophylaxis. Its therapeutic efficacy is mediated via negative chronotropic and inotropic effects which result in decreased myocardial oxygen demand and improved exercise tolerance. The pharmacokinetics of metoprolol is influenced by hepatic cytochrome P450 2D6 isoenzyme variability leading to significant interpatient variability in drug metabolism, necessitating individualized dosing. Adverse effects prominently include insomnia, asthenia, presyncope, and gastrointestinal disturbances, with higher doses presenting risk for pronounced toxicity. Though teratogenic risk during pregnancy has not been conclusively excluded, its excretion into breast milk is considered clinically insignificant. Metoprolol is widely dispensed, reflecting its inclusion in the WHO's Essential Medicines, and its prescription frequency underscores its pivotal role in cardiovascular therapeutics.\n\nDRUG 3 NAME: Perphenazine\nDRUG 3 BACKGROUND INFORMATION: Perphenazine is a typical antipsychotic drug.  Chemically, it is classified as a piperazinyl phenothiazine. Originally marketed in the United States as Trilafon, it has been in clinical use for decades.\nPerphenazine is roughly ten times as potent as chlorpromazine at the dopamine-2 (D2) receptor; thus perphenazine is considered a medium-potency antipsychotic.\n\nPROTEIN NAME: ADRA2A\nPROTEIN BACKGROUND INFORMATION: The alpha-2A adrenergic receptor (\u03b12A adrenoceptor), also known as ADRA2A, is an \u03b12-adrenergic receptor, and also denotes the human gene encoding it.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Lamivudine-dysarthria-Metoprolol\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Metoprolol-insulin dependent diabetes mellitus-Perphenazine\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Perphenazine-binding and inhibition-ADRA2A"}]}}
{"custom_id": "alendronic acid-Alprazolam-Doxazosin-ADRA1A-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: alendronic acid\nDRUG 1 BACKGROUND INFORMATION: Alendronic acid, sold under the brand name Fosamax among others, is a bisphosphonate medication used to treat osteoporosis and Paget's disease of bone. It is taken by mouth. Use is often recommended together with vitamin D, calcium supplementation, and lifestyle changes.\nCommon side effects (1 to 10% of patients) include constipation, abdominal pain, nausea, and acid reflux. Use is not recommended during pregnancy or in those with poor kidney function. Alendronic acid works by decreasing the activity of cells that break down bone.\nAlendronic acid was first described in 1978 and approved for medical use in the United States in 1995. It is available as a generic medication. In 2022, it was the 103rd most commonly prescribed medication in the United States, with more than 6 million prescriptions.\n\nDRUG 2 NAME: Alprazolam\nDRUG 2 BACKGROUND INFORMATION: Alprazolam is a high-affinity triazolobenzodiazepine functioning as a potent anxiolytic agent through modulation of the GABA_A receptor chloride channel activity, facilitating enhanced inhibitory neurotransmission. Its pharmacodynamic profile encompasses rapid onset and moderate duration of action, predominantly prescribed for anxiety spectrum disorders, including panic disorder and GAD, and adjunctively for chemotherapy-related emesis control. The pharmacokinetic trajectory involves oral administration, exhibiting bioavailability conducive to therapeutic efficacy within a week for GAD. The acute adverse neurological sequelae are characterized by CNS depression manifesting as somnolence, psychomotor impairment, cognitive attenuation, and dose-dependent anterograde amnesia. Tolerance development mitigates some sedative effects over time. Abrupt cessation precipitates benzodiazepine withdrawal symptomatology. As a Schedule IV controlled substance, alprazolam's potential for abuse and dependency necessitates judicious prescription monitoring. Its clinical ubiquity is substantiated by its standing as the 41st most prescribed drug in the US, with significant generic dissemination.\n\nDRUG 3 NAME: Doxazosin\nDRUG 3 BACKGROUND INFORMATION: Doxazosin, sold under the brand name Cardura among others, is a medication used to treat symptoms of benign prostatic hyperplasia (enlarged prostate), hypertension (high blood pressure), and post-traumatic stress disorder (PTSD). For high blood pressure, it is a less preferred option. It is taken by mouth.\nCommon side effects include dizziness, sleepiness, swelling, nausea, shortness of breath, and abdominal pain. Severe side effects may include low blood pressure with standing, an irregular heart beat, and priapism. It is a selective \u03b11-adrenergic blocker in the quinazoline class of compounds.\nDoxazosin was patented in 1977 and came into medical use in 1988. It is available as a generic medication. In 2022, it was the 180th most commonly prescribed medication in the United States, with more than 2 million prescriptions.\n\nPROTEIN NAME: ADRA1A\nPROTEIN BACKGROUND INFORMATION: The alpha-1A adrenergic receptor (\u03b11A adrenoreceptor), also known as ADRA1A, formerly known also as the  alpha-1C adrenergic receptor, is an alpha-1 adrenergic receptor, and also denotes the human gene encoding it. There is no longer a subtype \u03b11C receptor. At one time, there was a subtype known as \u03b11C, but it was found to be identical to the previously discovered \u03b11A receptor subtype. To avoid confusion, the naming convention was continued with the letter D.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): alendronic acid-cholecystitis-Alprazolam\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Alprazolam-myelodysplasia-Doxazosin\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Doxazosin-binding and inhibition-ADRA1A"}]}}
{"custom_id": "Metolazone-Metoprolol-Perphenazine-ADRA2A-DPI-3_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-PROTEIN INTERACTIONS. You are given background information on three drugs, one protein and their interaction triples (in subject-predicate-object format). \n\nYou will see 2 types of relations,\n1. DRUG-DRUG INTERACTION: This is the side effect of taking the two drugs together.\n2. DRUG-PROTEIN INTERACTION: This explains how the drug behaves with the protein.\n\nTASK REQUIREMENTS:\n1. Write exactly one question integrating the background knowledge of each drug, protein and their relationship. The answer must be the protein.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs or protein by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationships or interactions, not just isolated facts about the drugs or protein.**\n5. The answer should be only the name of the protein.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Metolazone\nDRUG 1 BACKGROUND INFORMATION: Metolazone is a thiazide-like diuretic marketed under the brand names Zytanix, Metoz, Zaroxolyn, and Mykrox. It is primarily used to treat congestive heart failure and high blood pressure. Metolazone indirectly decreases the amount of water reabsorbed into the bloodstream by the kidney, so that blood volume decreases and urine volume increases. This lowers blood pressure and prevents excess fluid accumulation in heart failure. Metolazone is sometimes used together with loop diuretics such as furosemide or bumetanide, but these highly effective combinations can lead to dehydration and electrolyte abnormalities.\nIt was patented in 1966 and approved for medical use in 1974.\n\nDRUG 2 NAME: Metoprolol\nDRUG 2 BACKGROUND INFORMATION: Metoprolol, a cardioselective \u03b21-adrenergic receptor antagonist, is clinically utilized in the management of angina pectoris, hypertension, tachyarrhythmias, post-myocardial infarction secondary prophylaxis, and migraine prophylaxis. Its therapeutic efficacy is mediated via negative chronotropic and inotropic effects which result in decreased myocardial oxygen demand and improved exercise tolerance. The pharmacokinetics of metoprolol is influenced by hepatic cytochrome P450 2D6 isoenzyme variability leading to significant interpatient variability in drug metabolism, necessitating individualized dosing. Adverse effects prominently include insomnia, asthenia, presyncope, and gastrointestinal disturbances, with higher doses presenting risk for pronounced toxicity. Though teratogenic risk during pregnancy has not been conclusively excluded, its excretion into breast milk is considered clinically insignificant. Metoprolol is widely dispensed, reflecting its inclusion in the WHO's Essential Medicines, and its prescription frequency underscores its pivotal role in cardiovascular therapeutics.\n\nDRUG 3 NAME: Perphenazine\nDRUG 3 BACKGROUND INFORMATION: Perphenazine is a typical antipsychotic drug.  Chemically, it is classified as a piperazinyl phenothiazine. Originally marketed in the United States as Trilafon, it has been in clinical use for decades.\nPerphenazine is roughly ten times as potent as chlorpromazine at the dopamine-2 (D2) receptor; thus perphenazine is considered a medium-potency antipsychotic.\n\nPROTEIN NAME: ADRA2A\nPROTEIN BACKGROUND INFORMATION: The alpha-2A adrenergic receptor (\u03b12A adrenoceptor), also known as ADRA2A, is an \u03b12-adrenergic receptor, and also denotes the human gene encoding it.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Metolazone-cholecystitis-Metoprolol\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Metoprolol-insulin dependent diabetes mellitus-Perphenazine\nDRUG 3 - PROTEIN INTERACTION TRIPLE (subject-predicate-object): Perphenazine-binding and inhibition-ADRA2A"}]}}
